

# CITATION REPORT

List of articles citing

**KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer**

**DOI: 10.1158/0008-5472.can-06-0191**  
**Cancer Research, 2006, 66, 3992-5.**

**Source:** <https://exaly.com/paper-pdf/39529811/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #    | Paper                                                                                                                                                                                       | IF | Citations |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|-----------|
| 2020 | International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant.                                                          |    |           |
| 2019 | Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. <b>2006</b> , 38, 545-51                                                                  |    | 47        |
| 2018 | Panitumumab in colon cancer: a review and summary of ongoing trials. <b>2006</b> , 6, 1229-35                                                                                               |    | 25        |
| 2017 | The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. <b>2006</b> , 24, 985-95                                                                |    | 108       |
| 2016 | Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. <b>2006</b> , 1766, 184-96                                                                                   |    | 80        |
| 2015 | Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. <b>2006</b> , 1766, 217-29                                                                          |    | 27        |
| 2014 | High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. <b>2006</b> , 6, 295 |    | 223       |
| 2013 | Point mutations of protein kinases and individualised cancer therapy. <b>2006</b> , 7, 2243-61                                                                                              |    | 23        |
| 2012 | Recurrent KRAS codon 146 mutations in human colorectal cancer. <b>2006</b> , 5, 928-32                                                                                                      |    | 171       |
| 2011 | Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. <b>2006</b> , 12, 7222-31                                               |    | 75        |
| 2010 | Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. <b>2006</b> , 24, 4914-21        |    | 450       |
| 2009 | Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma. <b>2006</b> , 10, 639-47                                                        |    | 16        |
| 2008 | Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. <b>2007</b> , 7, 821-36                                                              |    | 9         |
| 2007 | Emerging drugs for the treatment of pancreatic cancer. <b>2007</b> , 12, 301-11                                                                                                             |    | 2         |
| 2006 | Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. <b>2007</b> , 97, 1469-74                     |    | 64        |
| 2005 | Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. <b>2007</b> , 7, 503-18                                                                      |    | 27        |
| 2004 | New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era. <b>2007</b> , 7, 1027-41                                                                     |    | 2         |

|      |                                                                                                                                                                                                                     |     |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 2003 | Optimizing Anti-EGFR Strategies in Cancer Treatment. <b>2007</b> , 3, 267-275                                                                                                                                       |     |
| 2002 | Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab. <b>2007</b> , 3, 249-254                                                                                                   |     |
| 2001 | Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer. <b>2007</b> , 73, 185-91                                | 6   |
| 2000 | Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. <b>2007</b> , 72, 105-10                                                                      | 87  |
| 1999 | Genomic landscapes of cancers: prospects for targeted therapies. <b>2007</b> , 8, 1629-33                                                                                                                           | 10  |
| 1998 | Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. <b>2007</b> , 3, 805-17                                                                                                       | 42  |
| 1997 | The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. <b>2007</b> , 13, 6419-28                             | 118 |
| 1996 | Biological therapy and other novel therapies in early-stage disease: are they appropriate?. <b>2007</b> , 13, 6909s-12s                                                                                             | 6   |
| 1995 | FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. <b>2007</b> , 25, 3712-8 | 407 |
| 1994 | Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. <b>2007</b> , 5, 863-72                                       | 82  |
| 1993 | ESMO Handbook on Principles of Translational Research. <b>2007</b> ,                                                                                                                                                |     |
| 1992 | Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. <b>2007</b> , 37, 679-85                                                       | 27  |
| 1991 | Erlotinib in pancreatic cancer: are tumor cells the (only) target?. <b>2007</b> , 25, 5836-7                                                                                                                        | 4   |
| 1990 | Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment. <b>2007</b> , 3, 242-248                                                                           |     |
| 1989 | Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. <b>2007</b> , 3, 276-283                                                                                                                        |     |
| 1988 | Methodological Issues of Clinical Research with EGFR Inhibitors. <b>2007</b> , 3, 292-302                                                                                                                           | 3   |
| 1987 | Lessons learned in the management of advanced pancreatic cancer. <b>2007</b> , 25, 1949-52                                                                                                                          | 29  |
| 1986 | Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. <b>2007</b> , 25, 3238-45                                                          | 293 |

|      |                                                                                                                                                                                                                                  |      |      |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|------|
| 1985 | Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?. <b>2007</b> , 13, 4664-6                                                                                 |      | 40   |
| 1984 | [Predictive factors in the response of antiplatelet anti EGFR in gastro-intestinal tumor]. <b>2007</b> , 62, 95-8                                                                                                                |      |      |
| 1983 | Predictive and prognostic markers in colorectal cancer. <b>2007</b> , 4, 295-306                                                                                                                                                 |      | 1    |
| 1982 | Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. <b>2007</b> , 10, 59-67                             |      | 147  |
| 1981 | Molecular-based choice of cancer therapy: realities and expectations. <b>2007</b> , 379, 1-13                                                                                                                                    |      | 15   |
| 1980 | EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. <b>2007</b> , 83, 238-48                                                                                                                  |      | 157  |
| 1979 | Selective Raf inhibition in cancer therapy. <b>2007</b> , 11, 1587-609                                                                                                                                                           |      | 50   |
| 1978 | [Pharmacogenetics: from basic research to clinical applications]. <b>2007</b> , 65, 365-70                                                                                                                                       |      | 3    |
| 1977 | Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. <i>Cancer Research</i> , <b>2007</b> , 67, 2643-8       | 10.1 | 708  |
| 1976 | Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. <b>2007</b> , 25, 3230-7                                            |      | 988  |
| 1975 | Cetuximab in the treatment of metastatic colorectal cancer. <b>2007</b> , 7, 243-56                                                                                                                                              |      | 16   |
| 1974 | Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. <b>2007</b> , 25, 1658-64                    |      | 1611 |
| 1973 | [EGFR and colorectal cancer: what's new?]. <b>2007</b> , 27, 341-3                                                                                                                                                               |      | 0    |
| 1972 | Les techniques FISH/CISH : applications en histopathologie. <b>2007</b> , 27, 85-87                                                                                                                                              |      |      |
| 1971 | Le laboratoire de Génétique Somatique des Tumeurs du CHU de Rouen. <b>2007</b> , 27, 122-125                                                                                                                                     |      |      |
| 1970 | The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer. <b>2007</b> , 6 Suppl 2, S47-52                                                                                  |      | 1    |
| 1969 | Combining targeted therapies to enhance the effectiveness of chemotherapy in patients with treatment-refractory colorectal cancer. <b>2007</b> , 6 Suppl 2, S53-9                                                                |      | 1    |
| 1968 | A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients. <b>2007</b> , 7 Suppl 1, S8-15 |      | 2    |

|      |                                                                                                                                                                                         |     |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1967 | Exploring alternative individualized treatment strategies in colorectal cancer. <b>2007</b> , 7 Suppl 1, S28-36                                                                         | 5   |
| 1966 | A simple method for the routine detection of somatic quantitative genetic alterations in colorectal cancer. <b>2007</b> , 132, 645-53                                                   | 18  |
| 1965 | Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; June 18, 2007. <b>2007</b> , 6, 614-620                                             |     |
| 1964 | Development and Clinical Indications of Cetuximab. <b>2007</b> , 22, 40-46                                                                                                              | 10  |
| 1963 | Cetuximab in Colon Cancer. <b>2007</b> , 22, 62-70                                                                                                                                      | 5   |
| 1962 | Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. <b>2007</b> , 110, 980-8                                                                      | 178 |
| 1961 | The multidisciplinary management of gastrointestinal cancer. The use of molecular markers in the diagnosis and treatment of colorectal cancer. <b>2007</b> , 21, 1071-87                | 15  |
| 1960 | The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. <b>2007</b> , 21, 1089-108 | 31  |
| 1959 | EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. <b>2007</b> , 62, 53-61                                                | 101 |
| 1958 | Epidermal growth factor receptor and rectal cancer: in regard to Kim et al. (Int J Radiat Oncol Biol Phys 2006;66:195-200). <b>2007</b> , 67, 318                                       |     |
| 1957 | Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancer. <b>2007</b> , 68, 1094-101                                              | 20  |
| 1956 | From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. <b>2007</b> , 25, 1134-43                                                        | 165 |
| 1955 | Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. <b>2007</b> , 96, 1166-9                                          | 643 |
| 1954 | PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. <b>2007</b> , 97, 1139-45                                                                 | 459 |
| 1953 | Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. <b>2007</b> , 75, 788-99                                                                                 | 65  |
| 1952 | Pharmacogenetics of EGFR and VEGF inhibition. <b>2007</b> , 12, 1054-60                                                                                                                 | 40  |
| 1951 | Cetuximab efficacy in patients treated routinely in university hospitals. <b>2007</b> , 31, 941-9                                                                                       | 3   |
| 1950 | Cancer systems biology: exploring cancer-associated genes on cellular networks. <b>2007</b> , 64, 1752-62                                                                               | 94  |

|      |                                                                                                                                                                                                                          |     |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1949 | Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. <b>2007</b> , 8, 339-51                                                                                              | 15  |
| 1948 | Predicting benefit from adjuvant therapy in colon cancer. <b>2007</b> , 3, 150-157                                                                                                                                       |     |
| 1947 | Molecular markers in colorectal cancer: genetic bases for a customised treatment. <b>2007</b> , 9, 549-54                                                                                                                | 9   |
| 1946 | Have we made progress with biological agents in metastatic colorectal cancer?. <b>2007</b> , 2, 59-62                                                                                                                    | 1   |
| 1945 | Targeted therapy in advanced colorectal cancer, an update. <b>2007</b> , 2, 165-172                                                                                                                                      | 2   |
| 1944 | Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. <b>2008</b> , 27, 387-402                                                                                                                  | 26  |
| 1943 | [Molecular targets for colon cancer. VEGF, EGFR - and what else?]. <b>2008</b> , 29 Suppl 2, 200-3                                                                                                                       | 2   |
| 1942 | Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature. <b>2008</b> , 3, 127-130 | 4   |
| 1941 | What is the impact of biologicals in colorectal cancer?. <b>2008</b> , 3, 59-69                                                                                                                                          |     |
| 1940 | Can we predict the response to epidermal growth factor receptor targeted therapy?. <b>2008</b> , 3, 87-99                                                                                                                | 1   |
| 1939 | Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era. <b>2008</b> , 3, 223-225                                                                                                   |     |
| 1938 | Molekulardiagnostik von Mutationen des epidermalen Wachstumsfaktor-Rezeptors und Aktivierung nachgeschalteter Signalwege in nichtkleinzelligen Lungenkarzinomen. <b>2008</b> , 1, 101-108                                |     |
| 1937 | The role of targeted therapy in the treatment of advanced colorectal cancer. <b>2008</b> , 9, 357-74                                                                                                                     | 5   |
| 1936 | Molecular predictors of response to EGFR antibodies in colorectal cancer. <b>2008</b> , 4, 119-125                                                                                                                       |     |
| 1935 | Predictive markers of cetuximab efficacy in metastatic colorectal cancer. <b>2008</b> , 4, 184-192                                                                                                                       |     |
| 1934 | EGFR and colon cancer: a clinical view. <b>2008</b> , 10, 6-13                                                                                                                                                           | 47  |
| 1933 | Retrospective study of cetuximab in combination with chemotherapy for patients with colorectal cancer. <b>2008</b> , 7, 400-403                                                                                          | 1   |
| 1932 | KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. <b>2008</b> , 453, 417-31                                               | 241 |

|      |                                                                                                                                                                                                                                                                              |      |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 1931 | Targeting the epidermal growth factor receptor in metastatic colorectal cancer. <b>2008</b> , 65, 8-20                                                                                                                                                                       | 33   |
| 1930 | Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. <b>2008</b> , 66, 21-30                                                                                                                                                            | 35   |
| 1929 | The biological properties of cetuximab. <b>2008</b> , 68, 93-106                                                                                                                                                                                                             | 96   |
| 1928 | EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. <b>2008</b> , 19, 717-23                                                                                                                                           | 225  |
| 1927 | Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. <b>2008</b> , 15, 649-54                                                                                                    | 82   |
| 1926 | National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. <b>2008</b> , 54, e11-79                                                                        | 451  |
| 1925 | Pharmacogenetics in colorectal cancer: a systematic review. <b>2008</b> , 9, 1079-99                                                                                                                                                                                         | 28   |
| 1924 | Predicting the response to targeted therapy in metastatic colorectal cancer. <b>2008</b> , 4, 208-217                                                                                                                                                                        |      |
| 1923 | Targeted therapy of cancer: new roles for pathologists. <b>2008</b> , 21 Suppl 2, S1                                                                                                                                                                                         | 7    |
| 1922 | Molecular diagnosis in oncology. <b>2008</b> , 42, 687-698                                                                                                                                                                                                                   | 2    |
| 1921 | The role of PTEN signaling perturbations in cancer and in targeted therapy. <b>2008</b> , 27, 5477-85                                                                                                                                                                        | 291  |
| 1920 | Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. <b>2008</b> , 98, 749-55 | 87   |
| 1919 | Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. <b>2008</b> , 99, 83-9                                                                                                                                                             | 155  |
| 1918 | Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. <b>2008</b> , 99, 551-2                                                                                                                                       | 35   |
| 1917 | KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. <b>2008</b> , 99, 2020-8                                                                                                                                              | 73   |
| 1916 | EGFR inhibitors embrace KRAS. <b>2008</b> , 26, 839-40                                                                                                                                                                                                                       | 6    |
| 1915 | ERK and MDM2 prey on FOXO3a. <b>2008</b> , 10, 125-6                                                                                                                                                                                                                         | 40   |
| 1914 | Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. <b>2008</b> , 14, 1351-6                                                                                                                                           | 1121 |

|      |                                                                                                                                                                                             |      |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 1913 | Commentary. <b>2008</b> , 10, 218-221                                                                                                                                                       | 2    |
| 1912 | Chimiothérapie et chirurgie : comment optimiser la résection des métastases hépatiques du cancer colorectal?. <b>2008</b> , 145, 3S5-3S14                                                   |      |
| 1911 | Faits marquants du 3e Congrès francophone de chirurgie digestive et hépatobiliaire. <b>2008</b> , 145, 4S1-4S12                                                                             |      |
| 1910 | A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. <b>2008</b> , 8, 169 | 60   |
| 1909 | Molecular detection (k-ras) of exfoliated tumour cells in the pelvis is a prognostic factor after resection of rectal cancer?. <b>2008</b> , 8, 213                                         | 6    |
| 1908 | Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. <b>2008</b> , 8, 234                                                                   | 74   |
| 1907 | [Non-resectable metastases from colorectal cancers]. <b>2008</b> , 32, S140-4                                                                                                               |      |
| 1906 | A sweet new role for EGFR in cancer. <b>2008</b> , 13, 375-6                                                                                                                                | 35   |
| 1905 | K-ras mutations and benefit from cetuximab in advanced colorectal cancer. <b>2008</b> , 359, 1757-65                                                                                        | 2912 |
| 1904 | A personalized approach to cancer treatment: how biomarkers can help. <b>2008</b> , 54, 1770-9                                                                                              | 106  |
| 1903 | Current status of chemotherapy for advanced colorectal cancer in Japan. <b>2008</b> , 7, 15-24                                                                                              | 3    |
| 1902 | Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. <b>2008</b> , 7, 33-43                              | 46   |
| 1901 | Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. <b>2008</b> , 7, 184-90                             | 129  |
| 1900 | Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer. <b>2008</b> , 7, 300-8                                                              | 6    |
| 1899 | Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer. <b>2008</b> , 7 Suppl 2, S52-7                                     | 13   |
| 1898 | Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. <b>2008</b> , 19, 2033-8                                                                           | 29   |
| 1897 | Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. <b>2008</b> , 7, 92                                                                                             | 27   |
| 1896 | Cancer drug resistance. <b>2008</b> , 405-423                                                                                                                                               | 2    |



|      |                                                                                                                                                                                                                                                            |      |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 1895 | Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. <b>2008</b> , 6, 86-90                                                                                                                                     | 2    |
| 1894 | Adjuvant chemotherapy of colon cancer current strategies. <b>2008</b> , 6, 60-63                                                                                                                                                                           | 5    |
| 1893 | Signalling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. <b>2008</b> , 224-244                                                                                                                                    | 1    |
| 1892 | EGFR Signaling Networks in Cancer Therapy. <b>2008</b> ,                                                                                                                                                                                                   | 7    |
| 1891 | Many different tumor types have polyclonal tumor origin: evidence and implications. <b>2008</b> , 659, 232-47                                                                                                                                              | 67   |
| 1890 | EGFR antagonists in cancer treatment. <b>2008</b> , 358, 1160-74                                                                                                                                                                                           | 1570 |
| 1889 | Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. <b>2008</b> , 263, 170-81                                                                                                                  | 106  |
| 1888 | Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. <b>2008</b> , 11, 99-109                                                                                                                       | 27   |
| 1887 | The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials. <b>2008</b> , 44, 2133-43                                                                                                                           | 18   |
| 1886 | KRAS mutations predict response to EGFR inhibitors. <b>2008</b> , 8, 413-8                                                                                                                                                                                 | 95   |
| 1885 | Pharmacogenetics: improving drug and dose selection. <b>2008</b> , 8, 639-46                                                                                                                                                                               | 18   |
| 1884 | Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. <b>2008</b> , 28, 269-81                                                                                                           | 35   |
| 1883 | KRAS mutational testing in the selection of patients for EGFR-targeted therapies. <b>2008</b> , 25, 288-94                                                                                                                                                 | 13   |
| 1882 | First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent. <b>2008</b> , 34 Suppl 2, S3-7                                                                                                                   | 73   |
| 1881 | EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. <b>2008</b> , 26, 2311-9                                                                                  | 757  |
| 1880 | Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. <b>2008</b> , 9, 962-72 | 623  |
| 1879 | Predictive Markers in Colorectal Cancer. <b>2008</b> , 19, 231-238                                                                                                                                                                                         |      |
| 1878 | [Detection of KRAS mutations: evolution or revolution for the pathologists?]. <b>2008</b> , 28, 261-2                                                                                                                                                      | 1    |

|      |                                                                                                                                                                                                                                          |      |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 1877 | KRAS mutations: an old oncogene becomes a new predictive biomarker. <b>2008</b> , 10, 493-5                                                                                                                                              | 41   |
| 1876 | Optimal approach to potentially resectable liver metastases from colorectal cancer. <b>2008</b> , 8, 1533-9                                                                                                                              | 4    |
| 1875 | Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. <b>2008</b> , 8, 319-29                                                                                                                             | 9    |
| 1874 | Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. <b>2008</b> , 26, 1626-34                                                                                                             | 2666 |
| 1873 | KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. <b>2008</b> , 19, 508-15                                                                 | 651  |
| 1872 | Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. <b>2008</b> , 26, 5705-12                                                                                                           | 1358 |
| 1871 | The relevance of molecular diagnostics in the practice of surgical pathology. <b>2008</b> , 2, 1401-14                                                                                                                                   | 4    |
| 1870 | KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. <b>2008</b> , 26, 374-9                                                                                           | 1240 |
| 1869 | Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. <b>2008</b> , 10, 160-8 | 45   |
| 1868 | Genetic predictors of MEK dependence in non-small cell lung cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 9375-83 <sub>10.1</sub>                                                                                                   | 216  |
| 1867 | Therapy for Unresectable Metastatic Colorectal Cancer. <b>2008</b> , 19, 216-225                                                                                                                                                         |      |
| 1866 | First-line single-agent cetuximab in patients with advanced colorectal cancer. <b>2008</b> , 19, 711-6                                                                                                                                   | 34   |
| 1865 | Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. <b>2008</b> , 38, 762-9                                                          | 27   |
| 1864 | Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?. <b>2008</b> , 19 Suppl 7, vii281-8                                                                                                  | 3    |
| 1863 | Editorial: the long and winding road to better cancer cell-specific therapies. <b>2008</b> , 13, 593-5                                                                                                                                   |      |
| 1862 | Predictive tests for individualization of pharmacological cancer treatment. <b>2008</b> , 2, 349-60                                                                                                                                      | 13   |
| 1861 | Biomarkers in Colorectal Cancer. <b>2008</b> , 30, 1-12                                                                                                                                                                                  |      |
| 1860 | Challenges in developing targeted therapy for pancreatic adenocarcinoma. <b>2008</b> , 12, 1389-401                                                                                                                                      | 14   |

|      |                                                                                                                                                                                                |      |     |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 1859 | The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: outcome study in clinical practice. <b>2008</b> , 20, 374-9                                        |      | 3   |
| 1858 | Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?. <b>2008</b> , 8, 1471-80                                                                |      | 11  |
| 1857 | Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. <i>Cancer Research</i> , <b>2008</b> , 68, 7403-8                                             | 10.1 | 72  |
| 1856 | PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. <i>Cancer Research</i> , <b>2008</b> , 68, 1953-61 | 10.1 | 397 |
| 1855 | KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. <b>2008</b> , 26, 2228-30; author reply 2230-1                                      |      | 26  |
| 1854 | The effects of common genetic variants in oncogenes on ovarian cancer survival. <b>2008</b> , 14, 5833-9                                                                                       |      | 30  |
| 1853 | Application of proteome analysis to the assessment of prognosis and response prediction in clinical oncology. <b>2008</b> , 8, 141-5                                                           |      | 5   |
| 1852 | K-Ras mutation status as a predictive biomarker in metastatic colorectal cancer. <b>2008</b> , 2, 97-9                                                                                         |      | 2   |
| 1851 | Determinants of RASistance to anti-epidermal growth factor receptor agents. <b>2008</b> , 26, 1582-4                                                                                           |      | 69  |
| 1850 | Principles of Molecular Oncology. <b>2008</b> ,                                                                                                                                                |      | 1   |
| 1849 | Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. <b>2008</b> , 14, 502-8                                                                       |      | 101 |
| 1848 | Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. <b>2008</b> , 13, 1074-83                                                                   |      | 56  |
| 1847 | In Reply. <b>2008</b> , 26, 2601-2602                                                                                                                                                          |      | 3   |
| 1846 | Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. <b>2008</b> , 47, 9-19                                                                                               |      | 75  |
| 1845 | High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. <b>2008</b> , 13, 1270-5                                   |      | 197 |
| 1844 | K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. <b>2008</b> , 14, 4830-5                                                     |      | 130 |
| 1843 | Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. <b>2008</b> , 14, 7413-22                                                         |      | 91  |
| 1842 | Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. <b>2008</b> , 14, 4219-24                |      | 46  |

|      |                                                                                                                                                      |    |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1841 | Pharmacoeugenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. <b>2008</b> , 9, 1903-16                     | 21 |
| 1840 | ErbB antagonists patenting: "playing chess with cancer". <b>2008</b> , 2, 181-7                                                                      | 5  |
| 1839 | Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer. <b>2008</b> , 5, 415-25  | 16 |
| 1838 | EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. <b>2008</b> , 9, 55-69         | 11 |
| 1837 | Emerging drugs for colorectal cancer. <b>2008</b> , 13, 629-42                                                                                       | 9  |
| 1836 | Current status of antivasular therapy and targeted treatment in the clinic. <b>2008</b> , 24, 97-110                                                 | 0  |
| 1835 | Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer. <b>2008</b> ,                                                  | 5  |
| 1834 | Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer. <b>2008</b> , 3, 234-243       |    |
| 1833 | Cetuximab, its clinical use and future perspectives. <b>2008</b> , 19, 99-113                                                                        | 51 |
| 1832 | Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?. <b>2008</b> , 20, 454-8 | 14 |
| 1831 | Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. <b>2008</b> , 17               |    |
| 1830 | Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. <b>2008</b> , 4, 1221-7                     | 10 |
| 1829 | Monoclonal Antibody Therapy of Cancer. <b>2008</b> , 671-678                                                                                         |    |
| 1828 | EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. <b>2009</b> , 215                                                  |    |
| 1827 | Advancements in the use of chemotherapy for colorectal cancer. <b>2009</b> , 7, 28-37                                                                |    |
| 1826 | Evolving role of cetuximab in the treatment of colorectal cancer. <b>2009</b> , Volume 1, 79-88                                                      | 3  |
| 1825 | [Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view]. <b>2009</b> , 96 Suppl, S47-56                      | 4  |
| 1824 | [Prognostic role of KRAS mutation in colorectal cancer]. <b>2009</b> , 96 Suppl, S23-30                                                              | 1  |

|      |                                                                                                                                                                                                 |     |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1823 | [Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view]. <b>2009</b> , 96 Suppl, S15-22                                                               | 2   |
| 1822 | [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients]. <b>2009</b> , 96 Suppl, S31-40                           |     |
| 1821 | BITC Sensitizes Pancreatic Adenocarcinomas to TRAIL-induced Apoptosis. <b>2009</b> , 2, CGM.S3982                                                                                               | 7   |
| 1820 | [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis]. <b>2009</b> , 96 Suppl, S41-6                                                                  | 1   |
| 1819 | Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer. <b>2009</b> , 1, CMT.S2039                                                                                 | 1   |
| 1818 | [Chemotherapy for colorectal cancer]. <b>2009</b> , 54, 355-63                                                                                                                                  | 2   |
| 1817 | [Metastatic colorectal cancers and targeted therapy against EGFR]. <b>2009</b> , 25 Spec No 1, 13-21                                                                                            | 1   |
| 1816 | Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. <b>2009</b> , 2009, 967920                                                            | 6   |
| 1815 | Mutation detection by real-time PCR: a simple, robust and highly selective method. <b>2009</b> , 4, e4584                                                                                       | 73  |
| 1814 | Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. <b>2009</b> , 4, e7287                        | 209 |
| 1813 | Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. <b>2009</b> , 4, e7746                                                                         | 68  |
| 1812 | EGFR genomic alterations in cancer: prognostic and predictive values. <b>2009</b> , E3, 879                                                                                                     | 3   |
| 1811 | KRAS mutations in non-small cell lung cancer. <b>2009</b> , 6, 201-5                                                                                                                            | 399 |
| 1810 | Emerging drugs in the treatment of pancreatic cancer. <b>2009</b> , 14, 311-28                                                                                                                  | 9   |
| 1809 | The marriage of growth factor inhibitors and chemotherapy: bliss or bust?. <b>2009</b> , 27, 1545-8                                                                                             | 8   |
| 1808 | Medical treatment of advanced colorectal cancer in 2009. <b>2009</b> , 1, 55-68                                                                                                                 | 7   |
| 1807 | FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. <b>2009</b> , 14, 284-90                                                        | 45  |
| 1806 | Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <b>2009</b> , 1, 167-81 | 6   |

|      |                                                                                                                                                                                                                                                          |          |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| 1805 | Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer. <b>2009</b> , 58, 1234-41                                                                   | 49       |
| 1804 | KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. <b>2009</b> , 27, 158-9; author reply 159                                                                                              | 12       |
| 1803 | PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. <b>2009</b> , 20, 84-90                                                                                                                | 327      |
| 1802 | TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. <b>2009</b> , 100, 1330-5                                                                                                              | 75       |
| 1801 | Targeted cancer therapeutics. <i>Cancer Research</i> , <b>2009</b> , 69, 1263-7; discussion 1267                                                                                                                                                         | 10.1 122 |
| 1800 | KRAS and TP53 mutations in colorectal carcinoma. <b>2009</b> , 15, 217-9                                                                                                                                                                                 | 12       |
| 1799 | Mutations and response to epidermal growth factor receptor inhibitors. <b>2009</b> , 15, 1133-9                                                                                                                                                          | 107      |
| 1798 | Risk of high-grade skin rash in cancer patients treated with cetuximab—an antibody against epidermal growth factor receptor: systemic review and meta-analysis. <b>2009</b> , 77, 124-33                                                                 | 52       |
| 1797 | Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. <b>2009</b> , 66, 2105-12                                                                                          | 22       |
| 1796 | Mechanisms of tumor resistance to EGFR-targeted therapies. <b>2009</b> , 13, 339-62                                                                                                                                                                      | 66       |
| 1795 | Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. <b>2009</b> ,                                                                                                                                                        | 2        |
| 1794 | PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. <b>2009</b> , 15, 3184-8                                                                         | 276      |
| 1793 | The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. <b>2009</b> , 14, 22-8 | 189      |
| 1792 | Impact of Fc{gamma}RIIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. <b>2009</b> , 27, 1122-9                                          | 425      |
| 1791 | PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. <b>2009</b> , 27, 1477-84                                                                                                                        | 274      |
| 1790 | The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients. <b>2009</b> , 77, 224-30                                                               | 23       |
| 1789 | Systemic therapies in hepatocellular carcinoma. <b>2009</b> , 27, 175-88                                                                                                                                                                                 | 50       |
| 1788 | Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <b>2009</b> , 15, 7492-7501                                                                                            | 42       |

|      |                                                                                                                                                                                                                    |     |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1787 | How can we improve antibody-based cancer therapy?. <b>2009</b> , 1, 67-70                                                                                                                                          | 9   |
| 1786 | Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. <b>2009</b> , 21, 1283-7                                                                    | 36  |
| 1785 | Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours. <b>2009</b> , 9, 1108-29                                                                                      | 31  |
| 1784 | Importance and limitations of chemotherapy among the available treatments for gastrointestinal tumours. <b>2009</b> , 9, 162-84                                                                                    | 21  |
| 1783 | Current situation of zalutumumab. <b>2009</b> , 9, 667-74                                                                                                                                                          | 14  |
| 1782 | KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. <b>2009</b> , 9, 565-77                                                                       | 8   |
| 1781 | Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. <b>2009</b> , 9, 945-9                                                                          | 12  |
| 1780 | New trends in epidermal growth factor receptor-directed monoclonal antibodies. <b>2009</b> , 1, 965-82                                                                                                             | 10  |
| 1779 | Simultaneous Detection of Colorectal Cancer Mutations in Stool Samples with Biochip Arrays. <b>2009</b> , 28, 285-292                                                                                              |     |
| 1778 | K-RAS mutation in the screening, prognosis and treatment of cancer. <b>2009</b> , 3, 757-69                                                                                                                        | 31  |
| 1777 | Targeted therapies in solid tumours: pinpointing the tumour's Achilles heel. <b>2009</b> , 15, 207-42                                                                                                              | 9   |
| 1776 | Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. <b>2009</b> , 8, 1536-46                                        | 23  |
| 1775 | Novel ways to sensitise gastrointestinal cancer to apoptosis. <b>2009</b> , 58, 1010-24                                                                                                                            | 8   |
| 1774 | The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. <b>2009</b> , 77 Suppl 1, 57-68                                            | 38  |
| 1773 | Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. <b>2009</b> , 20, 469-74      | 73  |
| 1772 | KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. <b>2009</b> , 15, 7322-9                                                                                      | 159 |
| 1771 | Can epidermal growth factor receptor-fluorescent in situ hybridization predict clinical benefit from cetuximab treatment in patients with non-small-cell lung cancer?. <b>2009</b> , 27, 464-5; author reply 465-7 | 5   |
| 1770 | In Reply. <b>2009</b> , 27, 465-467                                                                                                                                                                                | 4   |

|      |                                                                                                                                                                                                              |    |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1769 | Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. <b>2009</b> , 14, 478-88                                                                                                | 80 |
| 1768 | Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. <b>2009</b> , 18, 62-71                                            | 44 |
| 1767 | Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. <b>2009</b> , 20, 213-26                                                       | 31 |
| 1766 | Are we hitting the right combination for hormonally sensitive breast cancer?. <b>2009</b> , 27, 2580-2                                                                                                       | 3  |
| 1765 | Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. <b>2009</b> , 8, 481-9                                                 | 17 |
| 1764 | KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas. <b>2009</b> , 45, 826-9                                                    | 18 |
| 1763 | A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. <b>2009</b> , 9, 145                      | 23 |
| 1762 | Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer. <b>2009</b> , 9, 282                                            | 27 |
| 1761 | ERBBs in the gastrointestinal tract: recent progress and new perspectives. <b>2009</b> , 315, 583-601                                                                                                        | 37 |
| 1760 | Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. <b>2009</b> , 113, 21-7 | 83 |
| 1759 | Roles of pathologists in molecular targeted cancer therapy. <b>2009</b> , 13, 4286-90                                                                                                                        | 3  |
| 1758 | Molecular perspectives on the non-responder phenomenon. <b>2009</b> , 14, 373-9                                                                                                                              | 2  |
| 1757 | Clinical and economic impact of the nonresponder phenomenon--implications for systems based discovery. <b>2009</b> , 14, 380-5                                                                               | 8  |
| 1756 | [Pathology: on the way to molecular analysis]. <b>2009</b> , 33, 767-74                                                                                                                                      |    |
| 1755 | [Targeted biotherapy: a revolution in the management of patients with colorectal cancer?]. <b>2009</b> , 33, 672-80                                                                                          | 6  |
| 1754 | CO.23 Impact des polymorphismes génétiques associés à l'EGFR sur la réponse au cetuximab dans le cancer colorectal métastatique (CCRM). <b>2009</b> , 33, A12                                                |    |
| 1753 | P.196 L'expression nucléaire de PTEN prédit la survie des patients traités par cetuximab dans le cancer colorectal métastatique (CCRM). <b>2009</b> , 33, A146                                               |    |
| 1752 | Antikörperliche Krebsmedikamente. Gezielt wirksame Biomedizin. <b>2009</b> , 43, 328-338                                                                                                                     | 1  |



|      |                                                                                                                                                                                                                   |     |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1751 | Mechanisms of resistance to EGFR inhibitors in head and neck cancer. <b>2009</b> , 31, 1086-94                                                                                                                    | 32  |
| 1750 | Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents. <b>2010</b> , 127, 1028-37                               | 19  |
| 1749 | Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. <b>2009</b> , 135, 395-402 | 37  |
| 1748 | Place des thérapeutiques moléculaires ciblées dans les carcinomes épidermoïdes des voies aérodigestives supérieures. <b>2009</b> , 11, 152-159                                                                    | 2   |
| 1747 | Pharmacogenomics in chemotherapy for GI tract cancer. <b>2009</b> , 44, 1016-25                                                                                                                                   | 9   |
| 1746 | The role of salvage treatment in advanced colorectal cancer. <b>2009</b> , 71, 53-61                                                                                                                              | 11  |
| 1745 | Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. <b>2009</b> , 115, 115-21                                                                                         | 101 |
| 1744 | Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. <b>2009</b> , 11, 737-747                                                                                                     | 7   |
| 1743 | EGFR FISH analysis in colorectal cancer as a tool in selecting patients for antiEGFR monoclonal antibodies therapy. <b>2009</b> , 3, 187-193                                                                      | 1   |
| 1742 | Molecular predictors of response to EGFR antibodies in colorectal cancer. <b>2009</b> , 5, 57-63                                                                                                                  | 1   |
| 1741 | Incidence of KRAS status in ongoing adjuvant trials in colon cancer. <b>2009</b> , 5, 171-178                                                                                                                     | 2   |
| 1740 | Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. <b>2009</b> , 4, 267-73                                                                                                                  | 19  |
| 1739 | Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. <b>2009</b> , 4, 311-22                                                                                                   | 3   |
| 1738 | Cancer colorectal métastatique et thérapies ciblées. <b>2009</b> , 3, 230-238                                                                                                                                     |     |
| 1737 | Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. <b>2009</b> , 219, 435-45                                                                          | 67  |
| 1736 | Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. <b>2009</b> , 158, 1-9                                                                                                             | 221 |
| 1735 | Comparative validation of c-kit exon 11 mutation analysis on cytology samples and corresponding surgical resections of gastrointestinal stromal tumours. <b>2009</b> , 20, 297-303                                | 6   |
| 1734 | GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. <b>2009</b> , 22, 718-24                                                                                                     | 79  |

|      |                                                                                                                                                                                                       |      |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 1733 | Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. <b>2009</b> , 22, 1023-31                                                                                       | 102  |
| 1732 | P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. <b>2009</b> , 16, 498-507                                                                     | 18   |
| 1731 | Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. <b>2009</b> , 28 Suppl 1, S38-45                                                                       | 25   |
| 1730 | Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. <b>2009</b> , 100, 1087-94                               | 103  |
| 1729 | Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. <b>2009</b> , 100, 1257-66                                          | 79   |
| 1728 | Treatment in advanced colorectal cancer: what, when and how?. <b>2009</b> , 100, 1704-19                                                                                                              | 81   |
| 1727 | Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. <b>2009</b> , 101, 465-72                                      | 243  |
| 1726 | KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. <b>2009</b> , 101, 715-21                       | 450  |
| 1725 | Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer. <b>2009</b> , 10, 247-57   | 14   |
| 1724 | Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. <b>2009</b> , 158, 610-20                                            | 75   |
| 1723 | Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. <b>2009</b> , 205, 858-62                                                                        | 223  |
| 1722 | Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. <b>2009</b> , 101, 1182-92 | 104  |
| 1721 | Are RAS mutations predictive markers of resistance to standard chemotherapy?. <b>2009</b> , 6, 528-34                                                                                                 | 66   |
| 1720 | Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. <b>2009</b> , 27, 663-71                                            | 1360 |
| 1719 | Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. <b>2009</b> , 15, 4508-13                 | 83   |
| 1718 | Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. <b>2009</b> , 11, 140-7                                                   | 78   |
| 1717 | Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. <b>2009</b> , 35, 167-74                                                                                 | 46   |
| 1716 | Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. <b>2009</b> , 35, 262-71                                      | 157  |

|      |                                                                                                                                                                                                                 |          |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| 1715 | Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. <b>2009</b> , 35, 354-63                                                                                                       | 99       |
| 1714 | Colon, rectal, and anal cancers. <b>2009</b> , 25, 32-47                                                                                                                                                        | 15       |
| 1713 | [What are the new therapeutic strategies in metastatic colorectal cancer including biotherapies?]. <b>2009</b> , 30, 411-5                                                                                      | 1        |
| 1712 | The irrepressible rise of biomarkers in oncology. <b>2009</b> , 57, 509-10                                                                                                                                      | 1        |
| 1711 | Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. <b>2009</b> , 6, 519-27                                                                                                             | 341      |
| 1710 | Molecular targets for tumor radiosensitization. <b>2009</b> , 109, 2974-88                                                                                                                                      | 39       |
| 1709 | Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. <b>2009</b> , 21, 1023-8  | 41       |
| 1708 | The multidisciplinary management of rectal cancer. <b>2009</b> , 89, 177-215, ix-x                                                                                                                              | 28       |
| 1707 | Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. <b>2009</b> , 360, 1408-17                                                                                                    | 3065     |
| 1706 | PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. <i>Cancer Research</i> , <b>2009</b> , 69, 1851-7                                         | 10.1 642 |
| 1705 | KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. <b>2009</b> , 27, 5931-7 | 459      |
| 1704 | Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. <b>2009</b> , 8, 15-21                                                                     | 16       |
| 1703 | Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. <b>2009</b> , 8, 38-42                                                                        | 11       |
| 1702 | KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents. <b>2009</b> , 8, 135-40                                                                                               | 3        |
| 1701 | Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. <b>2009</b> , 8, 94                                                                               | 41       |
| 1700 | Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. <b>2009</b> , 2, 18                                                                                      | 35       |
| 1699 | Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. <b>2009</b> , 62, 886-91                                                                                                  | 40       |
| 1698 | A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. <b>2009</b> , 11, 543-52                                                                                   | 92       |

|      |                                                                                                                                                                                                          |     |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1697 | PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. <b>2009</b> , 27, 2622-9 | 368 |
| 1696 | Treatment of patients with colorectal cancer: emphasis on liver metastases. <b>2009</b> , 10, 109-24                                                                                                     | 1   |
| 1695 | Clinical biomarkers in oncology: focus on colorectal cancer. <b>2009</b> , 13, 103-14                                                                                                                    | 37  |
| 1694 | Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. <b>2009</b> , 9, 1421-8                                                                                                    | 73  |
| 1693 | Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. <b>2009</b> , 101, 1308-24                                                  | 424 |
| 1692 | Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors. <b>2009</b> , 3, 5-9                                                                                                              | 12  |
| 1691 | Current management of colorectal hepatic metastasis. <b>2009</b> , 3, 131-44                                                                                                                             | 74  |
| 1690 | Emerging molecular targeted therapies in the treatment of head and neck cancer. <b>2009</b> , 14, 299-310                                                                                                | 40  |
| 1689 | Reverse resistance to radiation in KYSE-150R esophageal carcinoma cell after epidermal growth factor receptor signal pathway inhibition by cetuximab. <b>2009</b> , 93, 468-73                           | 42  |
| 1688 | Pharmacogenetics and biomarkers in colorectal cancer. <b>2009</b> , 9, 147-60                                                                                                                            | 19  |
| 1687 | Impact of molecular markers on treatment selection in advanced colorectal cancer. <b>2009</b> , 45 Suppl 1, 70-8                                                                                         | 8   |
| 1686 | New approaches and targets in advanced colorectal cancer. <b>2009</b> , 45 Suppl 1, 79-88                                                                                                                | 4   |
| 1685 | Gastrointestinal toxicities of novel agents in cancer therapy. <b>2009</b> , 45 Suppl 1, 332-42                                                                                                          | 23  |
| 1684 | Beyond the KRAS test. <b>2009</b> , 45 Suppl 1, 398-9                                                                                                                                                    | 3   |
| 1683 | Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. <b>2009</b> , 27, 5924-30                                               | 586 |
| 1682 | Advances in the treatment of metastatic colorectal cancer. <b>2009</b> , 16, 412-20                                                                                                                      | 34  |
| 1681 | Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts. <b>2009</b> , 20, 355-63                                                             | 28  |
| 1680 | PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. <b>2009</b> ,           | 1   |

|      |                                                                                                                                                                                      |    |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1679 | Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. <b>2009</b> , 2009, 213-214                                                       |    |
| 1678 | [From the ancient serotherapy to naked antibodies: a century of successful targeted therapies]. <b>2009</b> , 25, 999-1009                                                           | 1  |
| 1677 | [From orthoclone to denosumab, the fast growing market of monoclonal antibodies]. <b>2009</b> , 25, 1177-82                                                                          | 2  |
| 1676 | Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies. <b>2009</b> , 6, 145-157                                                | 2  |
| 1675 | Évaluation et validation des tests diagnostiques dans le cadre du ciblage thérapeutique. <b>2009</b> , 64, 187-194                                                                   | 5  |
| 1674 | Evaluation and validation of diagnostic tests for guiding therapeutic decisions. <b>2009</b> , 64, 187-201                                                                           | 3  |
| 1673 | KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. <b>2009</b> , 16, 554-61                                          | 22 |
| 1672 | Translational strategies to implement personalized medicine: rheumatoid arthritis examples. <b>2009</b> , 6, 429-437                                                                 | 1  |
| 1671 | Advances in targeted therapies for metastatic colorectal cancer. <b>2009</b> , 6, 321-333                                                                                            | 1  |
| 1670 | Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine. <b>2009</b> , 4, 6-21                                             |    |
| 1669 | High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor. <b>2009</b> , 32, 245-52 | 15 |
| 1668 | Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy. <b>2010</b> , 16, 226-34                                                                 | 5  |
| 1667 | Advocacy in personalized medicine: a developing strength in a complex space. <b>2010</b> , 7, 179-186                                                                                | 2  |
| 1666 | Insights into the role of Fc gamma receptors (FcγRs) genetic variations in monoclonal antibody-based anti-cancer therapy. <b>2010</b> , 5, 197-204                                   | 6  |
| 1665 | Cetuximab: from bench to bedside. <b>2010</b> , 10, 80-95                                                                                                                            | 93 |
| 1664 | KRAS Mutation Analysis Prior to EGFR-Directed Therapy for Metastatic Colorectal Cancer: A Review and Cost Analysis. <b>2010</b> , 6, 256-261                                         | 3  |
| 1663 | KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. <b>2010</b> , 36, 1137-44                         | 11 |
| 1662 | Is it prime time for personalized medicine in cancer treatment?. <b>2010</b> , 7, 387-397                                                                                            | 1  |

|      |                                                                                                                                                                                              |     |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1661 | Molecular markers in the treatment of metastatic colorectal cancer. <b>2010</b> , 16, 262-72                                                                                                 | 63  |
| 1660 | Cetuximab promotes immunotoxicity against rhabdomyosarcoma in vitro. <b>2010</b> , 33, 279-86                                                                                                | 12  |
| 1659 | Gastric carcinoma in China: Current status and future perspectives (Review). <b>2010</b> , 1, 407-412                                                                                        | 39  |
| 1658 | Gene alterations in head and neck carcinomas and their role in promoting malignant behavior (Review). <b>2010</b> , 36, 525-32                                                               | 3   |
| 1657 | Combination Effect of Cetuximab with Radiation in Colorectal Cancer Cells. <b>2010</b> , 96, 713-720                                                                                         | 11  |
| 1656 | KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine. <b>2010</b> , 17, 23-32                                                                  | 72  |
| 1655 | KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. <b>2010</b> , 17, 572-8                                                       | 131 |
| 1654 | KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. <b>2010</b> , 17, 416-24                     | 68  |
| 1653 | KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. <b>2010</b> , 17, 1168-76                                                                                           | 86  |
| 1652 | Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. <b>2010</b> , 17, 624-33 | 48  |
| 1651 | KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. <b>2010</b> , 17, 1429-34                                   | 96  |
| 1650 | Personalized medicine: marking a new epoch in cancer patient management. <b>2010</b> , 8, 1175-87                                                                                            | 125 |
| 1649 | Molekulardiagnostik des Lungenkarzinoms zur Therapiestratifizierung. <b>2010</b> , 3, 87-93                                                                                                  |     |
| 1648 | Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. <b>2010</b> , 65, 579-87                                        | 30  |
| 1647 | Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases. <b>2010</b> , 65, 825-31                  | 13  |
| 1646 | [Molecular diagnostics in lung carcinoma for therapy stratification]. <b>2010</b> , 31, 22-8                                                                                                 | 3   |
| 1645 | Imprint cytology in tumor tissue bank quality control: an efficient method to evaluate tumor necrosis and to detect samples without tumor cells. <b>2010</b> , 456, 443-7                    | 10  |
| 1644 | Molekulare Marker zur Responseprädiktion beim lokal fortgeschrittenen Rektumkarzinom. <b>2010</b> , 16, 779-788                                                                              | 1   |

|      |                                                                                                                                                                                                                                 |     |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1643 | Panitumumab: an arrow on target. <b>2010</b> , 16, 143-8                                                                                                                                                                        | 2   |
| 1642 | Effect of cetuximab treatment in squamous cell carcinomas. <b>2010</b> , 31, 141-7                                                                                                                                              | 11  |
| 1641 | Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. <b>2010</b> , 5, 19-28 | 26  |
| 1640 | Update on the surgical pathology standards on rectal cancer diagnosis, staging and quality assessment of surgery. <b>2010</b> , 12, 431-6                                                                                       | 6   |
| 1639 | Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. <b>2010</b> , 12, 533-42                                                                                                      | 48  |
| 1638 | Circulating Tumor Cells and Colorectal Cancer. <b>2010</b> , 6, 212-220                                                                                                                                                         | 46  |
| 1637 | KRAS testing and its importance in colorectal cancer. <b>2010</b> , 12, 160-7                                                                                                                                                   | 9   |
| 1636 | Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. <b>2010</b> , 28, 353-60                                                                               | 22  |
| 1635 | CEACAM-7: a predictive marker for rectal cancer recurrence. <b>2010</b> , 147, 713-9                                                                                                                                            | 17  |
| 1634 | Uncovering packaging features of co-regulated modules based on human protein interaction and transcriptional regulatory networks. <b>2010</b> , 11, 392                                                                         | 8   |
| 1633 | Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. <b>2010</b> , 10, 136                                                                                                                           | 44  |
| 1632 | Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. <b>2010</b> , 10, 189                                                                                                             | 58  |
| 1631 | Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. <b>2010</b> , 10, 340                                                                         | 56  |
| 1630 | KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. <b>2010</b> , 10, 660                                                                                 | 57  |
| 1629 | Progress towards personalized medicine. <b>2010</b> , 15, 115-20                                                                                                                                                                | 72  |
| 1628 | Therapeutic modulation of k-ras signaling in colorectal cancer. <b>2010</b> , 15, 502-16                                                                                                                                        | 27  |
| 1627 | Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. <b>2010</b> , 80, 613-23                                                                                                                   | 69  |
| 1626 | Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. <b>2010</b> , 584, 2699-706                                                                                                      | 110 |

|      |                                                                                                                                                                                                                       |     |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1625 | Gene signature is associated with early stage rectal cancer recurrence. <b>2010</b> , 211, 187-95                                                                                                                     | 15  |
| 1624 | Mechanisms of resistance to HER family targeting antibodies. <b>2010</b> , 316, 1083-100                                                                                                                              | 123 |
| 1623 | Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy. <b>2010</b> , 14, 805-17                                                                                        | 2   |
| 1622 | Oncomutations as biomarkers of cancer risk. <b>2010</b> , 51, 836-50                                                                                                                                                  | 27  |
| 1621 | Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. <b>2010</b> , 2, 146-58                                                                               | 333 |
| 1620 | Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. <b>2010</b> , 49, 1024-34                                                    | 157 |
| 1619 | Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. <b>2010</b> , 116, 3233-43                                                                                            | 36  |
| 1618 | Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. <b>2010</b> , 127, 1321-31                                          | 41  |
| 1617 | Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. <b>2010</b> , 111, 1082-6                                                                                               | 14  |
| 1616 | Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers. <b>2010</b> , 293, 1506-11                           | 13  |
| 1615 | Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab. <b>2010</b> , 74, 193-202                                                                                                         | 21  |
| 1614 | Colon cancer. <b>2010</b> , 74, 106-33                                                                                                                                                                                | 172 |
| 1613 | Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. <b>2010</b> , 69, 58-66                                                                             | 76  |
| 1612 | Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?. <b>2010</b> , 101, 2048-53 | 20  |
| 1611 | Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells. <b>2010</b> , 101, 2033-8                                                                         | 17  |
| 1610 | KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?. <b>2010</b> , 19, 167-71                                                                    |     |
| 1609 | Oncogenic mutations as predictive factors in colorectal cancer. <b>2010</b> , 29, 3033-43                                                                                                                             | 87  |
| 1608 | Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. <b>2010</b> , 102, 151-61                                     | 44  |



|      |                                                                                                                                                                                                                          |     |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1607 | Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. <b>2010</b> , 103, 1407-14                                         | 132 |
| 1606 | KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. <b>2010</b> , 103, 1627-36                                                                        | 38  |
| 1605 | Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. <b>2010</b> , 103, 1765-72                                                                                               | 61  |
| 1604 | Integrating molecular diagnostics into anticancer drug discovery. <b>2010</b> , 9, 523-35                                                                                                                                | 45  |
| 1603 | Tumour banking as part of routine clinical practice. <b>2010</b> , 80, 203-4                                                                                                                                             | 2   |
| 1602 | Analysis of KRAS Mutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing. <b>2010</b> , 2010, 789363                                                                            | 21  |
| 1601 | Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. <b>2010</b> , 2010, 568938                                                                         | 89  |
| 1600 | Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. <b>2010</b> , 5, 61-76                                                                                                           | 10  |
| 1599 | Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients. <b>2010</b> , 10, 68-79                                                                                                              | 21  |
| 1598 | Targeting Ras for Anticancer Drug Discovery. <b>2010</b> , 2837-2857                                                                                                                                                     |     |
| 1597 | Chemotherapy for Colorectal Cancer. <b>2010</b> , 53, 582                                                                                                                                                                | 3   |
| 1596 | Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. <b>2010</b> , 16, 497-508                                                                                                               | 57  |
| 1595 | A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. <b>2010</b> , 15, 699-731                                                                                           | 121 |
| 1594 | K-ras Mutations in the Plasma of Colorectal Cancer Patients. <b>2010</b> , 41, 156-158                                                                                                                                   | 1   |
| 1593 | Predictive and prognostic molecular markers for cancer medicine. <b>2010</b> , 2, 125-48                                                                                                                                 | 138 |
| 1592 | Reply to A. Ocana et al. <b>2010</b> , 28, e422-e423                                                                                                                                                                     |     |
| 1591 | New strategies for treatment of KRAS mutant metastatic colorectal cancer. <b>2010</b> , 16, 2921-6                                                                                                                       | 64  |
| 1590 | Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. <b>2010</b> , 16, 304-10 | 56  |

|      |                                                                                                                                                                                                       |      |     |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 1589 | Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. <b>2010</b> , 16, 2205-13                                |      | 89  |
| 1588 | Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. <b>2010</b> , 16, 2095-105                                                                             |      | 81  |
| 1587 | The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. <b>2010</b> , 15, 73-84                                                 |      | 38  |
| 1586 | Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. <b>2010</b> , 251, 254-60 |      | 68  |
| 1585 | High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples. <b>2010</b> , 19, 201-8                     |      | 7   |
| 1584 | Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. <i>Cancer Research</i> , <b>2010</b> , 70, 4982-94                  | 10.1 | 98  |
| 1583 | Reply to D.R. Catchpoole et al. <b>2010</b> , 28, e725-e725                                                                                                                                           |      | 1   |
| 1582 | Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. <b>2010</b> , 9, 358-68              |      | 38  |
| 1581 | Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). <i>Cancer Research</i> , <b>2010</b> , 70, 2264-73                                                    | 10.1 | 185 |
| 1580 | PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. <b>2010</b> , 12, 967-75                   |      | 29  |
| 1579 | Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. <b>2010</b> , 17, 623-36                                                                                                  |      | 54  |
| 1578 | Emerging drugs to treat squamous cell carcinomas of the head and neck. <b>2010</b> , 15, 355-73                                                                                                       |      | 88  |
| 1577 | Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. <b>2010</b> , 3, ra67                                                                                              |      | 118 |
| 1576 | Palliative treatment of unresectable metastatic colorectal cancer. <b>2010</b> , 11, 63-77                                                                                                            |      | 16  |
| 1575 | Understanding resistance to EGFR inhibitors-impact on future treatment strategies. <b>2010</b> , 7, 493-507                                                                                           |      | 503 |
| 1574 | Pharmacogenomics and the FDA: The Challenges of Incorporating Research into Practice—Is the FDA Hinder Progress?. <b>2010</b> , 29, 147-163                                                           |      |     |
| 1573 | Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. <b>2010</b> , 102, 693-703                                        |      | 139 |
| 1572 | Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. <b>2010</b> , 10, 1589-99                                                             |      | 5   |

|      |                                                                                                                                                                                                                                                 |     |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1571 | New and potential clinical applications of KRAS as a cancer biomarker. <b>2010</b> , 4, 383-95                                                                                                                                                  | 5   |
| 1570 | Cancer drug prices in the era of healthcare reform. <b>2010</b> , 6, 647-50                                                                                                                                                                     |     |
| 1569 | ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. <b>2010</b> , 28, 364-75                                                                                                              | 23  |
| 1568 | Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. <b>2010</b> , 21 Suppl 6, vi1-10 | 35  |
| 1567 | Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. <b>2010</b> , 12, 1061-70                                                                                                                          | 88  |
| 1566 | Clinical pharmacogenetics in oncology: the paradigm of molecular targeted therapies. <b>2010</b> , 16, 2184-93                                                                                                                                  | 9   |
| 1565 | Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer. <b>2010</b> , 5, 142-51                                                                                                                      | 2   |
| 1564 | Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. <b>2010</b> , 12, 508-16                                                              | 107 |
| 1563 | [Palliative chemotherapy for colorectal cancer--current state, significance, trends]. <b>2010</b> , 135, 535-40                                                                                                                                 | 1   |
| 1562 | Predictive genomic biomarkers. <b>2012</b> , 355, 173-88                                                                                                                                                                                        | 1   |
| 1561 | KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence. <b>2010</b> , 10, 813-23                                                                                                                              | 5   |
| 1560 | Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab. <b>2010</b> , 97, E9-E15                                                                    | 4   |
| 1559 | Application of a pharmacogenetic test adoption model to six oncology biomarkers. <b>2010</b> , 7, 441-450                                                                                                                                       | 19  |
| 1558 | Recent advances in cancer therapy: an overview. <b>2010</b> , 16, 3-10                                                                                                                                                                          | 232 |
| 1557 | Molecular bases of liver cancer refractoriness to pharmacological treatment. <b>2010</b> , 17, 709-40                                                                                                                                           | 50  |
| 1556 | [Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer]. <b>2010</b> , 97, 265-80                                                                                                          | 2   |
| 1555 | Targeted therapeutic agents for colorectal cancer. <b>2010</b> , 39, 601-13                                                                                                                                                                     | 19  |
| 1554 | Preface: Promises kept: robust discovery in psychiatric genetics. <b>2010</b> , 33, xiii-xvi                                                                                                                                                    |     |

|      |                                                                                                                                                                                                                        |     |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1553 | Molecular Testing in Colorectal Carcinoma. <b>2010</b> , 3, 429-45                                                                                                                                                     | 1   |
| 1552 | Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. <b>2010</b> , 11, 1149-67                                                    | 107 |
| 1551 | Treatment of Colorectal Cancer. <b>2010</b> , 359-388                                                                                                                                                                  |     |
| 1550 | Alterations in VHL as potential biomarkers in renal-cell carcinoma. <b>2010</b> , 7, 277-88                                                                                                                            | 126 |
| 1549 | Personalized medicine in oncology: tailoring the right drug to the right patient. <b>2010</b> , 4, 523-33                                                                                                              | 26  |
| 1548 | Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. <b>2010</b> , 67, 86-92 | 19  |
| 1547 | Metastatic colorectal cancer: from improved survival to potential cure. <b>2010</b> , 78, 237-48                                                                                                                       | 183 |
| 1546 | Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. <b>2010</b> , 9, 203                                                     | 22  |
| 1545 | Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. <b>2010</b> , 9, 75                                                                                                                   | 167 |
| 1544 | TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status. <b>2010</b> , 8, 15                                                                               | 6   |
| 1543 | KRAS mutation screening in colorectal cancer: From paper to practice. <b>2010</b> , 9, 22-30                                                                                                                           | 16  |
| 1542 | A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. <b>2010</b> , 9, 102-7                                                                            | 17  |
| 1541 | Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. <b>2010</b> , 138, 2163-76                                                             | 74  |
| 1540 | KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. <b>2010</b> , 12, 35-42                                                           | 77  |
| 1539 | Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. <b>2010</b> , 16, 790-9                                                     | 369 |
| 1538 | Pharmacogenetics: Making cancer treatment safer and more effective. <b>2010</b> ,                                                                                                                                      | 1   |
| 1537 | Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. <b>2010</b> , 28, 1254-61                                                                                                        | 582 |
| 1536 | Molecular predictive and prognostic markers in colon cancer. <b>2010</b> , 36, 550-6                                                                                                                                   | 51  |

|      |                                                                                                                                                                                       |      |     |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 1535 | Topics in clinical pharmacology: renal, gastrointestinal, and pain management. <b>2010</b> , 56, 187-250                                                                              |      | 1   |
| 1534 | Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation. <b>2010</b> , 46, 869-79                                                           |      | 42  |
| 1533 | Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. <b>2010</b> , 46, 1997-2009                   |      | 179 |
| 1532 | Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. <b>2010</b> , 46, 2781-7            |      | 74  |
| 1531 | The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. <b>2010</b> , 36 Suppl 1, S1-10                   |      | 21  |
| 1530 | Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. <b>2010</b> , 36 Suppl 3, S56-61               |      | 83  |
| 1529 | Rehabilitation secondaire des métastases hépatiques initialement non résectables chez les patients porteurs d'un cancer colorectal : un véritable enjeu !. <b>2010</b> , 147, S40-S54 |      |     |
| 1528 | Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues. <b>2010</b> , 12, 27-34                                                    |      | 25  |
| 1527 | Genomic and biological characterization of exon 4 KRAS mutations in human cancer. <i>Cancer Research</i> , <b>2010</b> , 70, 5901-11                                                  | 10.1 | 218 |
| 1526 | Cancer Gene Profiling. <b>2010</b> ,                                                                                                                                                  |      | 1   |
| 1525 | What can the molecular pathologist offer for optimal decision making?. <b>2010</b> , 21 Suppl 7, vii123-9                                                                             |      | 3   |
| 1524 | KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers. <b>2010</b> , 109, 123-43                                                                     |      | 10  |
| 1523 | Molecular biomarkers: a US FDA effort. <b>2010</b> , 4, 215-25                                                                                                                        |      | 17  |
| 1522 | New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. <b>2010</b> , 16, 2489-95                                            |      | 89  |
| 1521 | Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling. <b>2010</b> , 28, 775-87                                                            |      | 15  |
| 1520 | Targeted treatments in colorectal cancer: state of the art and future perspectives. <b>2010</b> , 59, 838-58                                                                          |      | 38  |
| 1519 | ACB-PCR Quantification of K-RAS Codon 12 GAT and GTT Mutant Fraction in Colon Tumor and Non-Tumor Tissue. <b>2010</b> , 28, 364-375                                                   |      | 36  |
| 1518 | EGFR and KRAS in colorectal cancer. <b>2010</b> , 51, 71-119                                                                                                                          |      | 83  |

|      |                                                                                                                                                                                                                                                           |      |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 1517 | Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. <b>2011</b> , 22, 1535-1546                                                                                   | 572  |
| 1516 | . <b>2011</b> ,                                                                                                                                                                                                                                           | 1    |
| 1515 | Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. <b>2011</b> , 11, 519-31                                                                                  | 3    |
| 1514 | Sensitive quantification of somatic mutations using molecular inversion probes. <b>2011</b> , 83, 8215-21                                                                                                                                                 | 6    |
| 1513 | Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. <b>2011</b> , 29, 2011-9                         | 1463 |
| 1512 | KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. <b>2011</b> , 17, 1122-30                                                                                                                        | 161  |
| 1511 | Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. <b>2011</b> , 13, 64-73                                                       | 120  |
| 1510 | [In practice for the pathologist: practical and technical limitations]. <b>2011</b> , 31, S43-5                                                                                                                                                           |      |
| 1509 | Digestive oncology and the next generation of gastroenterologists. <b>2011</b> , 43, 665                                                                                                                                                                  | 1    |
| 1508 | Comment to "risk factors for serum alanine aminotransferase elevation: a cross-sectional study of healthy adult males in Tokyo, Japan". <b>2011</b> , 43, 665-6                                                                                           | 1    |
| 1507 | Individualizing therapy of monoclonal antibodies and fusion proteins: emerging potential in the age of personalized medicine. <b>2011</b> , 2, 369-81                                                                                                     | 2    |
| 1506 | Exome sequencing reveals comprehensive genomic alterations across eight cancer cell lines. <b>2011</b> , 6, e21097                                                                                                                                        | 27   |
| 1505 | Targeted biotherapy in metastatic colorectal carcinoma: Current practice. <b>2011</b> , 148, 12-8                                                                                                                                                         | 12   |
| 1504 | Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. <b>2011</b> , 12, 113-24                                                                                              | 81   |
| 1503 | Optimal management of metastatic colorectal cancer: current status. <b>2011</b> , 71, 869-84                                                                                                                                                              | 8    |
| 1502 | Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. <b>2011</b> , 10, 63-9                                        | 35   |
| 1501 | Intramural and mesorectal distal spread detected by whole-mount sections in the determination of optimal distal resection margin in patients undergoing surgery for rectosigmoid or rectal cancer without preoperative therapy. <b>2011</b> , 54, 1510-20 | 39   |
| 1500 | Implementing prognostic and predictive biomarkers in CRC clinical trials. <b>2011</b> , 8, 222-32                                                                                                                                                         | 104  |

|      |                                                                                                                                                                                                                                                                           |     |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1499 | Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. <b>2011</b> , 29, 1050-8 | 92  |
| 1498 | Principles of Anticancer Drug Development. <b>2011</b> ,                                                                                                                                                                                                                  |     |
| 1497 | A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue. <b>2011</b> , 49, 191-5                                            | 14  |
| 1496 | Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing. <b>2011</b> , 12, R124                                                                                                                                                 | 73  |
| 1495 | Gastrointestinal Oncology. <b>2011</b> ,                                                                                                                                                                                                                                  |     |
| 1494 | Cancer Systems Biology, Bioinformatics and Medicine. <b>2011</b> ,                                                                                                                                                                                                        | 3   |
| 1493 | A high expression EGFR/cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening EGFR antagonists from Rhizoma Polygoni Cuspidati. <b>2011</b> , 1, 115-120                                                   | 10  |
| 1492 | Development of molecular biomarkers in individualized treatment of colorectal cancer. <b>2011</b> , 10, 279-89                                                                                                                                                            | 22  |
| 1491 | All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. <b>2011</b> , 37, 221-33                                                                           | 39  |
| 1490 | Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib. <b>2011</b> , 306, 85-91                                                                                                           | 10  |
| 1489 | A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. <b>2011</b> , 47, 1343-54                                                             | 53  |
| 1488 | Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. <b>2011</b> , 17, 5935-44                                                                                                            | 76  |
| 1487 | Integrating predictive biomarkers and classifiers into oncology clinical development programmes. <b>2011</b> , 10, 735-48                                                                                                                                                 | 76  |
| 1486 | ThÉrapies ciblÉes dans le traitement des cancers colorectaux mÉtastatiques : place actuelle. <b>2011</b> , 148, 12-19                                                                                                                                                     |     |
| 1485 | A model of primary culture of colorectal cancer and liver metastasis to predict chemosensitivity. <b>2011</b> , 166, 247-54                                                                                                                                               | 8   |
| 1484 | Pharmacogenomic biomarkers: new tools in current and future drug therapy. <b>2011</b> , 32, 72-81                                                                                                                                                                         | 78  |
| 1483 | KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. <b>2011</b> , 12, 594-603                                                                                                                                    | 453 |
| 1482 | Molecular Detection of Circulating Tumor Cells With Multiple mRNA Markers by Genechip for Colorectal Cancer Early Diagnosis and Prognosis Prediction. <b>2011</b> , 3, 9-16                                                                                               | 0   |

|      |                                                                                                                                                                                                          |     |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1481 | Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study. <b>2011</b> , 81, 677-83              | 50  |
| 1480 | KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. <b>2011</b> , 81, 1032-8                                     | 45  |
| 1479 | Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. <b>2011</b> , 377, 2103-14 | 762 |
| 1478 | Trastuzumab-Resistance and Breast Cancer. <b>2011</b> ,                                                                                                                                                  | 1   |
| 1477 | Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues. <b>2010</b> , 2, 26-35                                             | 19  |
| 1476 | EGFR genomic alterations in cancer: prognostic and predictive values. <b>2011</b> , 3, 879-87                                                                                                            | 23  |
| 1475 | Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors. <b>2011</b> , 15, 501-8                                                                    | 11  |
| 1474 | EGFR Signaling in Colorectal Carcinoma. <b>2011</b> , 2011, 932932                                                                                                                                       | 81  |
| 1473 | The Role of Genetics. <b>2011</b> , 26, 38-43                                                                                                                                                            |     |
| 1472 | Novel Oncology Drug Development Strategies in the Era of Personalised Medicine. <b>2011</b> ,                                                                                                            |     |
| 1471 | Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in 2 <sup>nd</sup> line cetuximab-based therapy of colorectal cancer patients. <b>2011</b> , 6, e15980                 | 101 |
| 1470 | Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. <b>2011</b> , 6, e25080                         | 28  |
| 1469 | Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. <b>2011</b> , 9, 13-25                                                             | 28  |
| 1468 | New directions in neoadjuvant therapy for rectal cancer. <b>2011</b> , 22, 351-361                                                                                                                       |     |
| 1467 | Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. <b>2011</b> , 54, 1170-8                                                 | 63  |
| 1466 | Molecular predictors of response to chemotherapy in colorectal cancer. <b>2011</b> , 17, 114-26                                                                                                          | 31  |
| 1465 | Personalized medicine: are payers the weak link?. <b>2011</b> , 8, 293-296                                                                                                                               | 1   |
| 1464 | Tumor genotyping for breast cancer: at the front door. <b>2011</b> , 8, 383-385                                                                                                                          |     |



|      |                                                                                                                                                                                                                                                    |     |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1463 | Predicting tumour response to anti-HER1 therapy using medical imaging: a literature review and in vitro study of [18F]-FDG incorporation by breast cancer cells responding to cetuximab. <b>2011</b> , 68, 158-66                                  | 5   |
| 1462 | The effect of a dimeric Affibody molecule (ZEGFR:1907) <sub>2</sub> targeting EGFR in combination with radiation in colon cancer cell lines. <b>2012</b> , 40, 176-84                                                                              | 6   |
| 1461 | Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. <b>2011</b> , 154, 37-49                                                                                   | 131 |
| 1460 | Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis. <b>2011</b> , 25, 789-94                                                                                                                 | 42  |
| 1459 | Mechanism of EGFR-related cancer drug resistance. <b>2011</b> , 22, 963-70                                                                                                                                                                         | 7   |
| 1458 | Molecular detection of epidermal growth factor receptor in colorectal cancer: does it still make sense?. <b>2011</b> , 13, 542-8                                                                                                                   | 3   |
| 1457 | KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma. <b>2011</b> , 22, 358-64                                                                                          | 24  |
| 1456 | Detection of KRAS mutations in tumor cells using biochips. <b>2011</b> , 45, 797-803                                                                                                                                                               | 3   |
| 1455 | Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. <b>2011</b> , 30, 561-74                                                                                                                                                          | 105 |
| 1454 | Towards novel paradigms for cancer therapy. <b>2011</b> , 30, 1-20                                                                                                                                                                                 | 93  |
| 1453 | Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma. <b>2011</b> , 47, 946-50                                                                                                                                           | 47  |
| 1452 | Predictive molecular classifiers in colorectal cancer. <b>2011</b> , 38, 576-87                                                                                                                                                                    | 22  |
| 1451 | Regulation of homeostasis and oncogenesis in the intestinal epithelium by Ras. <b>2011</b> , 317, 2732-9                                                                                                                                           | 12  |
| 1450 | Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. <b>2011</b> , 212, 1008-1017.e1                                                                                             | 30  |
| 1449 | Colon Cancer. <b>2011</b> , 325-377                                                                                                                                                                                                                |     |
| 1448 | Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. <b>2011</b> , 29, 3783-90 | 70  |
| 1447 | Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. <b>2011</b> , 11, 2156-66                                                                                                                                | 389 |
| 1446 | Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs. <b>2011</b> , 12, 827-43                                                                                     | 13  |

|      |                                                                                                                                                                                                         |    |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1445 | Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. <b>2011</b> , 28, 427-35                                                                                            | 40 |
| 1444 | KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. <b>2011</b> , 38, 1315-20                                                                                           | 27 |
| 1443 | PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population. <b>2011</b> , 38, 1347-51                                                                        | 12 |
| 1442 | BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. <b>2011</b> , 38, 2219-23                                         | 63 |
| 1441 | Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. <b>2011</b> , 26, 823-33                                                                                                | 49 |
| 1440 | Pathophysiologie und Molekular Diagnostik beim nichtkleinzelligen Lungenkarzinom. <b>2011</b> , 17, 670-678                                                                                             |    |
| 1439 | [Molecular diagnostics of lung cancer for treatment stratification]. <b>2011</b> , 52, 146, 148-50, 152-4                                                                                               | 3  |
| 1438 | Overview of the development of personalized genomic medicine and surgery. <b>2011</b> , 35, 1693-9                                                                                                      | 13 |
| 1437 | Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. <b>2011</b> , 68, 1045-55      | 59 |
| 1436 | Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. <b>2011</b> , 68, 1207-13                                                                    | 58 |
| 1435 | [WHO classification 2010 for the lower gastrointestinal tract: what is new?]. <b>2011</b> , 32 Suppl 2, 326-31                                                                                          | 10 |
| 1434 | Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications. <b>2011</b> , 34, 155-76                                                                 | 42 |
| 1433 | Treatment recommendations for metastatic colorectal cancer. <b>2011</b> , 13, 162-78                                                                                                                    | 21 |
| 1432 | Multidisciplinary approach of colorectal liver metastases. <b>2011</b> , 13, 721-7                                                                                                                      | 14 |
| 1431 | Phospho-STAT5 expression is associated with poor prognosis of human colonic adenocarcinoma. <b>2011</b> , 17, 333-9                                                                                     | 10 |
| 1430 | Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. <b>2011</b> , 32, 417-24 | 12 |
| 1429 | Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. <b>2011</b> , 6, 133-45                                                                | 40 |
| 1428 | Future Solutions for Patients with Metastatic Colorectal Cancer Positive for K-RAS Mutations. <b>2011</b> , 7, 275-280                                                                                  |    |

|      |                                                                                                                                                                                                |     |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1427 | Predictive and prognostic markers in colorectal cancer. <b>2011</b> , 13, 206-15                                                                                                               | 39  |
| 1426 | EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer. <b>2011</b> , 11, 107                                   | 15  |
| 1425 | A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. <b>2011</b> , 9, 204                | 412 |
| 1424 | Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. <b>2011</b> , 223, 15-27                                                                   | 37  |
| 1423 | The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. <b>2011</b> , 223, 295-306                                                              | 38  |
| 1422 | The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. <b>2011</b> , 104, 661-6 | 12  |
| 1421 | Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. <b>2011</b> , 55, 832-43                                                                               | 91  |
| 1420 | The inhibitory effects of 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone on human colon cancer cells. <b>2011</b> , 55, 1523-32                                                                    | 28  |
| 1419 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. <b>2011</b> , 226, 2762-81                                                           | 124 |
| 1418 | Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. <b>2011</b> , 50, 307-12                                                                                                     | 274 |
| 1417 | Targeted anti-cancer therapy in the elderly. <b>2011</b> , 78, 227-42                                                                                                                          | 27  |
| 1416 | Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. <b>2011</b> , 78, 243-51   | 26  |
| 1415 | Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. <b>2011</b> , 79, 224-50                                                        | 30  |
| 1414 | Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases. <b>2011</b> , 207, 399-402                                                       | 5   |
| 1413 | XELOX in colorectal cancer: a convenient option for the future?. <b>2011</b> , 5, 9-19                                                                                                         | 4   |
| 1412 | Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. <b>2011</b> , 24, 1090-100                                                                             | 75  |
| 1411 | Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. <b>2011</b> , 11, 777-92                                                                                         | 170 |
| 1410 | Epidermal growth factor receptor pathway mutations and colorectal cancer therapy. <b>2011</b> , 135, 1278-82                                                                                   | 17  |

|      |                                                                                                                                                                                                                                                                                  |         |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 1409 | Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer. <b>2011</b> , 15, 777-83                                                                                                                                          | 16      |
| 1408 | Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. <i>Cancer Research</i> , <b>2011</b> , 71, 1041-9                                                                                                                                         | 10.1 62 |
| 1407 | Colorectal cancer molecular biology moves into clinical practice. <b>2011</b> , 60, 116-29                                                                                                                                                                                       | 235     |
| 1406 | Rapid and sensitive detection of KRAS mutation after fast-COLD-PCR enrichment and high-resolution melting analysis. <b>2011</b> , 20, 81-9                                                                                                                                       | 17      |
| 1405 | EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients. <b>2011</b> , 17, 382-90                                                                                        | 25      |
| 1404 | Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. <b>2011</b> , 17, 3469-77                                                                                                                                                        | 48      |
| 1403 | Biology-driven phase II trials: what is the optimal model for molecular selection?. <b>2011</b> , 29, 1236-8                                                                                                                                                                     | 56      |
| 1402 | Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. <b>2011</b> , 22, 235-237                                                                                                                                   | 137     |
| 1401 | Predictors of lithium response in bipolar disorder. <b>2011</b> , 2, 209-26                                                                                                                                                                                                      | 42      |
| 1400 | Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. <b>2011</b> , 29, 3419-26                                                                                                                       | 299     |
| 1399 | A new frontier in personalized cancer therapy: mapping molecular changes. <b>2011</b> , 7, 873-94                                                                                                                                                                                | 12      |
| 1398 | [Targeting the RAS signalling pathway in cancer]. <b>2011</b> , 98, 1019-28                                                                                                                                                                                                      | 8       |
| 1397 | The Effects of Storage Time of Colorectal Cancer Tissue on the Detection of K-rasGene. <b>2011</b> , 42, 478-481                                                                                                                                                                 | 2       |
| 1396 | Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. <b>2011</b> , 136, 228-38                                                                                                                                                       | 33      |
| 1395 | Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. <b>2011</b> , 12, 239-51                                                                                                                                                                     | 36      |
| 1394 | Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. <b>2011</b> , 22, 1078-1087 | 182     |
| 1393 | Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistance. <b>2011</b> , 10, 917-28                                                                                           | 21      |
| 1392 | Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. <b>2011</b> , 16, 1006-20                                                                                                                                                                        | 12      |

|      |                                                                                                                                                                                                                       |    |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1391 | External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. <b>2011</b> , 16, 467-78                                       | 75 |
| 1390 | KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. <b>2011</b> , 16, 1061-8                                                             | 14 |
| 1389 | Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. <b>2011</b> , 103, 1540-51                                                                                        | 58 |
| 1388 | Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer. <b>2011</b> , 41, 210-6                                                                              | 7  |
| 1387 | Where now for anti-EGF receptor therapies in colorectal cancer?. <b>2011</b> , 11, 1543-53                                                                                                                            | 2  |
| 1386 | Adaptive elastic-net sparse principal component analysis for pathway association testing. <b>2011</b> , 10,                                                                                                           | 6  |
| 1385 | Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. <b>2011</b> , 22, 1141-1146                            | 46 |
| 1384 | Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer patients. <b>2011</b> , 81, 359-64                        | 10 |
| 1383 | Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. <b>2011</b> , 39, 483-91 | 20 |
| 1382 | KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. <b>2011</b> , 25, 1691-7                                                                                  | 56 |
| 1381 | Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate. <b>2011</b> , 11, 368-70                                                                                                                 | 1  |
| 1380 | [Carcinoma of the anal canal: state of art, issues in geriatric oncology and molecular targeted therapies]. <b>2011</b> , 98, 146-53                                                                                  |    |
| 1379 | Curing patients with liver metastases from colorectal cancer. <b>2011</b> , 49, 42-5; quiz i-ii                                                                                                                       | 1  |
| 1378 | Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer. <b>2012</b> , 40, 217-26                                            | 9  |
| 1377 | Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens. <b>2011</b> , 64, 30-6                                                                                        | 19 |
| 1376 | Should oncologists be aware in their clinical practice of KRAS molecular analysis?. <b>2011</b> , 29, e206-7; author reply e208-9                                                                                     | 15 |
| 1375 | Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. <b>2011</b> , 105, 246-54                                                            | 23 |
| 1374 | EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. <b>2011</b> , 105, 255-62                                                       | 39 |

|      |                                                                                                                                                                                                               |         |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 1373 | One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. <b>2011</b> , 43, 539-49                                                                             | 41      |
| 1372 | Detection of KRAS and BRAF mutations in advanced colorectal cancer by allele-specific single-base primer extension. <b>2011</b> , 11, 799-802                                                                 | 5       |
| 1371 | Prognostic value of colorectal cancer biomarkers. <b>2011</b> , 3, 2080-105                                                                                                                                   | 3       |
| 1370 | MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. <i>Cancer Research</i> , <b>2011</b> , 71, 445-53 | 10.1 73 |
| 1369 | KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. <b>2011</b> , 17, 6338-46                                                            | 54      |
| 1368 | Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. <b>2011</b> , 48, 47-54                                                                                                         | 22      |
| 1367 | Biomarkers in advanced colorectal cancer: challenges in translating clinical research into practice. <b>2011</b> , 3, 1844-60                                                                                 | 1       |
| 1366 | EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. <b>2011</b> , 3, 2014-31                                                                                                | 23      |
| 1365 | KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues. <b>2011</b> , 12, 3191-204                                                                    | 48      |
| 1364 | Perspectives on the History and Evolution of Tumor Models. <b>2011</b> , 3-20                                                                                                                                 | 4       |
| 1363 | Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. <b>2011</b> , 17, 6329-37                                                                           | 77      |
| 1362 | Resistance--the true face of biological defiance. <b>2012</b> , 51, 413-22                                                                                                                                    | 3       |
| 1361 | Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer. <b>2012</b> , 2012, 198197                                                                                     | 3       |
| 1360 | The role of molecular pathology in non-small-cell lung carcinoma-now and in the future. <b>2012</b> , 19, S24-32                                                                                              | 25      |
| 1359 | High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. <b>2012</b> , 136, 983-92      | 35      |
| 1358 | MAPK14/p38 $\beta$ confers irinotecan resistance to TP53-defective cells by inducing survival autophagy. <b>2012</b> , 8, 1098-112                                                                            | 66      |
| 1357 | KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment. <b>2012</b> , 25, 731-9                                                                            | 27      |
| 1356 | The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together. <b>2012</b> , 109, 149-54                                                                            | 118     |

|      |                                                                                                                                                                                                        |     |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1355 | Hurdles in anticancer drug development from a regulatory perspective. <b>2012</b> , 9, 236-43                                                                                                          | 26  |
| 1354 | Hurdles and complexities of codon 13 KRAS mutations. <b>2012</b> , 30, 3565-7                                                                                                                          | 21  |
| 1353 | The flow-metabolic phenotype of primary colorectal cancer: assessment by integrated 18F-FDG PET/perfusion CT with histopathologic correlation. <b>2012</b> , 53, 687-92                                | 22  |
| 1352 | Genetic polymorphisms of FcR11a and FcR111a are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer. <b>2012</b> , 82, 83-9 | 18  |
| 1351 | KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach. <b>2012</b> , 63, 145-64                                    | 27  |
| 1350 | EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome. <b>2012</b> , 65, 133-9                                                                                      | 24  |
| 1349 | Therapeutic Kinase Inhibitors. <b>2012</b> ,                                                                                                                                                           | 1   |
| 1348 | KRAS mutational status of endoscopic biopsies matches resection specimens. <b>2012</b> , 65, 604-7                                                                                                     | 7   |
| 1347 | Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas. <b>2012</b> , 23, 3129-3137                                                             | 13  |
| 1346 | Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance. <b>2012</b> , 11, 1656-63                                                                        | 47  |
| 1345 | Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: implications for cancer therapy. <b>2012</b> , 12, 124-31          | 34  |
| 1344 | What can molecular pathology offer for optimal decision making?. <b>2012</b> , 23 Suppl 10, x63-70                                                                                                     | 2   |
| 1343 | KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. <b>2012</b> , 107, 340-4                                                                           | 24  |
| 1342 | Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas. <b>2012</b> , 65, 466-9                                                                    | 12  |
| 1341 | Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. <b>2012</b> , 109, E353-9                                                        | 42  |
| 1340 | Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. <b>2012</b> , 18, 688-99                  | 113 |
| 1339 | Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients. <b>2012</b> , 40, 1589-98                                     | 20  |
| 1338 | Unlabeled-probe high-resolution melting to detect KRAS codon 12 and 13 mutations in pancreatic adenocarcinoma tissues. <b>2012</b> , 50, 1035-40                                                       | 2   |

|      |                                                                                                                                                                                                                                           |    |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1337 | Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review. <b>2012</b> , 2012, 387172                                                             | 11 |
| 1336 | A Japanese post-marketing surveillance of cetuximab (Erbixim <sup>®</sup> ) in patients with metastatic colorectal cancer. <b>2012</b> , 42, 287-94                                                                                       | 36 |
| 1335 | Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumors. <b>2012</b> , 6, 407-19                                                                                                            | 4  |
| 1334 | Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. <b>2012</b> , 12, 316-28                                                                                                 | 23 |
| 1333 | Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials. <b>2012</b> , 13, 1525-34                                                                                                             | 27 |
| 1332 | Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. <b>2011</b> , 10, 63-9                                                                                                          | 32 |
| 1331 | Resistance to EGF receptor-targeted monoclonal antibodies in the management of advanced colorectal cancer. <b>2012</b> , 1, 137-148                                                                                                       | 1  |
| 1330 | Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. <b>2012</b> , 256, 642-50 | 51 |
| 1329 | Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis. <b>2012</b> , 23, 666-73                                                                  | 12 |
| 1328 | Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era. <b>2012</b> , 44, 166-80                                                                                   | 17 |
| 1327 | The prognostic value of KRAS mutations in patients with colorectal cancer. <b>2012</b> , 28, 1579-84                                                                                                                                      | 20 |
| 1326 | KRAS mutations and subtyping in colorectal cancer in Jordanian patients. <b>2012</b> , 4, 705-710                                                                                                                                         | 13 |
| 1325 | [EGFR/HER1: a target life]. <b>2012</b> , 99, 181-9                                                                                                                                                                                       | 2  |
| 1324 | Fluid biopsy for solid tumors: a patient's companion for lifelong characterization of their disease. <b>2012</b> , 8, 989-98                                                                                                              | 15 |
| 1323 | Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines. <b>2012</b> , 41, 733-44                                                                                                                         | 25 |
| 1322 | Recent advances in treatment of metastatic colorectal cancer. <b>2012</b> , 2, 1109-1122                                                                                                                                                  |    |
| 1321 | Development of an immunohistochemical protein quantification system in conjunction with tissue microarray technology for identifying predictive biomarkers for phosphatidylinositol 3-kinase inhibitors. <b>2012</b> , 35, 1607-13        | 4  |
| 1320 | Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. <b>2012</b> , 106, 1648-59                                                 | 34 |



|      |                                                                                                                                                                                                                                          |     |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1319 | Promoter CpG island methylation markers in colorectal cancer: the road ahead. <b>2012</b> , 4, 179-94                                                                                                                                    | 32  |
| 1318 | Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. <b>2012</b> , 11, 923-36                                                                                                                                    | 196 |
| 1317 | Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. <b>2012</b> , 14, 1023-31                                                                                                  | 78  |
| 1316 | Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. <b>2012</b> , 11, 291-6                                                                                                          | 29  |
| 1315 | A virtual pyrogram generator to resolve complex pyrosequencing results. <b>2012</b> , 14, 149-59                                                                                                                                         | 19  |
| 1314 | Genetic and epigenetic biomarkers of colorectal cancer. <b>2012</b> , 10, 9-15                                                                                                                                                           | 31  |
| 1313 | Molecular Pathology of Gastrointestinal Cancer. <b>2012</b> , 5, 821-42                                                                                                                                                                  |     |
| 1312 | A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. <b>2012</b> , 8, 1553-70                                                               | 28  |
| 1311 | PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. <b>2012</b> , 23, 1518-25                     | 135 |
| 1310 | K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy. <b>2012</b> , 19 Suppl 3, S675-81                                   | 38  |
| 1309 | A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. <b>2012</b> , 61, 673-84                                      | 476 |
| 1308 | What are we learning from the cancer genome?. <b>2012</b> , 9, 621-30                                                                                                                                                                    | 43  |
| 1307 | Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. <b>2012</b> , 12, 593-602                                                                                                                  | 70  |
| 1306 | Tripitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. <b>2012</b> , 422, 532-44                                                                                                | 27  |
| 1305 | Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach. <b>2012</b> , 43, 1157-68                                                                       | 21  |
| 1304 | PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. <b>2012</b> , 11, 143-50 | 80  |
| 1303 | Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. <b>2012</b> , 48, 1466-75                             | 432 |
| 1302 | From drug discovery to biomarker-driven clinical trials in lymphoma. <b>2012</b> , 9, 643-53                                                                                                                                             | 23  |

|      |                                                                                                                                                                                                                                              |    |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1301 | Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer. <b>2012</b> , 12, 548                                                                                     | 11 |
| 1300 | Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report. <b>2012</b> , 10, 129                                                                     |    |
| 1299 | Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. <b>2012</b> , 10, 87                                                                                           | 31 |
| 1298 | Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis. <b>2012</b> , 7, 56                                                                                                                         | 19 |
| 1297 | EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis. <b>2012</b> , 5, 52                                                                 | 32 |
| 1296 | Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. <b>2012</b> , 83, 241-7 | 20 |
| 1295 | KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. <b>2012</b> , 107, 1997-2004                                                                                       | 52 |
| 1294 | Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice. <b>2012</b> , 13, 663-75                                                                                                                   | 17 |
| 1293 | Predictors of EGF receptor monoclonal antibody activity in metastatic colorectal cancer: current status. <b>2012</b> , 1, 423-432                                                                                                            |    |
| 1292 | Functional drug-gene interactions in lung cancer. <b>2012</b> , 12, 291-302                                                                                                                                                                  | 5  |
| 1291 | Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine. <b>2012</b> , 137, 847-59                                                                                                              | 36 |
| 1290 | A framework for understanding cancer comparative effectiveness research data needs. <b>2012</b> , 65, 1150-8                                                                                                                                 | 21 |
| 1289 | Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer. <b>2012</b> , 36, 341-6                                                                   | 8  |
| 1288 | The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. <b>2012</b> , 36, 490-6                                                                                                                           | 61 |
| 1287 | Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. <b>2012</b> , 84, 301-13                                                                                                       | 60 |
| 1286 | MicroRNA and colorectal cancer. <b>2012</b> , 44, 195-200                                                                                                                                                                                    | 59 |
| 1285 | Chemoprevention in colorectal cancer--where we stand and what we have learned from twenty year's experience. <b>2012</b> , 10, 43-52                                                                                                         | 17 |
| 1284 | KRAS and BRAF mutations in sinonasal cancer. <b>2012</b> , 48, 692-7                                                                                                                                                                         | 47 |

|      |                                                                                                                                                                                                          |     |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1283 | Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. <b>2012</b> , 6, 15-26                                                                                         | 62  |
| 1282 | Co-development of a companion diagnostic for targeted cancer therapy. <b>2012</b> , 29, 682-8                                                                                                            | 34  |
| 1281 | Clinical update: colon, rectal, and anal cancers. <b>2012</b> , 28, e1-22                                                                                                                                | 11  |
| 1280 | Targeted therapies: how personal should we go?. <b>2011</b> , 9, 87-97                                                                                                                                   | 87  |
| 1279 | Le statut mutationnel de KRAS est prédictif de la réponse au cetuximab dans le cancer colorectal. <b>2012</b> , 6, 256-258                                                                               |     |
| 1278 | Study of KRAS new predictive marker in a clinical laboratory. <b>2012</b> , 14, 937-42                                                                                                                   | 3   |
| 1277 | Prognostic and predictive roles of KRAS mutation in colorectal cancer. <b>2012</b> , 13, 12153-68                                                                                                        | 135 |
| 1276 | Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. <b>2012</b> , 18, 382-4                                                                                         | 664 |
| 1275 | Molecular Characterization of Head and Neck Cancer. <b>2012</b> , 16, 209-222                                                                                                                            | 20  |
| 1274 | KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. <b>2012</b> , 7, e50701                                                                                                   | 30  |
| 1273 | Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas. <b>2012</b> , 59, 508-15 | 30  |
| 1272 | Histopathological growth pattern, proteolysis and angiogenesis in chemo-naïve patients resected for multiple colorectal liver metastases. <b>2012</b> , 2012, 907971                                     | 36  |
| 1271 | [Genomics and clinical research for breast cancer]. <b>2012</b> , 28 Spec No 1, 14-8                                                                                                                     | 2   |
| 1270 | Improving the limit of detection for Sanger sequencing: a comparison of methodologies for KRAS variant detection. <b>2012</b> , 53, 182-8                                                                | 34  |
| 1269 | Therapeutic targeting of the epidermal growth factor receptor in human cancer. <b>2012</b> , 17, 31-50                                                                                                   | 51  |
| 1268 | Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?. <b>2012</b> , 12, 163-71                                                                                  | 93  |
| 1267 | Serum concentrations of human chorionic gonadotropin beta and its association with survival in patients with colorectal cancer. <b>2012</b> , 11, 173-81                                                 | 6   |
| 1266 | Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients. <b>2012</b> , 27, e366-74                                                                       | 16  |

|      |                                                                                                                                                                                                       |     |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1265 | Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma. <b>2013</b> , 60, 83-91                                                                  | 3   |
| 1264 | Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies. <b>2012</b> , 6, 42-59                                                                            | 13  |
| 1263 | High-expression EGFR/cell membrane chromatography-online-high-performance liquid chromatography/mass spectrometry: rapid screening of EGFR antagonists from Semen Strychni. <b>2012</b> , 26, 2027-32 | 22  |
| 1262 | Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. <b>2012</b> , 18, 1177-85              | 214 |
| 1261 | Chapter 11:Combination Agents Versus Multi-Targeted Agents [Pros and Cons. <b>2012</b> , 155-180                                                                                                      | 4   |
| 1260 | Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. <b>2012</b> , 30, 282-90                                                        | 571 |
| 1259 | The ERBB network: at last, cancer therapy meets systems biology. <b>2012</b> , 12, 553-63                                                                                                             | 600 |
| 1258 | Cancer Biomarkers for Diagnosis, Prognosis and Therapy. <b>2012</b> , 18-68                                                                                                                           | 1   |
| 1257 | Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma. <b>2012</b> , 34, 663-6                                                                          | 21  |
| 1256 | Data for cancer comparative effectiveness research: past, present, and future potential. <b>2012</b> , 118, 5186-97                                                                                   | 22  |
| 1255 | The complex intratumoral heterogeneity of colon cancer highlighted by laser microdissection. <b>2012</b> , 57, 1271-80                                                                                | 12  |
| 1254 | KRAS und weitere Signalmoleküle ff die Therapieentscheidung beim metastasierten Kolonkarzinom. <b>2012</b> , 7, 24-29                                                                                 | 1   |
| 1253 | Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. <b>2012</b> , 69, 1647-55                  | 27  |
| 1252 | Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer. <b>2012</b> , 47, 266-75                                                                   | 18  |
| 1251 | Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. <b>2012</b> , 42, 460-9                                               | 28  |
| 1250 | Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells. <b>2012</b> , 24, 162-9                                                                        | 58  |
| 1249 | KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. <b>2012</b> , 61, 1036-42                                                                                      | 17  |
| 1248 | Phosphorylation of epidermal growth factor receptor and chromosome 7 polysomy in gastric adenocarcinoma. <b>2012</b> , 13, 350-9                                                                      | 3   |

|      |                                                                                                                                                                                                  |     |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1247 | Immunotherapy for treating metastatic colorectal cancer. <b>2012</b> , 21, 67-77                                                                                                                 | 9   |
| 1246 | CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. <b>2012</b> , 48, 585-93                                              | 49  |
| 1245 | Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy. <b>2012</b> , 103, 791-6    | 25  |
| 1244 | MicroRNA profiling differentiates colorectal cancer according to KRAS status. <b>2012</b> , 51, 1-9                                                                                              | 89  |
| 1243 | Competitive amplification of differentially melting amplicons (CADMA) enables sensitive and direct detection of all mutation types by high-resolution melting analysis. <b>2012</b> , 33, 264-71 | 17  |
| 1242 | PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. <b>2012</b> , 227, 927-33                             | 5   |
| 1241 | Clinical Implications and Quality Assurance of Molecular Testing for EGFR-Targeting Agents in Colorectal Cancer. <b>2012</b> , 8, 42-50                                                          | 4   |
| 1240 | First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. <b>2012</b> , 138, 65-72                                               | 68  |
| 1239 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. <b>2012</b> , 17, 1-29                                                       | 578 |
| 1238 | Biologie moléculaire et prise en charge des cancers colorectaux. <b>2012</b> , 14, 45-51                                                                                                         |     |
| 1237 | Increased radioresistance via G12S K-Ras by compensatory upregulation of MAPK and PI3K pathways in epithelial cancer. <b>2013</b> , 35, 220-8                                                    | 23  |
| 1236 | Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. <b>2013</b> , 119, 266-76                                                          | 28  |
| 1235 | EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines. <b>2013</b> , 42, 26-36                                                              | 44  |
| 1234 | Targeted therapies in colorectal cancer-an integrative view by PPPM. <b>2013</b> , 4, 3                                                                                                          | 57  |
| 1233 | Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. <b>2013</b> , 34, 8690-707                                                                              | 323 |
| 1232 | KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. <b>2013</b> , 133, 130-41                                    | 111 |
| 1231 | Resistance to Immunotherapeutic Antibodies in Cancer. <b>2013</b> ,                                                                                                                              | 1   |
| 1230 | Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery. <b>2013</b> , 13, 200                                                     | 20  |

|      |                                                                                                                                                                                            |     |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1229 | Fool's gold, lost treasures, and the randomized clinical trial. <b>2013</b> , 13, 193                                                                                                      | 36  |
| 1228 | Pharmacogenetics and Pharmacogenomics. <b>2013</b> , 1-27                                                                                                                                  |     |
| 1227 | Integrin $\beta$ 1 subunit is up-regulated in colorectal cancer. <b>2013</b> , 1, 16                                                                                                       | 21  |
| 1226 | Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer. <b>2013</b> , 30, 620                                                                     | 31  |
| 1225 | A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. <b>2013</b> , 139, 367-78              | 24  |
| 1224 | Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. <b>2013</b> , 20, 223-33                                                             | 42  |
| 1223 | Newer Agents in Colon Cancer: What's Next?. <b>2013</b> , 9, 74-84                                                                                                                         |     |
| 1222 | Next Generation Sequencing in Cancer Research. <b>2013</b> ,                                                                                                                               | 4   |
| 1221 | Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. <b>2013</b> , 71, 389-97                    | 11  |
| 1220 | Molecular alterations of EGFR in small intestinal adenocarcinoma. <b>2013</b> , 28, 1329-35                                                                                                | 9   |
| 1219 | Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?. <b>2013</b> , 2, 185                            | 1   |
| 1218 | Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms. <b>2013</b> , 30, 329-61                                                                 | 10  |
| 1217 | Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models. <b>2013</b> , 15, 125-32                                                      | 8   |
| 1216 | Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. <b>2013</b> , 59, 1722-31                                     | 377 |
| 1215 | Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients. <b>2013</b> , 30, 686                                                                | 32  |
| 1214 | The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. <b>2013</b> , 12, 267-274.e2 | 14  |
| 1213 | Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer. <b>2013</b> , 94, 155-9                                                                                 | 19  |
| 1212 | Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. <b>2013</b> , 24, 1267-73                                                     | 79  |

|      |                                                                                                                                                                                                                                                        |         |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 1211 | K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. <b>2013</b> , 503, 548-51                                                                                                                                        | 1133    |
| 1210 | Circulating tumor cells in colorectal cancer patients. <b>2013</b> , 39, 759-72                                                                                                                                                                        | 40      |
| 1209 | Liquid Chromatography Coupled to Mass Spectrometry-Based Metabolomics and the Concept of Biomarker. <b>2013</b> , 67, 159-218                                                                                                                          | 5       |
| 1208 | Sensitive, simultaneous quantitation of two unlabeled DNA targets using a magnetic nanoparticle-enzyme sandwich assay. <b>2013</b> , 85, 9238-44                                                                                                       | 30      |
| 1207 | Evaluating many treatments and biomarkers in oncology: a new design. <b>2013</b> , 31, 4562-8                                                                                                                                                          | 105     |
| 1206 | Molecular Pathology of Neoplastic Gastrointestinal Diseases. <b>2013</b> ,                                                                                                                                                                             | 2       |
| 1205 | Resistance to targeted therapies: a role for microRNAs?. <b>2013</b> , 19, 633-42                                                                                                                                                                      | 24      |
| 1204 | Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. <b>2013</b> , 119, 4137-44                                                                                                   | 133     |
| 1203 | Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. <b>2013</b> , 72, 643-52 | 18      |
| 1202 | EGFR and HER2 inhibition in pancreatic cancer. <b>2013</b> , 31, 558-66                                                                                                                                                                                | 21      |
| 1201 | Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review. <b>2013</b> , 31, 215-28                                                                         | 23      |
| 1200 | Biomarkers in Oncology. <b>2013</b> ,                                                                                                                                                                                                                  | 1       |
| 1199 | Cancer drug resistance: an evolving paradigm. <b>2013</b> , 13, 714-26                                                                                                                                                                                 | 2864    |
| 1198 | Sensitive detection of KRAS mutations using enhanced-ice-COLD-PCR mutation enrichment and direct sequence identification. <b>2013</b> , 34, 1568-80                                                                                                    | 34      |
| 1197 | Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!. <b>2013</b> , 14, 2203-20                                                                                 | 4       |
| 1196 | Clinical and economic challenges facing pharmacogenomics. <b>2013</b> , 13, 378-88                                                                                                                                                                     | 45      |
| 1195 | Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. <i>Cancer Research</i> , <b>2013</b> , 73, 6770-9                                                                                           | 10.1 61 |
| 1194 | Challenges and opportunities for oncology biomarker discovery. <b>2013</b> , 18, 614-24                                                                                                                                                                | 37      |

|      |                                                                                                                                                                                                                            |     |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1193 | Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. <b>2013</b> , 13, 241-55                                                     | 44  |
| 1192 | GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. <b>2013</b> , 19, 1126-38                                                 | 89  |
| 1191 | Ovarian cancer : making its own rules-again. <b>2013</b> , 119, 474-6                                                                                                                                                      | 10  |
| 1190 | Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer. <b>2013</b> , 12, 28-36                                                            | 35  |
| 1189 | The KRAS StripAssay for detection of KRAS mutation in Egyptian patients with colorectal cancer (CRC): a pilot study. <b>2013</b> , 25, 37-41                                                                               | 4   |
| 1188 | Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer. <b>2013</b> , 6, 363-9                                                                          | 7   |
| 1187 | The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. <b>2013</b> , 44, 2768-73                                                                        | 66  |
| 1186 | Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. <b>2013</b> , 95, 74-82                                                                                            | 12  |
| 1185 | Comparison of KRAS genotype: the raser screen assay vs. LNA-mediated qPCR clamping assay. <b>2013</b> , 12, 195-203.e3                                                                                                     |     |
| 1184 | Second-line therapy in advanced biliary tract cancer: what should be the standard?. <b>2013</b> , 88, 368-74                                                                                                               | 17  |
| 1183 | Cancer concepts and principles: primer for the interventional oncologist-part II. <b>2013</b> , 24, 1167-88                                                                                                                | 20  |
| 1182 | Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay. <b>2013</b> , 209, 233-6                                                                     | 18  |
| 1181 | Tumor prognostic factors and the challenge of developing predictive factors. <b>2013</b> , 15, 33-46                                                                                                                       | 1   |
| 1180 | New paradigms and future challenges in radiation oncology: an update of biological targets and technology. <b>2013</b> , 5, 173sr2                                                                                         | 151 |
| 1179 | Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. <b>2013</b> , 462, 329-35          | 29  |
| 1178 | Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. <b>2013</b> , 18, 670-7 | 23  |
| 1177 | Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. <b>2013</b> , 14, 315-24                                                                                                                 | 66  |
| 1176 | A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. <b>2013</b> , 62, 540-9                                             | 107 |



|      |                                                                                                                                                                                                                  |     |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1175 | Individualized therapy for metastatic colorectal cancer. <b>2013</b> , 274, 1-24                                                                                                                                 | 19  |
| 1174 | The role of high-throughput technologies in clinical cancer genomics. <b>2013</b> , 13, 167-81                                                                                                                   | 19  |
| 1173 | Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma. <b>2013</b> , 108, 1743-9                                                          | 29  |
| 1172 | Predictive and Prognostic Biomarkers for Colorectal Cancer. <b>2013</b> , 131-162                                                                                                                                | 2   |
| 1171 | Role of targeted agents in metastatic colorectal cancer. <b>2013</b> , 8, 83-96                                                                                                                                  | 52  |
| 1170 | The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. <b>2013</b> , 108, 2153-63                                                                                                              | 126 |
| 1169 | Pharmacogenomics in Cancer Therapeutics. <b>2013</b> , 89-116                                                                                                                                                    |     |
| 1168 | The TRAIL of oncogenes to apoptosis. <b>2013</b> , 39, 343-54                                                                                                                                                    | 29  |
| 1167 | Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. <b>2013</b> , 85, 45-81                                                  | 78  |
| 1166 | Anion-exchanged nanosolid support of magnetic nanoparticle in combination with PNA probes for DNA sequence analysis. <b>2013</b> , 15, 1                                                                         | 8   |
| 1165 | An Empirical Analysis of Topic Modeling for Mining Cancer Clinical Notes. <b>2013</b> ,                                                                                                                          | 13  |
| 1164 | Assessing colorectal cancer heterogeneity: one step closer to tailored medicine. <b>2013</b> , 11, 115-129                                                                                                       | 2   |
| 1163 | Rolle und Aufgaben der chirurgischen Onkologie im Rahmen molekular definierter Therapien. <b>2013</b> , 19, 858-862                                                                                              |     |
| 1162 | Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma. <b>2013</b> , 29, 199-211                                                                                                           | 7   |
| 1161 | KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. <b>2013</b> , 119, 714-21 | 72  |
| 1160 | Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. <b>2013</b> , 19, 4149-62                                | 58  |
| 1159 | Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab. <b>2013</b> , 14, 883-7                                                           | 3   |
| 1158 | Harnessing massively parallel DNA sequencing for the personalization of cancer management. <b>2013</b> , 10, 183-190                                                                                             | 2   |

|      |                                                                                                                                                                                                                  |    |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1157 | RAS mutations: impact on treatment outcome. <b>2013</b> , 2, 525-534                                                                                                                                             |    |
| 1156 | Médecine personnalisée en oncologie digestive. <b>2013</b> ,                                                                                                                                                     |    |
| 1155 | Colorectal Cancer: Basic and Translational Research. <b>2013</b> , 1, 18-24                                                                                                                                      |    |
| 1154 | [Small intestinal signet-ring cell carcinoma in Crohn's disease: case report and review of the literature]. <b>2013</b> , 138 Suppl 2, e120-3                                                                    | 1  |
| 1153 | Immunotherapeutic strategies to target prognostic and predictive markers of cancer. <b>2013</b> , 7, 23-35                                                                                                       | 7  |
| 1152 | Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. <b>2013</b> , 98, 887-91                                                                                                                    | 55 |
| 1151 | A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors. <b>2013</b> , 2013, 632461                                                      | 35 |
| 1150 | Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. <b>2013</b> , 6, 988-1038                                                                                                   | 12 |
| 1149 | Ras chaperones: new targets for cancer and immunotherapy. <b>2013</b> , 33 Pt A, 267-89                                                                                                                          | 7  |
| 1148 | Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer. <b>2013</b> , 13, 89-97                                                                   | 13 |
| 1147 | Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial. <b>2013</b> , 137, 820-7 | 26 |
| 1146 | KRAS mutations are associated with specific morphologic features in colon cancer. <b>2013</b> , 47, 509-14                                                                                                       | 10 |
| 1145 | Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. <b>2013</b> , 42, 411-21                                                                                                      | 33 |
| 1144 | Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. <b>2013</b> , 19, 2929-40                                                                              | 30 |
| 1143 | Immunohistochemistry in the era of personalised medicine. <b>2013</b> , 66, 58-61                                                                                                                                | 30 |
| 1142 | Biomarkers in precision therapy in colorectal cancer. <b>2013</b> , 1, 166-83                                                                                                                                    | 69 |
| 1141 | Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. <b>2013</b> , 8, e55793                                                                    | 48 |
| 1140 | EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis. <b>2013</b> , 8, e56205                                 | 40 |

|      |                                                                                                                                                                                                                                            |     |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1139 | Personalized medicine: does the molecular suit fit?. <b>2013</b> , 18, 653-4                                                                                                                                                               | 4   |
| 1138 | Human variation 2.0: using GWAS to probe intermediate phenotypes. <b>2013</b> , 34, iv                                                                                                                                                     | 2   |
| 1137 | Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis. <b>2013</b> , 14, 409-16                         | 37  |
| 1136 | Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer. <b>2013</b> , 65, 1351-95                                                                                                     | 26  |
| 1135 | Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer. <b>2013</b> , 2, 11-20                                                | 16  |
| 1134 | . <b>2013</b> ,                                                                                                                                                                                                                            |     |
| 1133 | Colorectal cancer. <b>2013</b> , 10-26                                                                                                                                                                                                     |     |
| 1132 | Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance. <b>2013</b> , 18, 850-64                                                               | 70  |
| 1131 | Phase II study of everolimus in metastatic urothelial cancer. <b>2013</b> , 112, 462-70                                                                                                                                                    | 133 |
| 1130 | From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. <b>2013</b> , 105, 1441-56                                                                                                           | 41  |
| 1129 | Monoclonal Antibodies Targeting EGFR/HER2 and Clinical Outcomes in Cancer Treatment. <b>2013</b> ,                                                                                                                                         |     |
| 1128 | Pharmacogénétique et pharmacogénomie. <b>2013</b> , 59-74                                                                                                                                                                                  |     |
| 1127 | Detection of the epidermal growth factor receptor, amphiregulin and epiregulin in formalin-fixed paraffin-embedded human placenta tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging. <b>2013</b> , 19, 17-28 | 9   |
| 1126 | Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro. <b>2013</b> , 30, 1081-6                                                                                                                | 12  |
| 1125 | Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. <b>2013</b> , 183-232                                                                                                                                       |     |
| 1124 | Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer. <b>2013</b> , 5, 1295-1300                                                                                  | 7   |
| 1123 | Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity. <b>2013</b> , 5, 1741-1743                                                     | 9   |
| 1122 | A national study of breast and colorectal cancer patients' decision-making for novel personalized medicine genomic diagnostics. <b>2013</b> , 10, 245-256                                                                                  | 6   |

|      |                                                                                                                                                                                     |    |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1121 | The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors. <b>2013</b> , 19, 907-917    | 21 |
| 1120 | Simultaneous detection of 19 K-ras mutations by free-solution conjugate electrophoresis of ligase detection reaction products on glass microchips. <b>2013</b> , 34, 590-7          | 13 |
| 1119 | Autres biomarqueurs potentiels des anti-EGFR. <b>2013</b> , 177-191                                                                                                                 |    |
| 1118 | Adjuvant therapy in patients with stage II and III colon cancer under 70 years of age. <b>2013</b> , 2, 205-217                                                                     |    |
| 1117 | Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. <b>2013</b> , 8, e62264          | 18 |
| 1116 | Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications. <b>2013</b> , 5, 249-254                             | 10 |
| 1115 | A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy. <b>2013</b> , 3, 2992                                                          | 68 |
| 1114 | Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. <b>2013</b> , 6, 1761-9                                                           | 7  |
| 1113 | Prognostic significance and targeting of HER family in colorectal cancer. <b>2013</b> , 18, 394-421                                                                                 | 23 |
| 1112 | Predicting tumour response. <b>2013</b> , 13, 381-90                                                                                                                                | 6  |
| 1111 | [Method validation according to ISO 15189 and SH GTA 04: application for the detection of KRAS mutations using PCR TaqMan assay]. <b>2013</b> , 71, 603-7                           |    |
| 1110 | Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. <b>2013</b> , 8, e62175                                                            | 33 |
| 1109 | Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. <b>2013</b> , 8, e69604       | 86 |
| 1108 | TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells. <b>2013</b> , 8, e70604                                                                        | 21 |
| 1107 | Measurement of cetuximab and panitumumab-unbound serum EGFR extracellular domain using an assay based on slow off-rate modified aptamer (SOMAmer) reagents. <b>2013</b> , 8, e71703 | 14 |
| 1106 | Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition. <b>2013</b> , 8, e77553                           | 40 |
| 1105 | Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. <b>2013</b> , 8, e77901   | 13 |
| 1104 | Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients. <b>2013</b> , 8, e79014                                   | 19 |

|      |                                                                                                                                                                                                                   |    |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1103 | Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells. <b>2013</b> , 8, e66302                     | 20 |
| 1102 | A view on EGFR-targeted therapies from the oncogene-addiction perspective. <b>2013</b> , 4, 53                                                                                                                    | 29 |
| 1101 | [Kras oncogene and pancreatic cancer: thirty years after]. <b>2013</b> , 29, 991-7                                                                                                                                | 4  |
| 1100 | Molecular pathology of colorectal cancer. <b>2014</b> , 65, 257-66                                                                                                                                                | 26 |
| 1099 | KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). <b>2014</b> , 9, e92071                                                                                                                      | 43 |
| 1098 | Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy. <b>2014</b> , 9, e99590                                                                    | 13 |
| 1097 | PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis. <b>2014</b> , 9, e107926 | 6  |
| 1096 | Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. <b>2014</b> , 2, 345-358                                                                                            | 24 |
| 1095 | Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. <b>2014</b> , 10, 1-9     | 26 |
| 1094 | Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. <b>2014</b> , 20, 9862-71                                                      | 15 |
| 1093 | Predicting cetuximab efficacy in patients with advanced colorectal cancer. <b>2014</b> , 61                                                                                                                       | 1  |
| 1092 | Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. <b>2014</b> , 18, 7-16                                            | 9  |
| 1091 | Mechanisms of resistance to EGFR inhibitors in colorectal cancers. <b>2014</b> , 3, 511-520                                                                                                                       |    |
| 1090 | Structural Systems Biology: Modeling Interactions and Networks for Systems Studies. <b>2014</b> , 9-19                                                                                                            |    |
| 1089 | Pharmacodynamic Pharmacogenomics. <b>2014</b> , 365-383                                                                                                                                                           | 2  |
| 1088 | Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor. <b>2014</b> , 6, 1013-25                                                                          | 10 |
| 1087 | Panitumumab : leading to better overall survival in metastatic colorectal cancer?. <b>2014</b> , 14, 535-48                                                                                                       | 1  |
| 1086 | Panitumumab safety for treating colorectal cancer. <b>2014</b> , 13, 843-51                                                                                                                                       | 9  |

|      |                                                                                                                                                                 |     |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1085 | Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. <b>2014</b> , 15, 623-32                                                  | 25  |
| 1084 | Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives. <b>2014</b> , 10, 380-394                                                 | 1   |
| 1083 | KRAS mutation in adenocarcinoma of the gastrointestinal type arising from a mature cystic teratoma of the ovary. <b>2014</b> , 7, 85                            | 4   |
| 1082 | Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. <b>2014</b> , 110, 1221-7                 | 20  |
| 1081 | Role of aflibercept in the treatment of advanced colorectal cancer. <b>2014</b> , 3, 27-40                                                                      |     |
| 1080 | Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer. <b>2014</b> , 111, 2203-4 | 30  |
| 1079 | Prognosis in autoimmune and infectious disease: new insights from genetics. <b>2014</b> , 3, e15                                                                | 7   |
| 1078 | 'Druggable' alterations detected by Ion Torrent in metastatic colorectal cancer patients. <b>2014</b> , 7, 1761-1766                                            | 7   |
| 1077 | Pathway-driven discovery of rare mutational impact on cancer. <b>2014</b> , 2014, 171892                                                                        | 3   |
| 1076 | Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies. <b>2014</b> , 3, 223-232                                                  | 1   |
| 1075 | Development of image-guided targeted two-photon PDT for the treatment of head and neck cancers. <b>2014</b> ,                                                   | 2   |
| 1074 | Impact of cetuximab in current treatment of metastatic colorectal cancer. <b>2014</b> , 14, 387-99                                                              | 4   |
| 1073 | Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. <b>2014</b> , 4, 1418-29                                                       | 121 |
| 1072 | The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target. <b>2014</b> , 55, 24-34                                               | 22  |
| 1071 | Sensitive detection of trace amounts of KRAS codon 12 mutations by a fast and novel one-step technique. <b>2014</b> , 47, 237-42                                | 7   |
| 1070 | Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. <b>2014</b> , 120, 77-85                        | 22  |
| 1069 | Growing indication for FNA to study and analyze tumor heterogeneity at metastatic sites. <b>2014</b> , 122, 504-11                                              | 15  |
| 1068 | Pharmacogenomics in Developing Countries. <b>2014</b> , 327-351                                                                                                 |     |

|      |                                                                                                                                                                                                                                                                            |     |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1067 | Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3. <b>2014</b> , 7, 103                                                                                                                                        | 4   |
| 1066 | Molecular Predictive and Prognostic Markers of Colorectal Carcinoma. <b>2014</b> , 19, 252-255                                                                                                                                                                             |     |
| 1065 | Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms. <b>2014</b> , 22, 231-5                                                                                                                                           | 8   |
| 1064 | Molecular Pathology and Diagnostics of Colorectal Cancer. <b>2014</b> , 119-175                                                                                                                                                                                            |     |
| 1063 | Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancer. <b>2014</b> , 16, 751-6                                                                                                                                                             | 4   |
| 1062 | Cytopathology in Oncology. <b>2014</b> ,                                                                                                                                                                                                                                   | 3   |
| 1061 | Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer. <b>2014</b> , 89, 18-23                                                                                                                    | 15  |
| 1060 | Results of first proficiency test for KRAS testing with formalin-fixed, paraffin-embedded cell lines in China. <b>2014</b> , 52, 1851-7                                                                                                                                    | 3   |
| 1059 | Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer. <b>2014</b> , 10, 308-14                                                                                                                          | 3   |
| 1058 | KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells. <b>2014</b> , 13, 1611-24                                                                                                                   | 37  |
| 1057 | Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). <b>2014</b> , 87, 7-20 | 67  |
| 1056 | KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. <b>2014</b> , 43, 578-83                                                                                                                                         | 31  |
| 1055 | Acquired resistance to EGFR-targeted therapies in colorectal cancer. <b>2014</b> , 8, 1084-94                                                                                                                                                                              | 94  |
| 1054 | Personalizing therapy for colorectal cancer. <b>2014</b> , 12, 139-44                                                                                                                                                                                                      | 21  |
| 1053 | Application of Translational Science to Clinical Development. <b>2014</b> , 1-21                                                                                                                                                                                           |     |
| 1052 | Translating Biomarker Discovery into Companion Diagnostics through Validation and Regulatory Consideration. <b>2014</b> , 157-181                                                                                                                                          |     |
| 1051 | Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. <b>2014</b> , 20, 430-5                                                                                                                                                        | 474 |
| 1050 | Des mutations de KRAS aux mutations de RAS : vers une meilleure définition de la réponse aux anticorps anti-EGFR dans le cancer colorectal métastatique. <b>2014</b> , 16, 120-128                                                                                         | 3   |

|      |                                                                                                                                                                                                                      |     |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1049 | A case report on efficacy of Abound for anti-EGFR antibody-associated skin disorder in metastatic colon cancer. <b>2014</b> , 12, 35                                                                                 | 4   |
| 1048 | Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS. <b>2014</b> , 73, 749-57                                                                 | 21  |
| 1047 | KRAS insertions in colorectal cancer: what do we know about unusual KRAS mutations?. <b>2014</b> , 96, 257-60                                                                                                        | 9   |
| 1046 | Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. <b>2014</b> , 25, 1346-1355                                               | 353 |
| 1045 | Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. <b>2014</b> , 20, 3338-47                               | 77  |
| 1044 | Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data. <b>2014</b> , 16, 75-88                                                     | 87  |
| 1043 | Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. <b>2014</b> , 433, 284-9                                                 | 51  |
| 1042 | Genomics of Colorectal Cancer. <b>2014</b> , 247-264                                                                                                                                                                 | 2   |
| 1041 | Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. <b>2014</b> , 141, 856-66                                                                                           | 115 |
| 1040 | Molecular alterations and biomarkers in colorectal cancer. <b>2014</b> , 42, 124-39                                                                                                                                  | 62  |
| 1039 | Methods of overcoming treatment resistance in colorectal cancer. <b>2014</b> , 89, 217-30                                                                                                                            | 48  |
| 1038 | Clinical relevance of KRAS mutations in codon 13: Where are we?. <b>2014</b> , 343, 1-5                                                                                                                              | 21  |
| 1037 | Thérapies ciblées et biomarqueurs compagnons dans les cancers de la prostate métastatiques. <b>2014</b> , 38, 31-37                                                                                                  |     |
| 1036 | Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. <b>2014</b> , 25, 107-16                                                       | 137 |
| 1035 | Sinodiellide A exerts thermosensitizing effects and induces apoptosis and G2/M cell cycle arrest in DU145 human prostate cancer cells via the Ras/Raf/MAPK and PI3K/Akt signaling pathways. <b>2014</b> , 33, 406-14 | 15  |
| 1034 | Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. <b>2014</b> , 15, 1043-52                                                                                                      | 15  |
| 1033 | Computer-assisted management of unconsumed drugs as a cost-containment strategy in oncology. <b>2014</b> , 36, 892-5                                                                                                 | 5   |
| 1032 | High frequency of BRAF V600E mutations in ameloblastoma. <b>2014</b> , 232, 492-8                                                                                                                                    | 173 |



|      |                                                                                                                                                                                                                          |     |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1031 | Optimization of Anti-EGFR Treatment of Advanced Colorectal Cancer. <b>2014</b> , 10, 263-271                                                                                                                             | 1   |
| 1030 | Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer. <b>2014</b> , 10, 279-287                                                                                           |     |
| 1029 | Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: a future opportunity?. <b>2014</b> , 10 Suppl 1, 2-10                                                   | 4   |
| 1028 | Cetuximab (Erbix). <b>2014</b> , 1501-1520                                                                                                                                                                               |     |
| 1027 | Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. <b>2014</b> , 4, 1269-80                                                                                               | 326 |
| 1026 | Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. <b>2014</b> , 31, 124                                                       | 20  |
| 1025 | Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response. <b>2014</b> , 7, 337                                                                     | 29  |
| 1024 | Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. <b>2014</b> , 138, 166-70                                                                         | 36  |
| 1023 | Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. <b>2014</b> , 9, 1104-14                                                                                            | 36  |
| 1022 | Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer. <b>2014</b> , 55, 386-91                                                               | 60  |
| 1021 | Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. <b>2014</b> , 92, 709-22                                                                         | 64  |
| 1020 | EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. <b>2014</b> , 140, 737-48                               | 29  |
| 1019 | Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan. <b>2014</b> , 44, 1457-64                                   | 4   |
| 1018 | Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. <b>2014</b> , 8, 927-41                                                                                           | 145 |
| 1017 | A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?. <b>2014</b> , 110, 2178-86 | 22  |
| 1016 | Toxicogenomics and cancer susceptibility: advances with next-generation sequencing. <b>2014</b> , 32, 121-58                                                                                                             | 30  |
| 1015 | A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment. <b>2014</b> , 9, 177-80                                                                                                 | 8   |
| 1014 | Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes. <b>2014</b> , 10, 55-61                                                                                                                  | 4   |

|      |                                                                                                                                                                                      |    |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1013 | The Evolving Use of Prognostic Factors After Resection of Colorectal Liver Metastases. <b>2014</b> , 10, 218-226                                                                     |    |
| 1012 | FcR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer. <b>2014</b> , 18, 541-8                                                      | 8  |
| 1011 | Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer. <b>2014</b> , 14, 1051-61                                                             | 2  |
| 1010 | Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins. <b>2014</b> , 354, 365-77                                                                             | 45 |
| 1009 | Options for metastatic colorectal cancer beyond the second line of treatment. <b>2014</b> , 46, 105-12                                                                               | 37 |
| 1008 | Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. <b>2014</b> , 50, 1819-1828             | 57 |
| 1007 | Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay. <b>2014</b> , 436, 169-75                                                                                  | 8  |
| 1006 | Clinical application of pharmacogenomics through clinical exercises and online resources. <b>2014</b> , 6, 571-576                                                                   | 2  |
| 1005 | Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. <b>2014</b> , 20, 9732-43                       | 25 |
| 1004 | Novel KRAS gene mutations in sporadic colorectal cancer. <b>2014</b> , 9, e113350                                                                                                    | 9  |
| 1003 | A 3-weekly schedule of irinotecan and panitumumab for wild-typeKRASmetastatic colorectal cancer. <b>2014</b> , 3, 135-145                                                            | 3  |
| 1002 | [The current issues on development and clinical use of companion diagnostics and prospects of personalized medicine for the future]. <b>2014</b> , 134, 491-8                        |    |
| 1001 | Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. <b>2014</b> , 32, 887-92                                                | 14 |
| 1000 | Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity. <b>2014</b> , 45, 1583-93                                                 | 8  |
| 999  | [Intratumoral immune microenvironment and survival: the immunoscore]. <b>2014</b> , 30, 439-44                                                                                       | 15 |
| 998  | Predictive biomarkers for anti-epidermal growth factor receptor therapy: beyond KRAS testing. <b>2014</b> , 12, 1433-42                                                              | 5  |
| 997  | The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer. <b>2014</b> , 5, 2041731414544183                                            | 25 |
| 996  | Conversion Therapy Using mFOLFOX6 With Panitumumab for Unresectable Liver Metastases From Multiple Colorectal Cancers With Familial Adenomatous Polyposis. <b>2014</b> , 99, 795-801 | 2  |

|     |                                                                                                                                                                                          |     |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 995 | Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. <b>2015</b> , 102, 1175-83                                                                  | 133 |
| 994 | From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. <b>2015</b> , 97, 234-46                                          | 133 |
| 993 | Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer. <b>2015</b> , 13, 998-1003                                                     | 31  |
| 992 | Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474. <b>2015</b> , 106, 171-8 | 10  |
| 991 | Cetuximab-induced insulin-like growth factor receptor $\beta$ activation mediates cetuximab resistance in gastric cancer cells. <b>2015</b> , 11, 4547-54                                | 6   |
| 990 | Cancer Pharmacogenomics. <b>2015</b> , 1, 164-191                                                                                                                                        |     |
| 989 | Contribution of biobanks to care services. <b>2015</b> , 14, 21-24                                                                                                                       | 1   |
| 988 | Toward Personalized Therapy for Cancer. <b>2015</b> , 3-13                                                                                                                               |     |
| 987 | Targeted Therapy in Solid Tumors: Colorectal Cancer. <b>2015</b> , 193-204                                                                                                               |     |
| 986 | Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer. <b>2015</b> , 10, 2519-2526                                                    | 8   |
| 985 | Prognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon Cancer. <b>2015</b> , 7, 29-37                                                                    | 8   |
| 984 | The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. <b>2015</b> , 13, 287                           | 14  |
| 983 | Wahl der Behandlungsstrategie auf der Basis molekularer Marker. <b>2015</b> , 18, 51-59                                                                                                  |     |
| 982 | Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. <b>2015</b> , 13, 217                                                          | 30  |
| 981 | Biomarkers predicting chemotherapy response in head and neck squamous cell carcinoma: a review. <b>2015</b> , 129, 1046-52                                                               | 3   |
| 980 | Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique. <b>2015</b> , 10, 132                                                  | 27  |
| 979 | Diagnostic Molecular Cytopathology - a further decade of progress. <b>2015</b> , 26, 269-70                                                                                              | 6   |
| 978 | Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?. <b>2015</b> , 20, 1448-56                                                     | 2   |

|     |                                                                                                                                                                                                                                         |     |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 977 | Genetic Heterogeneity in Colorectal Cancer and its Clinical Implications. <b>2015</b> , 28, 370-5                                                                                                                                       | 9   |
| 976 | rs712 polymorphism within let-7 microRNA-binding site might be involved in the initiation and progression of colorectal cancer in Chinese population. <b>2015</b> , 8, 3041-5                                                           | 7   |
| 975 | Anticoagulant therapy of cancer patients: Will patient selection increase overall survival?. <b>2015</b> , 114, 530-6                                                                                                                   | 16  |
| 974 | K-Ras, intestinal homeostasis and colon cancer. <b>2015</b> , 10, 73-81                                                                                                                                                                 | 27  |
| 973 | NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. <b>2015</b> , 6, 368                                                                                                                                 | 288 |
| 972 | Targeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells. <b>2015</b> , 11, 1100-12                                                                                                                        | 85  |
| 971 | Positive feedback between oncogenic KRAS and HIF-1 $\beta$ confers drug resistance in colorectal cancer. <b>2015</b> , 8, 1229-37                                                                                                       | 10  |
| 970 | Treatment of metastatic colorectal cancer: focus on panitumumab. <b>2015</b> , 7, 189-98                                                                                                                                                | 11  |
| 969 | Article Commentary: Predictive Modeling of Drug Treatment in the Area of Personalized Medicine. <b>2015</b> , 14s4, CIN.S19330                                                                                                          | 0   |
| 968 | KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?. <b>2015</b> , 2015, 753903                                                                                 | 18  |
| 967 | Lack of Association between Membrane-Type 1 Matrix Metalloproteinase Expression and Clinically Relevant Molecular or Morphologic Tumor Characteristics at the Leading Edge of Invasive Colorectal Carcinoma. <b>2015</b> , 2015, 185404 | 2   |
| 966 | . <b>2015</b> ,                                                                                                                                                                                                                         | 2   |
| 965 | Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. <b>2015</b> , 6, 12035-47                                                                                  | 47  |
| 964 | Biomarkers For Colon Cancer. <b>2015</b> , 7, 49-50                                                                                                                                                                                     | 3   |
| 963 | A Case of Krukenberg Tumor Metastasized from Colon Cancer Subsequent to Synchronous Multiple Liver Metastasis. <b>2015</b> , 27, 285-289                                                                                                |     |
| 962 | Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. <b>2015</b> , 6, 133-41                                                                    | 59  |
| 961 | Transcriptional changes associated with resistance to inhibitors of epidermal growth factor receptor revealed using metaanalysis. <b>2015</b> , 15, 369                                                                                 | 3   |
| 960 | Biomarkers for personalized medicine in GI cancers. <b>2015</b> , 45, 14-27                                                                                                                                                             | 9   |

|     |                                                                                                                                                                                      |    |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 959 | Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology. <b>2015</b> , 24, 484-9                                     | 10 |
| 958 | Sym004: Truly a New Level of Anti-EGFR Treatment?. <b>2015</b> , 5, 578-80                                                                                                           | 1  |
| 957 | Monitoring Trastuzumab Resistance and Cardiotoxicity: A Tale of Personalized Medicine. <b>2015</b> , 70, 95-130                                                                      | 10 |
| 956 | Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. <b>2015</b> , 21, 4153-64 | 13 |
| 955 | EGFR signaling in colorectal cancer: a clinical perspective. <b>2015</b> , 21                                                                                                        | 4  |
| 954 | Eprobe-mediated screening system for somatic mutations in the KRAS locus. <b>2015</b> , 33, 2719-27                                                                                  | 8  |
| 953 | Dynamic Regulation of Adherens Junctions: Implication in Cell Differentiation and Tumor Development. <b>2015</b> , 53-149                                                            | 1  |
| 952 | eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. <b>2015</b> , 13, 258         | 23 |
| 951 | Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. <b>2015</b> , 8, 40-6 | 14 |
| 950 | Optimization of Pharmaceutical R&D Programs and Portfolios. <b>2015</b> ,                                                                                                            | 8  |
| 949 | Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. <b>2015</b> , 15, 354-62                                | 36 |
| 948 | Association between KRAS mutation and lung metastasis in advanced colorectal cancer. <b>2015</b> , 112, 424-8                                                                        | 61 |
| 947 | KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. <b>2015</b> , 112, 720-8                                          | 58 |
| 946 | Survival in ampullary cancer: potential role of different KRAS mutations. <b>2015</b> , 157, 260-8                                                                                   | 26 |
| 945 | Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. <b>2015</b> , 400, 129-43                                                      | 12 |
| 944 | International differences in companion diagnostic approvals: how are we able to manage the differences?. <b>2015</b> , 15, 157-9                                                     | 9  |
| 943 | Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer. <b>2015</b> , 102, 117-25                                                       | 5  |
| 942 | Serial in vivo imaging using a fluorescence probe allows identification of tumor early response to cetuximab immunotherapy. <b>2015</b> , 12, 10-7                                   | 10 |

|     |                                                                                                                                                                                        |    |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 941 | KRAS mutation testing in clinical practice. <b>2015</b> , 15, 375-84                                                                                                                   | 9  |
| 940 | Dissecting the mechanism of colorectal tumorigenesis based on RNA-sequencing data. <b>2015</b> , 98, 246-53                                                                            | 6  |
| 939 | Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency. <b>2015</b> , 7, 440-50          | 16 |
| 938 | Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. <b>2015</b> , 7, 153-69                                                                          | 31 |
| 937 | Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping?. <b>2015</b> , 10, 415-21                                            | 4  |
| 936 | CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab. <b>2015</b> , 19, 79-89           | 7  |
| 935 | Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer. <b>2015</b> , 4, e231                                                     | 57 |
| 934 | methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. <b>2015</b> , 9, 1432-1438                                                                 | 3  |
| 933 | Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations. <b>2015</b> , 15, 715-25                                                                            | 5  |
| 932 | EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. <b>2015</b> , 154, 67-77                                              | 35 |
| 931 | Current controversies in the management of metastatic colorectal cancer. <b>2015</b> , 76, 659-77                                                                                      | 11 |
| 930 | Molecular biomarkers in colorectal carcinoma. <b>2015</b> , 16, 1189-222                                                                                                               | 10 |
| 929 | Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond. <b>2015</b> , 91, 294-302                                                     | 7  |
| 928 | KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases. <b>2015</b> , 26, 1102-11 | 37 |
| 927 | Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour. <b>2015</b> , 113, 204-11 | 81 |
| 926 | Surgery in the era of the 'omics revolution. <b>2015</b> , 102, e29-40                                                                                                                 | 9  |
| 925 | Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. <b>2015</b> , 113, 37-45                                         | 41 |
| 924 | Genetic mutations in human rectal cancers detected by targeted sequencing. <b>2015</b> , 60, 589-96                                                                                    | 15 |

|     |                                                                                                                                                                                                                      |     |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 923 | Estrogen and breast cancer: can less mean more?. <b>2015</b> , 14, 2197-8                                                                                                                                            |     |
| 922 | Development of pyrosequencing methods for the rapid detection of RAS mutations in clinical samples. <b>2015</b> , 99, 207-11                                                                                         | 7   |
| 921 | The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors. <b>2015</b> , 15, 1205-20 | 17  |
| 920 | Kras, Egfr, and Tp53 Mutations in B6C3F1/N Mouse and F344/NTac Rat Alveolar/Bronchiolar Carcinomas Resulting from Chronic Inhalation Exposure to Cobalt Metal. <b>2015</b> , 43, 872-82                              | 11  |
| 919 | Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer. <b>2015</b> , 23, 1532-40                                                          | 103 |
| 918 | Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. <b>2015</b> , 150, 722-9                                                                                                    | 82  |
| 917 | MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. <b>2015</b> , 112, 1480-90                            | 50  |
| 916 | Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. <b>2015</b> , 363, 1-6                                                                                                       | 16  |
| 915 | KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR. <b>2015</b> , 98, 563-7                       | 4   |
| 914 | The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?. <b>2015</b> , 15, 81-100                                                                                          | 3   |
| 913 | Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer. <b>2015</b> , 48, 908-10                                                                         | 23  |
| 912 | First-Line Therapy in Metastatic Colorectal Cancer Patients Not Candidates for Curative Surgery. <b>2015</b> , 11, 54-69                                                                                             |     |
| 911 | Emerging drugs for head and neck cancer. <b>2015</b> , 20, 313-29                                                                                                                                                    | 23  |
| 910 | The role of epigenetics in personalized medicine: challenges and opportunities. <b>2015</b> , 8 Suppl 1, S5                                                                                                          | 38  |
| 909 | Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer. <b>2015</b> , 4, 7                                                                                     | 7   |
| 908 | Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond. <b>2015</b> , 34, 149-60                                                                                                 | 18  |
| 907 | Application of biomarkers in oncology clinical trials. <b>2015</b> , 5, 61-74                                                                                                                                        | 1   |
| 906 | BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. <b>2015</b> , 112, 1921-8                                                                          | 111 |

|     |                                                                                                                                                                                                                                  |     |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 905 | Translational value of mouse models in oncology drug development. <b>2015</b> , 21, 431-9                                                                                                                                        | 192 |
| 904 | Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. <b>2015</b> , 9, 363-75                                                                 | 6   |
| 903 | Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. <b>2015</b> , 7, 252-62                                                                                                              | 52  |
| 902 | Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. <b>2015</b> , 34, 384-93                                                                                                            | 52  |
| 901 | Markers in Colorectal Cancer and Clinical Trials Based Upon Them. <b>2015</b> , 11, 317-325                                                                                                                                      |     |
| 900 | The Personalization of Therapy: Molecular Profiling Technologies and Their Application. <b>2015</b> , 42, 775-87                                                                                                                 | 4   |
| 899 | Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study. <b>2015</b> , 2, 317-23                                                   | 46  |
| 898 | Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development. <b>2015</b> , 867, 81-90                                                                                                     | 5   |
| 897 | Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. <b>2015</b> , 350, 1391-6                                                                                                           | 537 |
| 896 | Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). <b>2015</b> , 15, 365 | 47  |
| 895 | STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. <b>2015</b> , 15, 496                                                     | 17  |
| 894 | Prognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon. <b>2015</b> , 22, 3433-50                                                                                                      | 18  |
| 893 | How can we identify new biomarkers for patients with for lung metastasectomy in colorectal cancer. <b>2015</b> , 11, 2109-11                                                                                                     | 1   |
| 892 | Reply to the letter to the editor 'new life for retrospective study in the precision oncology era' by Orlandi et al. <b>2015</b> , 26, 2353                                                                                      |     |
| 891 | How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC). <b>2015</b> , 11, 151-159                                                                                                     | 2   |
| 890 | Personalized Approaches to Gastrointestinal Cancers: Importance of Integrating Genomic Information to Guide Therapy. <b>2015</b> , 95, 1081-94                                                                                   | 5   |
| 889 | CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice. <b>2015</b> , 21, 3578-80                                                                         | 12  |
| 888 | Biochip detection of KRAS, BRAF, and PIK3CA somatic mutations in colorectal cancer patients. <b>2015</b> , 49, 550-559                                                                                                           | 2   |



|     |                                                                                                                                                                                                                                                                                           |     |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 887 | Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. <b>2015</b> , 19, 397-408                                      | 21  |
| 886 | Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2. <b>2015</b> , 75, 1739-56                                                                                                                                                          | 6   |
| 885 | Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. <b>2015</b> , 11, 2711-2719                                                                                                                                                                   | 4   |
| 884 | Designs of preoperative biomarkers trials in oncology: a systematic review of the literature. <b>2015</b> , 26, 2419-28                                                                                                                                                                   | 15  |
| 883 | Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. <b>2015</b> , 36, 614-26                                                                                                                                   | 15  |
| 882 | Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. <b>2015</b> , 30, 1-6                                                                                                                                                                               | 52  |
| 881 | Predictive In Vivo Models for Oncology. <b>2016</b> , 232, 203-21                                                                                                                                                                                                                         | 6   |
| 880 | Defining an optimal surgical strategy for synchronous colorectal liver metastases: staged versus simultaneous resection?. <b>2015</b> , 85, 829-33                                                                                                                                        | 13  |
| 879 | Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. <b>2015</b> , 112, 313-8                                                                                                                                             | 21  |
| 878 | Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. <b>2015</b> , 29, 43-60                                                                                                                                         | 24  |
| 877 | Portrait of the PI3K/AKT pathway in colorectal cancer. <b>2015</b> , 1855, 104-21                                                                                                                                                                                                         | 148 |
| 876 | Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. <b>2015</b> , 136, 83-90                                                                                                                                                                     | 92  |
| 875 | Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non-invasive companion diagnostics. <b>2015</b> , 64, 627-35                                                                                                                                  | 23  |
| 874 | Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. <b>2015</b> , 33, 22-8 | 69  |
| 873 | Ethyl acetate extract from <i>Glycosmis parva</i> leaf induces apoptosis and cell-cycle arrest by decreasing expression of COX-2 and altering BCL-2 family gene expression in human colorectal cancer HT-29 cells. <b>2015</b> , 53, 540-7                                                | 14  |
| 872 | Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. <b>2015</b> , 2, 4-12                                                                                                                                                                             | 70  |
| 871 | A review of the evolution of systemic chemotherapy in the management of colorectal cancer. <b>2015</b> , 14, 1-10                                                                                                                                                                         | 289 |
| 870 | Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer. <b>2015</b> , 21, 399-404                                                                                                                                                                              | 7   |

|     |                                                                                                                                                                                    |     |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 869 | Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. <b>2015</b> , 10, 179-88                                            | 28  |
| 868 | RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. <b>2015</b> , 22, 834-842          | 79  |
| 867 | Focal adhesion signaling and therapy resistance in cancer. <b>2015</b> , 31, 65-75                                                                                                 | 158 |
| 866 | Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer. <b>2015</b> , 10, 125-33 | 13  |
| 865 | Genomic Applications in Pathology. <b>2015</b> ,                                                                                                                                   |     |
| 864 | Synergistic Anti-proliferative Effects of Cucurbitacin I and Irinotecan on Human Colorectal Cancer Cell Lines. <b>2016</b> , 6,                                                    |     |
| 863 | Kirsten Ras* oncogene: significance of its discovery in human cancer research. <b>2016</b> , 7, 46717-46733                                                                        | 38  |
| 862 | Predicating Candidate Cancer-Associated Genes in the Human Signaling Network Using Centrality. <b>2016</b> , 11, 87-92                                                             | 3   |
| 861 | Role of targeted therapy in metastatic colorectal cancer. <b>2016</b> , 8, 642-55                                                                                                  | 67  |
| 860 | Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy. <b>2016</b> , 9, 4695-703                            | 11  |
| 859 | Developing Smart Point-of-Care Diagnostic Tools for Next-Generation Wound Care. <b>2016</b> , 251-264                                                                              | 3   |
| 858 | RAS and BRAF in metastatic colorectal cancer management. <b>2016</b> , 7, 687-704                                                                                                  | 39  |
| 857 | Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options. <b>2016</b> , 2016, 6896024                                               | 17  |
| 856 | Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. <b>2016</b> , 9, 1899-920                                                                 | 33  |
| 855 | Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. <b>2016</b> , 6, 21-30                                                               | 7   |
| 854 | A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics. <b>2015</b> , 6, 357                                           | 9   |
| 853 | High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer. <b>2016</b> , 17,                                                                               | 31  |
| 852 | Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers. <b>2016</b> , 17,                                                                              | 11  |

|     |                                                                                                                                                                      |        |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| 851 | CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. <b>2016</b> , 11, e0149099                                                                                | 47     |
| 850 | Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations. <b>2016</b> , 11, e0159094                 | 64     |
| 849 | Biomarker Development in Targeting Cancer Epigenetic. <b>2016</b> , 123-142                                                                                          |        |
| 848 | Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS. <b>2016</b> , 9, 557-65   | 15     |
| 847 | A recellularized human colon model identifies cancer driver genes. <b>2016</b> , 34, 845-51                                                                          | 67     |
| 846 | Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. <b>2016</b> , 16, 2670-5                                                    | 36     |
| 845 | DrugTargetInspector: An assistance tool for patient treatment stratification. <b>2016</b> , 138, 1765-76                                                             | 8      |
| 844 | The pharmacogenomics of drug resistance to protein kinase inhibitors. <b>2016</b> , 28, 28-42                                                                        | 19     |
| 843 | The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer. <i>Cancer Research</i> , <b>2016</b> , 76, 6443-6444        | 10.1 6 |
| 842 | Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method. <b>2016</b> , 16, 454                                 | 7      |
| 841 | Touch imprint cytology with massively parallel sequencing (TIC-seq): a simple and rapid method to snapshot genetic alterations in tumors. <b>2016</b> , 5, 3426-3436 | 27     |
| 840 | Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy. <b>2016</b> ,   | 6      |
| 839 | Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression. <b>2016</b> , 35, 107-16 | 21     |
| 838 | Identification and characterization of EGF receptor in individual exosomes by fluorescence-activated vesicle sorting. <b>2016</b> , 5, 29254                         | 73     |
| 837 | Biomarker in Colorectal Cancer. <b>2016</b> , 22, 156-64                                                                                                             | 31     |
| 836 | Regulatory mechanisms underlying sepsis progression in patients with tumor necrosis factor- $\beta$ genetic variations. <b>2016</b> , 12, 323-328                    | 3      |
| 835 | New Approaches to Drug Discovery. <b>2016</b> ,                                                                                                                      | 4      |
| 834 | BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer. <b>2016</b> , 33, 39                                            | 18     |

|     |                                                                                                                                                                                                                                                 |        |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| 833 | KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. <b>2016</b> , 7, e157                                                                                                                                 | 94     |
| 832 | KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. <b>2016</b> , 23, 2548-55                                                                  | 51     |
| 831 | The safety of monoclonal antibodies for treatment of colorectal cancer. <b>2016</b> , 15, 799-808                                                                                                                                               | 21     |
| 830 | L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells. <b>2016</b> , 95, 200-8                                                                                                 | 27     |
| 829 | The path from big data to precision medicine. <b>2016</b> , 1, 129-143                                                                                                                                                                          | 24     |
| 828 | Cetuximab treatment alters the content of extracellular vesicles released from tumor cells. <b>2016</b> , 11, 881-90                                                                                                                            | 14     |
| 827 | QIAGEN Therascreen KRAS RGQ Assay, QIAGEN KRAS Pyro Assay, and Dideoxy Sequencing for Clinical Laboratory Analysis of KRAS Mutations in Tumor Specimens. <b>2016</b> , 47, 30-8                                                                 | 3      |
| 826 | Mimicking Metastases Including Tumor Stroma: A New Technique to Generate a Three-Dimensional Colorectal Cancer Model Based on a Biological Decellularized Intestinal Scaffold. <b>2016</b> , 22, 621-35                                         | 29     |
| 825 | BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. <b>2016</b> , 22, 4923-4933                                                                        | 34     |
| 824 | Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <b>2016</b> , 34, 2258-64               | 41     |
| 823 | Circulating Tumor Cells and Circulating Tumor DNA in Colorectal Cancer. <b>2016</b> , 1, 181-194                                                                                                                                                | 1      |
| 822 | Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer. <b>2016</b> , 12, 141-150                                                                                                                                          | 32     |
| 821 | - Omics Approaches in Cancer Biomarker and Targeted Anticancer Drug Discovery. <b>2016</b> , 356-381                                                                                                                                            |        |
| 820 | Sur8 mediates tumorigenesis and metastasis in colorectal cancer. <b>2016</b> , 48, e249                                                                                                                                                         | 4      |
| 819 | Biomarkers in Search of Precision Medicine in IBD. <b>2016</b> , 111, 1682-1690                                                                                                                                                                 | 32     |
| 818 | Fast Characterization of Fc-Containing Proteins by Middle-Down Mass Spectrometry Following IdeS Digestion. <b>2016</b> , 79, 1491-1505                                                                                                          | 5      |
| 817 | CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. <b>2016</b> , 21, 1091-1101 | 14     |
| 816 | Commentary on "KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer". <i>Cancer Research</i> , <b>2016</b> , 76, 4309-10                                                                                    | 10.1 3 |

|     |                                                                                                                                                                                                             |    |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 815 | Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies. <b>2016</b> , 66, 481-495                                                    | 40 |
| 814 | SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate. <b>2016</b> , 151, 945-960.e6 | 65 |
| 813 | Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer. <b>2016</b> , 107, 936-43                                                                          | 62 |
| 812 | Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma. <b>2016</b> , 5, e240                                                               | 14 |
| 811 | Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer. <b>2016</b> , 9, 340-7                                                   | 26 |
| 810 | The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms. <b>2016</b> , 29, 232-8                                                                                                | 14 |
| 809 | Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer. <b>2016</b> , 21, 676-83                                                              | 7  |
| 808 | Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer. <b>2016</b> , 160, 69-77                                                        | 13 |
| 807 | Brazilian health-care policy for targeted oncology therapies and companion diagnostic testing. <b>2016</b> , 17, e363-e370                                                                                  | 6  |
| 806 | Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. <b>2016</b> , 62, 1238-47                                                      | 34 |
| 805 | A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. <b>2016</b> , 115, 1206-1214                | 34 |
| 804 | Assessment of pathological response to therapy using lipid mass spectrometry imaging. <b>2016</b> , 6, 36814                                                                                                | 26 |
| 803 | Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. <b>2016</b> , 51, 54-62                     | 19 |
| 802 | Intrinsic K-Ras dynamics: A novel molecular dynamics data analysis method shows causality between residue pair motions. <b>2016</b> , 6, 37012                                                              | 19 |
| 801 | Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics. <b>2016</b> , 18, 842-850                                  | 32 |
| 800 | Resistance to Tyrosine Kinase Inhibitors. <b>2016</b> ,                                                                                                                                                     | 1  |
| 799 | Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer. <b>2016</b> , 9, 65                                                                                          | 19 |
| 798 | Patients with genetically heterogeneous synchronous colorectal cancer carry rare damaging germline mutations in immune-related genes. <b>2016</b> , 7, 12072                                                | 32 |

|     |                                                                                                                                                                               |     |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 797 | Low expression of PKC $\eta$ and high expression of KRAS predict poor prognosis in patients with colorectal cancer. <b>2016</b> , 12, 1655-1660                               | 9   |
| 796 | Implementing personalized medicine with asymmetric information on prevalence rates. <b>2016</b> , 6, 35                                                                       | 2   |
| 795 | Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies. <b>2016</b> , 55, 268-77                                    | 18  |
| 794 | KSR1 and EPHB4 Regulate Myc and PGC1 $\alpha$ to Promote Survival of Human Colon Tumors. <b>2016</b> , 36, 2246-61                                                            | 17  |
| 793 | Molecular Radio-Oncology. <b>2016</b> ,                                                                                                                                       | 1   |
| 792 | Stigma and Prejudice. <b>2016</b> ,                                                                                                                                           | 1   |
| 791 | Long noncoding RNAs in cancer: mechanisms of action and technological advancements. <b>2016</b> , 15, 43                                                                      | 308 |
| 790 | [Surgery for pulmonary metastases from colorectal cancer: Predictive factors for survival]. <b>2016</b> , 33, 838-852                                                         | 10  |
| 789 | Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. <b>2016</b> , 12, 911-22                                             | 41  |
| 788 | A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. <b>2016</b> , 16, 153         | 49  |
| 787 | Hybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors. <b>2016</b> , 18, 546-53                  | 2   |
| 786 | Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. <b>2016</b> , 45, 286-92                  | 9   |
| 785 | Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery. <b>2016</b> , 10, 1221-31                           | 62  |
| 784 | Selective $\beta$ -AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt/ERK1/2 Signaling, G1-Phase Arrest, and Apoptosis. <b>2016</b> , 231, 459-72 | 39  |
| 783 | Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan. <b>2016</b> , 23, 19-23                        | 8   |
| 782 | Adaptive responses to antibody based therapy. <b>2016</b> , 50, 153-63                                                                                                        | 5   |
| 781 | CD73-adenosine: a next-generation target in immuno-oncology. <b>2016</b> , 8, 145-63                                                                                          | 82  |
| 780 | Epidermal growth factor receptor expression and gene copy number analysis in gastric carcinoma samples from Chinese patients. <b>2016</b> , 11, 173-181                       | 5   |

|     |                                                                                                                                                                                           |     |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 779 | From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy. <b>2016</b> , 15, 104-15                                                                        | 17  |
| 778 | Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer. <b>2016</b> , 37, 8841-8                                                        | 7   |
| 777 | Current and advancing treatments for metastatic colorectal cancer. <b>2016</b> , 16, 93-110                                                                                               | 26  |
| 776 | Drug-diagnostic co-development: challenges and issues. <b>2016</b> , 16, 187-204                                                                                                          | 3   |
| 775 | Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing. <b>2016</b> , 11, 363-70                                      | 18  |
| 774 | Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. <b>2016</b> , 12, 576-92                                                                                  | 35  |
| 773 | Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. <b>2016</b> , 108,                                                                     | 60  |
| 772 | Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. <b>2016</b> , 22, 4057-66                          | 306 |
| 771 | A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. <b>2016</b> , 141, 108-12                                                                       | 6   |
| 770 | Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells. <b>2016</b> , 45, 9-16                                                               | 14  |
| 769 | Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <b>2016</b> , 130, 95-190                               | 120 |
| 768 | Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. <b>2016</b> , 382, 118-126                                                    | 11  |
| 767 | G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. <b>2016</b> , 37, 6823-30                           | 29  |
| 766 | Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. <b>2016</b> , 22, 3067-77                                               | 110 |
| 765 | Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker. <b>2016</b> , 39, 253-63 | 25  |
| 764 | Molecular pathology in real time. <b>2016</b> , 35, 129-40                                                                                                                                | 7   |
| 763 | Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis. <b>2016</b> , 30, 95-104                                                          | 6   |
| 762 | Pharmacologic resistance in colorectal cancer: a review. <b>2016</b> , 8, 57-84                                                                                                           | 259 |

|     |                                                                                                                                                                                                  |     |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 761 | Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. <b>2016</b> , 69, 35-41                                                                               | 16  |
| 760 | Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. <b>2016</b> , 11, 371-81 | 18  |
| 759 | Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. <b>2016</b> , 54, 75-83                                                                        | 107 |
| 758 | Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6. <b>2016</b> , 22, 405-14                                                                     | 54  |
| 757 | Predictive value of pAKT/PTEN expression in oral squamous cell carcinoma treated with cetuximab-based chemotherapy. <b>2016</b> , 121, 67-72                                                     | 13  |
| 756 | Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers. <b>2016</b> , 15, 573-82                                                                              | 6   |
| 755 | NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRASQ61R or KRASQ61R Mutation in Colorectal Carcinoma. <b>2017</b> , 25, 475-480                                   | 9   |
| 754 | STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics. <b>2017</b> , 451, 15-23                                                                                               | 32  |
| 753 | Droplet-Based Microfluidics Digital PCR for the Detection of KRAS Mutations. <b>2017</b> , 1547, 143-164                                                                                         | 7   |
| 752 | Antibodies for Treatment of Metastatic Colorectal Cancer. <b>2017</b> , 217-244                                                                                                                  |     |
| 751 | Present Situation and Prospect of Diagnosis and Treatment of Colorectal Cancer. <b>2017</b> , 1-16                                                                                               |     |
| 750 | Strategies to design clinical studies to identify predictive biomarkers in cancer research. <b>2017</b> , 53, 79-97                                                                              | 64  |
| 749 | Multiplex Detection of KRAS Mutations Using Passive Droplet Fusion. <b>2017</b> , 1547, 133-142                                                                                                  | 1   |
| 748 | Patient subgroup identification for clinical drug development. <b>2017</b> , 36, 1414-1428                                                                                                       | 26  |
| 747 | Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. <b>2017</b> , 16, e153-e163                          | 70  |
| 746 | Colorectal Cancer Metastasis. <b>2017</b> , 95-116                                                                                                                                               | 1   |
| 745 | Chemotherapy in Patients with Initially Unresectable Liver Metastasis of Colorectal Cancer. <b>2017</b> , 213-223                                                                                |     |
| 744 | Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. <b>2017</b> , 174, 145-172                          | 19  |



- 743 La génétique somatique des tumeurs solides, un incontournable de la médecine de précision. **2017**, 72, 217-230
- 742 Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. **2017**, 140, 2331-2343 23
- 741 BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?. **2017**, 18, 9 41
- 740 From single-molecule detection to next-generation sequencing: microfluidic droplets for high-throughput nucleic acid analysis. **2017**, 21, 58 34
- 739 Cancer genomics guide clinical practice in personalized medicine. **2017**, 72, 439-451 8
- 738 Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. **2017**, 8, 14262 177
- 737 Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. **2017**, 28, 958-968 53
- 736 Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FOLFIRI+cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis. **2017**, 96, e6335 5
- 735 Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. **2017**, 23, 4578-4591 58
- 734 A branch-migration based fluorescent probe for straightforward, sensitive and specific discrimination of DNA mutations. **2017**, 45, e90 20
- 733 Combating mutations in genetic disease and drug resistance: understanding molecular mechanisms to guide drug design. **2017**, 12, 553-563 19
- 732 Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration. **2017**, 8, 15090 91
- 731 Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering. **2017**, 31, 151-166 42
- 730 Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with or Mutations. **2017**, 23, 5547-5560 32
- 729 A Novel Combination Treatment Targeting BCL-X and MCL1 for -mutated and -amplified Colorectal Cancers. **2017**, 16, 2178-2190 12
- 728 Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. **2017**, 81, 81-89 9
- 727 Preparing pathology for precision medicine: challenges and opportunities. **2017**, 471, 141-146 6
- 726 Mechanisms of Molecular Carcinogenesis Volume 2. **2017**, 1

|     |                                                                                                                                                                                                                                                                                                             |         |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 725 | Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells. <b>2017</b> , 46, 4245-4280                                                                                                                                                                         | 101     |
| 724 | Genetic and epigenetic markers in colorectal cancer screening: recent advances. <b>2017</b> , 17, 665-685                                                                                                                                                                                                   | 15      |
| 723 | Drug-biomarker co-development in oncology - 20 years and counting. <b>2017</b> , 30, 48-62                                                                                                                                                                                                                  | 38      |
| 722 | Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. <b>2018</b> , 249, 145-159                                                                                                                                                    | 1       |
| 721 | Comprehensive somatic genome alterations of urachal carcinoma. <b>2017</b> , 54, 572-578                                                                                                                                                                                                                    | 20      |
| 720 | Current and future biomarkers in the treatment of colorectal cancer. <b>2017</b> , 72, 103-115                                                                                                                                                                                                              | 21      |
| 719 | Loopback rolling circle amplification for ultrasensitive detection of Kras gene. <b>2017</b> , 164, 511-517                                                                                                                                                                                                 | 16      |
| 718 | EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. <b>2017</b> , 23, 673-677                                                                                                                                                       | 23      |
| 717 | Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K Polymorphism. <i>Cancer Research</i> , <b>2017</b> , 77, 1188-1199                                                                                                                                                                       | 10.1 53 |
| 716 | Microchip Diagnostics. <b>2017</b> ,                                                                                                                                                                                                                                                                        |         |
| 715 | Immunotherapy for Gastrointestinal Cancer. <b>2017</b> ,                                                                                                                                                                                                                                                    | 0       |
| 714 | Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. <b>2017</b> , 143, 573-600                                                                                                                                                            | 11      |
| 713 | International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant. <b>2017</b> , 89, 1724-1733                                                                                                                                              | 31      |
| 712 | Lifetime alcohol intake is associated with an increased risk of KRAS+ and BRAF-/KRAS- but not BRAF+ colorectal cancer. <b>2017</b> , 140, 1485-1493                                                                                                                                                         | 20      |
| 711 | Multidisciplinary Management of Liver Metastases in Colorectal Cancer. <b>2017</b> ,                                                                                                                                                                                                                        | 3       |
| 710 | Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. <b>2017</b> , 86, 305-317 | 17      |
| 709 | Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. <b>2017</b> , 9,                                                                                                                                                                  | 144     |
| 708 | [Personalized Treatment for Colorectal Carcinomas]. <b>2017</b> , 142, 1652-1659                                                                                                                                                                                                                            | 4       |

|     |                                                                                                                                                                                                                           |    |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 707 | Molecular stratification of colorectal cancer populations and its use in directing precision medicine. <b>2017</b> , 2, 205-215                                                                                           | 3  |
| 706 | Bayesian, Utility-Based, Adaptive Enrichment Designs with Frequentist Error Control. <b>2017</b> , 105-123                                                                                                                |    |
| 705 | Building Translational Research Infrastructure and Access to Expertise for Biomarker Discovery in Cancer. <b>2017</b> , 1-25                                                                                              | 1  |
| 704 | Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents. <b>2017</b> , 142, 493-505                                                                                     | 26 |
| 703 | ANO9/TMEM16J promotes tumorigenesis via EGFR and is a novel therapeutic target for pancreatic cancer. <b>2017</b> , 117, 1798-1809                                                                                        | 24 |
| 702 | The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care. <b>2017</b> , 4, 2374289517708309                                                                                              | 17 |
| 701 | Superior Properties of Fc-comprising scTRAIL Fusion Proteins. <b>2017</b> , 16, 2792-2802                                                                                                                                 | 25 |
| 700 | Establishing PNB-qPCR for quantifying minimal ctDNA concentrations during tumour resection. <b>2017</b> , 7, 8876                                                                                                         | 4  |
| 699 | Molecular profiling of locally-advanced rectal adenocarcinoma using microRNA expression (Review). <b>2017</b> , 51, 393-404                                                                                               | 9  |
| 698 | Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification. <b>2017</b> , 1, 714-723                                                                                         | 47 |
| 697 | Simple and rapid LC-MS/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin. <b>2017</b> , 146, 266-272                                                                      | 23 |
| 696 | [Detection of RAS genes mutation using the Cobas method in a private laboratory of pathology: Medical and economical study in comparison to a public platform of molecular biology of cancer]. <b>2017</b> , 104, 662-674 | 2  |
| 695 | Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology. <b>2017</b> , 130, 23-35                                                                                     | 24 |
| 694 | Patient-Derived Xenografts as Cancer Models for Preclinical Drug Screening. <b>2017</b> , 141-154                                                                                                                         | 1  |
| 693 | Precision Oncology: Present Status and Perspectives. <b>2017</b> , 7-26                                                                                                                                                   |    |
| 692 | Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS. <b>2017</b> , 38, 926-932                                                                     | 3  |
| 691 | Next-Generation Sequencing in Diagnostic Pathology. <b>2017</b> , 84, 292-305                                                                                                                                             | 15 |
| 690 | Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. <b>2017</b> , 7, 2602                                                                            | 21 |

- 689 Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. **2017**, 6, CD007047 42
- 688 Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. **2017**, 3, 1520-1528<sup>107</sup>
- 687 Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. **2017**, 28, 2429-2435 61
- 686 Patient-Derived Xenograft Models of Human Cancer. **2017**, 5
- 685 The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing. **2017**, 21, 587-600 24
- 684 Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. **2017**, 28, 2149-2159 73
- 683 Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90. **2017**, 42, 451-459 12
- 682 Mutant KRAS Status Is Associated with Increased KRAS Copy Number Imbalance: a Potential Mechanism of Molecular Heterogeneity. **2017**, 23, 417-423 3
- 681 Targeting Oncoproteins for Molecular Cancer Therapy. **2017**, 727-756
- 680 Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing. **2017**, 19, 84-91 100
- 679 Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. **2017**, 8, 580-590 2
- 678 The MACC1-SPON2 axis: a new biomarker and therapeutic target in colorectal cancer. **2017**, 36, 1474-1475 8
- 677 Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry. **2017**, 23, 387-398 98
- 676 K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives. **2017**, 125, 299-314 32
- 675 Clinical Equipoise for Trials of Novel Biologic Therapies, Therapeutic Success Rates, and Predictors of Success: A Meta-Analysis.. **2017**, 1, 1-12
- 674 Significance of Phosphorylated Epidermal Growth Factor Receptor and Its Signal Transducers in Human Soft Tissue Sarcoma. **2017**, 18, 9
- 673 A Critical Review on the Effect of Docosahexaenoic Acid (DHA) on Cancer Cell Cycle Progression. **2017**, 18, 58
- 672 *Phellinus linteus* Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer. **2017**, 18, 9

|     |                                                                                                                                                                                                                                               |    |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 671 | ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. <b>2017</b> , 9,                                                                                                                                         | 14 |
| 670 | Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma. <b>2017</b> , 2017, 2321052                                                        | 8  |
| 669 | Identification of "BRAF-Positive" Cases Based on Whole-Slide Image Analysis. <b>2017</b> , 2017, 3926498                                                                                                                                      | 1  |
| 668 | Measurement of Telomere Length in Colorectal Cancers for Improved Molecular Diagnosis. <b>2017</b> , 18,                                                                                                                                      | 10 |
| 667 | Thermodynamic framework to assess low abundance DNA mutation detection by hybridization. <b>2017</b> , 12, e0177384                                                                                                                           | 4  |
| 666 | Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. <b>2017</b> , 2, 2381468317729650                                                                                            | 3  |
| 665 | Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. <b>2017</b> , 7, 9388                                                                                                 | 33 |
| 664 | Genetic Variations of Selected Genes Using Target Deep Sequencing in Colorectal Cancer Patients. <b>2017</b> , 9,                                                                                                                             | 1  |
| 663 | MicroRNA-326 inhibits melanoma progression by targeting KRAS and suppressing the AKT and ERK signalling pathways. <b>2018</b> , 39, 401-410                                                                                                   | 20 |
| 662 | Molecular Testing in Colorectal Cancer. <b>2017</b> , 305-320                                                                                                                                                                                 | 1  |
| 661 | Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence hybridization (FISH) to select the optimal patients for matched therapy?. <b>2017</b> , 8, 100863-100898 | 11 |
| 660 | Primary and acquired resistance to biologic therapies in gastrointestinal cancers. <b>2017</b> , 8, 499-512                                                                                                                                   | 9  |
| 659 | Molecular Tests for the Choice of Cancer Therapy. <b>2017</b> , 23, 4794-4806                                                                                                                                                                 | 6  |
| 658 | ATLANTIS - Attractor Landscape Analysis Toolbox for Cell Fate Discovery and Reprogramming. <b>2018</b> , 8, 3554                                                                                                                              | 8  |
| 657 | MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. <b>2018</b> , 144, 1197-1204   | 11 |
| 656 | Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143. <b>2018</b> , 109, 1455-1467                                                                       | 25 |
| 655 | Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer. <b>2018</b> , 41, 18-27                                                                                                           | 14 |
| 654 | Single Locked Nucleic Acid-Enhanced Nanopore Genetic Discrimination of Pathogenic Serotypes and Cancer Driver Mutations. <b>2018</b> , 12, 4194-4205                                                                                          | 14 |

|     |                                                                                                                                                                           |    |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 653 | Resistance of Colorectal Tumors to Anti-EGFR Antibodies. <b>2018</b> , 1-27                                                                                               | 1  |
| 652 | Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. <b>2018</b> , 10,                                          | 50 |
| 651 | Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?. <b>2018</b> , 36, 733-743                            | 13 |
| 650 | Clinicopathological, genomic and immunological factors in colorectal cancer prognosis. <b>2018</b> , 105, e99-e109                                                        | 25 |
| 649 | Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. <b>2018</b> , 52, 26-38                                     | 26 |
| 648 | The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. <b>2018</b> , 124, 1650-1659                                             | 23 |
| 647 | Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology. <b>2018</b> ,                                 | 3  |
| 646 | Colorectal Cancer. <b>2018</b> ,                                                                                                                                          |    |
| 645 | SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. <b>2018</b> , 44, 684-692                                   | 45 |
| 644 | Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. <b>2018</b> , 1765, 281-297                                                               | 6  |
| 643 | Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. <b>2018</b> , 37, 3440-3455 | 27 |
| 642 | Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer. <b>2018</b> , 15, 5553-5560                                                           | 8  |
| 641 | Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer. <b>2018</b> , 8, 4470                                                  | 21 |
| 640 | Biomarker-driven and molecular targeted therapies for colorectal cancers. <b>2018</b> , 45, 124-132                                                                       | 7  |
| 639 | Association between clinicopathological characteristics and RAS mutation in colorectal cancer. <b>2018</b> , 31, 517-526                                                  | 27 |
| 638 | Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?. <b>2018</b> , 25, 179-187                  | 17 |
| 637 | Use of Liquid Biopsy in Monitoring Colorectal Cancer Progression Shows Strong Clinical Correlation. <b>2018</b> , 355, 220-227                                            | 15 |
| 636 | Clinical Presentation and Prognostic Factors in Lung Cancer. <b>2018</b> , 186-198.e6                                                                                     |    |

|     |                                                                                                                                                                                                                       |    |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 635 | Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. <b>2018</b> , 142, 238-250            | 53 |
| 634 | Precision Medicine from a Public Health Perspective. <b>2018</b> , 39, 153-168                                                                                                                                        | 54 |
| 633 | Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. <b>2018</b> , 3, 162-171                        | 37 |
| 632 | Molecular Markers and Mutational Analysis. <b>2018</b> , 295-312                                                                                                                                                      | 0  |
| 631 | LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity. <b>2018</b> , 118, 558-565                                                                                   | 9  |
| 630 | The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA. <b>2018</b> , 17, 297-305                                                                                            | 24 |
| 629 | Single index methods for evaluation of marker-guided treatment rules based on multivariate marker panels. <b>2018</b> , 74, 663-672                                                                                   | 1  |
| 628 | Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example. <b>2018</b> , 17, 355-367                                   | 21 |
| 627 | Mechanisms of Drug Resistance in Cancer Therapy. <b>2018</b> ,                                                                                                                                                        |    |
| 626 | Multidimensional range queries on modern hardware. <b>2018</b> ,                                                                                                                                                      | 3  |
| 625 | Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights. <b>2018</b> , 9, E23-E27                                                        | 6  |
| 624 | Serum level of octanoic acid predicts the efficacy of chemotherapy for colorectal cancer. <b>2019</b> , 17, 831-842                                                                                                   | 7  |
| 623 | Patient with Lynch syndrome with subsequent development of small bowel adenocarcinoma. <b>2018</b> ,                                                                                                                  | 3  |
| 622 | Construction and characterization of regulated cycle inhibiting factors induced upon Tet-On system in human colon cancer cell lines. <b>2018</b> , 29, 854-860                                                        | 1  |
| 621 | Acquired and Intrinsic Resistance to Colorectal Cancer Treatment. <b>2018</b> ,                                                                                                                                       | 3  |
| 620 | Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin. <b>2018</b> , 8, 16579                                                                                          | 5  |
| 619 | Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study. <b>2018</b> , 20, 1219-1226 | 15 |
| 618 | Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer. <b>2018</b> , 9, 4782                                                                                       | 51 |

|     |                                                                                                                                                                                                        |     |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 617 | miRNAs as Modulators of EGFR Therapy in Colorectal Cancer. <b>2018</b> , 1110, 133-147                                                                                                                 | 2   |
| 616 | Targeted Therapy of Colorectal Cancer Subtypes. <b>2018</b> ,                                                                                                                                          |     |
| 615 | How the V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications. <b>2018</b> , 2018, 9250757                                                              | 25  |
| 614 | Biology of Nodal Spread in Colon Cancer: Insights from Molecular and Genetic Studies. <b>2018</b> , 59, 361-370                                                                                        | 2   |
| 613 | Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. <b>2018</b> , 9, 1300                                                                                              | 337 |
| 612 | The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line. <b>2018</b> , 9, 4255-4262 | 2   |
| 611 | GSK3 suppression upregulates E-catenin and c-Myc to abrogate KRas-dependent tumors. <b>2018</b> , 9, 5154                                                                                              | 47  |
| 610 | Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. <b>2018</b> , 10, 5895-5908                                          | 12  |
| 609 | Emerging paradigms in the treatment of liver metastases in colorectal cancer. <b>2018</b> , 132, 39-50                                                                                                 | 11  |
| 608 | Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. <b>2018</b> , 50, 1399-1411                                                                               | 94  |
| 607 | Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree?. <b>2018</b> , 5, 234                                                            | 41  |
| 606 | Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <b>2018</b> , 9, 4112                                                            | 36  |
| 605 | EPA significantly improves anti-EGFR targeted therapy by regulating miR-378 expression in colorectal cancer. <b>2018</b> , 16, 6188-6194                                                               | 5   |
| 604 | Comprehensive Validation of Snapback Primer-Based Melting Curve Analysis to Detect Nucleotide Variation in the Codon 12 and 13 of KRAS Gene. <b>2018</b> , 2018, 8727941                               | 1   |
| 603 | Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells. <b>2018</b> , 22, 133-142                                                                     | 4   |
| 602 | Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review. <b>2018</b> , 19,                                                                                                                | 50  |
| 601 | Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications. <b>2018</b> , 19,                                                                                                          | 19  |
| 600 | Sixteen Years of Experience with the Treatment of Advanced Colorectal Cancer in Iran; A Report from Three Institutions. <b>2018</b> , 10, 160-168                                                      | 4   |



|     |                                                                                                                                                                            |    |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 599 | Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations. <b>2018</b> , 19, 1203-1216                             | 8  |
| 598 | Personalized Medicine. <b>2018</b> , 109-135                                                                                                                               | 3  |
| 597 | Down-Regulated LncRNA-HOTAIR Suppressed Colorectal Cancer Cell Proliferation, Invasion, and Migration by Mediating p21. <b>2018</b> , 63, 2320-2331                        | 23 |
| 596 | Expression of NOX Family Genes and Their Clinical Significance in Colorectal Cancer. <b>2018</b> , 63, 2332-2340                                                           | 12 |
| 595 | Colorectal Cancer: Why Does Side Matter?. <b>2018</b> , 78, 789-798                                                                                                        | 26 |
| 594 | The Role of HGF/MET and MSP/RON Signaling in Tumor Progression and Resistance to Anticancer Therapy. <b>2018</b> , 45-68                                                   |    |
| 593 | Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. <b>2018</b> , 31, 1882-1890                | 24 |
| 592 | Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls. <b>2018</b> , 430, 2900-2912                                                                      | 14 |
| 591 | Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer. <b>2018</b> , 11, 465-471         | 5  |
| 590 | Clinical update on K-Ras targeted therapy in gastrointestinal cancers. <b>2018</b> , 130, 78-91                                                                            | 11 |
| 589 | Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response. <b>2018</b> , 10,                                       | 10 |
| 588 | Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects. <b>2018</b> , 9, 2943                                                | 16 |
| 587 | Molecular Applications in Cytology. <b>2018</b> ,                                                                                                                          | 1  |
| 586 | Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field. <b>2018</b> , 7,                                                                                      | 54 |
| 585 | Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/ $\beta$ Catenin Pathway Associated with Oncogenic EGFR Mutations. <b>2018</b> , 8, | 3  |
| 584 | Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. <b>2018</b> , 2018, 2397863                                        | 43 |
| 583 | Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth. <b>2018</b> , 13, e0200163                                                 | 0  |
| 582 | Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. <b>2018</b> , 37, 4599-4610                                      | 23 |

|     |                                                                                                                                                                                                                                                                       |    |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 581 | Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells. <b>2018</b> , 10, 2                                                                                                         | 2  |
| 580 | Expression of factors and key components associated with the PI3K signaling pathway in colon cancer. <b>2018</b> , 15, 5465-5472                                                                                                                                      | 6  |
| 579 | Genetic and epigenetic alterations of colorectal cancer. <b>2018</b> , 16, 327-337                                                                                                                                                                                    | 60 |
| 578 | EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer. <b>2018</b> , 82, 163-171                                                                                                                                                     | 1  |
| 577 | Evidence-based medicine and precision medicine: Complementary approaches to clinical decision-making. <b>2018</b> , 1, 60-64                                                                                                                                          | 18 |
| 576 | Molecular Diagnosis of Human Disease. <b>2018</b> , 691-707                                                                                                                                                                                                           | 1  |
| 575 | Dose-escalation strategies which use subgroup information. <b>2018</b> , 17, 414-436                                                                                                                                                                                  | 5  |
| 574 | A Guanidyl-Based Bivalent Peptidomimetic Inhibits K-Ras Prenylation and Association with c-Raf. <b>2019</b> , 25, 13531-13536                                                                                                                                         | 5  |
| 573 | Oncogenic G12D mutation alters local conformations and dynamics of K-Ras. <b>2019</b> , 9, 11730                                                                                                                                                                      | 20 |
| 572 | Immuno-oncology for surgeons. <b>2019</b> , 106, 1273-1282                                                                                                                                                                                                            | 1  |
| 571 | A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival. <b>2019</b> , 11, 109                                                                                                      | 3  |
| 570 | Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation. <b>2019</b> , 14, e0219204 | 11 |
| 569 | Anti-Apoptotic Effects of Docosahexaenoic Acid in IL-1 $\beta$ Induced Human Chondrosarcoma Cell Death through Involvement of the MAPK Signaling Pathway. <b>2019</b> , 158, 17-24                                                                                    | 9  |
| 568 | Application of immune repertoire sequencing in cancer immunotherapy. <b>2019</b> , 74, 105688                                                                                                                                                                         | 3  |
| 567 | The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents. <b>2019</b> , 39, 5645-5652                                                                                                                             | 4  |
| 566 | Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial. <b>2019</b> , 70, 157-163                                                                                                         | 1  |
| 565 | KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer. <b>2019</b> , 18, e309-e315                                                                                                                                        | 8  |
| 564 | MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers. <b>2019</b> , 16, 1480-1491                                                                                                                                                          | 22 |

|     |                                                                                                                                                                                                                                                                                      |      |    |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----|
| 563 | KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer. <b>2019</b> , 19, 1131-1140                                                                                                             |      | 4  |
| 562 | Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02). <b>2019</b> , 24, e1115-e1122                                                                                                                                                  |      | 6  |
| 561 | A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations. <b>2019</b> , 18, 600-626                                                                                                                              |      | 5  |
| 560 | Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters. <b>2019</b> , 11,                                                                                                                                                                                        |      | 34 |
| 559 | Kras/ADAM17-Dependent Jag1-ICD Reverse Signaling Sustains Colorectal Cancer Progression and Chemoresistance. <i>Cancer Research</i> , <b>2019</b> , 79, 5575-5586                                                                                                                    | 10.1 | 12 |
| 558 | Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers. <b>2019</b> , 18, 2368-2380                                                                                                                                                                              |      | 24 |
| 557 | Targeted next-generation DNA sequencing identifies Notch signaling pathway mutation as a predictor of radiation response. <b>2019</b> , 95, 1640-1647                                                                                                                                |      | 0  |
| 556 | Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer. <b>2019</b> , 19, 219-224                                                                                              |      | 14 |
| 555 | Alteration of the tumor suppressor SARDH in sporadic colorectal cancer: A functional and transcriptome profiling-based study. <b>2019</b> , 58, 957-966                                                                                                                              |      | 2  |
| 554 | Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status. <b>2019</b> , 13, 890                                                                               |      | 9  |
| 553 | Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. <b>2019</b> , 51, 1-14                                                                                                                                                       |      | 47 |
| 552 | Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer. <b>2019</b> , 26, 1824-1832                                                                                                                                |      | 21 |
| 551 | The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. <b>2019</b> , 7, 1-32                                                                                                                                                                                 |      | 9  |
| 550 | CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. <b>2019</b> , 39, 28 |      | 2  |
| 549 | Mutation Status of , and is Superior to Mutation Status of Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases. <b>2019</b> , 25, 5843-5851                                                                                                                |      | 69 |
| 548 | Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors. <b>2019</b> , 25, 5984-5996                                                                                                                                     |      | 24 |
| 547 | Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. <b>2019</b> , 14, 62                                                                                                                                                           |      | 4  |
| 546 | Decoding Metastatic Colorectal Cancer to Improve Clinical Decision Making. <b>2019</b> , 37, 1847-1850                                                                                                                                                                               |      | 2  |

|     |                                                                                                                                                                                                                                                                      |     |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 545 | Molecular and histological correlations in liver cancer. <b>2019</b> , 71, 616-630                                                                                                                                                                                   | 131 |
| 544 | A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer. <b>2019</b> , 5, eaav6528                                                                                                                | 35  |
| 543 | RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score. <b>2019</b> , 26, 2595-2604 | 13  |
| 542 | Evaluation of the Physicochemical and Biological Stability of Cetuximab under Various Stress Condition. <b>2019</b> , 22, 171-190                                                                                                                                    | 3   |
| 541 | Emergency Surgical Management of Colorectal Cancer. <b>2019</b> ,                                                                                                                                                                                                    | 0   |
| 540 | Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data. <b>2019</b> , 25, 1840-1853                                 | 11  |
| 539 | Uncommon mutational profiles of metastatic colorectal cancer detected during routine genotyping using next generation sequencing. <b>2019</b> , 9, 7083                                                                                                              | 2   |
| 538 | Postoperative Oncologic Management of Colorectal Cancer Emergencies. <b>2019</b> , 233-239                                                                                                                                                                           |     |
| 537 | Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review. <b>2019</b> , 781, 100-129                                                                                                                                                    | 14  |
| 536 | Engineering tumor vasculature on an injection-molded plastic array 3D culture (IMPACT) platform. <b>2019</b> , 19, 2071-2080                                                                                                                                         | 26  |
| 535 | ASO Author Reflections: Perioperative Genomic Profiles and Prognosis of Peripheral and Perihepatic Circulating Tumor DNA in Patients with Colorectal Liver Metastases. <b>2019</b> , 26, 583-584                                                                     |     |
| 534 | Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab. <b>2019</b> , 16, 207-219                                                                                                                                 | 6   |
| 533 | Exome and immune cell score analyses reveal great variation within synchronous primary colorectal cancers. <b>2019</b> , 120, 922-930                                                                                                                                | 4   |
| 532 | MicroRNA-7 Exerts Antiangiogenic Effect on Colorectal Cancer via ERK Signaling. <b>2019</b> , 240, 48-59                                                                                                                                                             | 12  |
| 531 | Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. <b>2019</b> , 15, 61-69                                                                                                                                              | 15  |
| 530 | An ultrasensitive and simple fluorescence biosensor for detection of the Kras wild type by using the three-way DNA junction-driven catalyzed hairpin assembly strategy. <b>2019</b> , 144, 3088-3093                                                                 | 7   |
| 529 | Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma. <b>2019</b> , 34, 288-296                                                                                                                   | 5   |
| 528 | Characterization of early recurrences following liver resection by ALPPS and two stage hepatectomy in patients with colorectal liver-metastases and small future liver remnants; a translational substudy of the LIGRO-RCT. <b>2019</b> , 21, 1017-1023              | 10  |

|     |                                                                                                                                                                                                                                                                                    |    |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 527 | Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers. <b>2019</b> , 3,                                                                                                       | 6  |
| 526 | Clinical development of targeted and immune based anti-cancer therapies. <b>2019</b> , 38, 156                                                                                                                                                                                     | 93 |
| 525 | The Yin and Yang of cancer genes. <b>2019</b> , 704, 121-133                                                                                                                                                                                                                       | 9  |
| 524 | The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis. <b>2019</b> , 8, 1218-1231                                                                                                                        | 11 |
| 523 | Clinicopathological characterization of SMAD4-mutated intestinal adenocarcinomas: A case-control study. <b>2019</b> , 14, e0212142                                                                                                                                                 | 12 |
| 522 | Biomarker concordance between primary colorectal cancer and its metastases. <b>2019</b> , 40, 363-374                                                                                                                                                                              | 38 |
| 521 | MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. <b>2019</b> , 145, 748-762                                                                                                                                        | 16 |
| 520 | Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma. <b>2019</b> , 14, e0212801 | 10 |
| 519 | Small non-coding RNAs as a tool for personalized therapy in familial cancers. <b>2019</b> , 179-208                                                                                                                                                                                |    |
| 518 | Programmable RNA detection with a fluorescent RNA aptamer using optimized three-way junction formation. <b>2019</b> , 25, 590-599                                                                                                                                                  | 9  |
| 517 | Heuristics and Explanation in Translational Medicine. <b>2019</b> , 62, 675-689                                                                                                                                                                                                    |    |
| 516 | Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance. <b>2019</b> , 18, 1909-1915                                                                                                                                | 13 |
| 515 | Importance of translational and regulatory sciences (TRS) from the perspective of drug development. <b>2019</b> , 1, 4-7                                                                                                                                                           |    |
| 514 | Personalized Medicine in Oncology Drug Development. <b>2019</b> , 1-11                                                                                                                                                                                                             |    |
| 513 | Rare case of triple mutant (KRAS + NRAS + BRAF) metastatic colon adenocarcinoma. <b>2019</b> , 12,                                                                                                                                                                                 | 3  |
| 512 | Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer. <b>2019</b> , 37, 209-225                                                                                                                                              | 4  |
| 511 | From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development. <b>2019</b> , 25, 245-253                                                                                              | 3  |
| 510 | microRNAs Tune Oxidative Stress in Cancer Therapeutic Tolerance and Resistance. <b>2019</b> , 20,                                                                                                                                                                                  | 12 |

|     |                                                                                                                                                                       |    |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 509 | Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data. <b>2019</b> , 11,                                        | 7  |
| 508 | Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours. <b>2019</b> , 11, 20261-20273           | 20 |
| 507 | Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review. <b>2019</b> , 3,                                                                          | 6  |
| 506 | The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis. <b>2019</b> , 165, 476-484 | 8  |
| 505 | Grown on Germinated Soybean Suppresses KRAS-Driven Colorectal Cancer by Inhibiting the RAS/ERK Pathway. <b>2018</b> , 11,                                             | 9  |
| 504 | Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. <b>2019</b> , 73, 41-53                  | 44 |
| 503 | A Pilot Prospective Study of Refractory Solid Tumor Patients for NGS-Based Targeted Anticancer Therapy. <b>2019</b> , 12, 301-307                                     | 5  |
| 502 | Current status of immunotherapy in metastatic colorectal cancer. <b>2019</b> , 34, 13-25                                                                              | 64 |
| 501 | Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting. <b>2019</b> , 12, 502-512                        | 9  |
| 500 | Development of Isoselenocyanate Compounds' Syntheses and Biological Applications. <b>2019</b> , 62, 5261-5275                                                         | 18 |
| 499 | Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers. <b>2019</b> , 442, 202-212                                              | 12 |
| 498 | Diagnostic, prognostic, and therapeutic potency of microRNA 21 in the pathogenesis of colon cancer, current status and prospective. <b>2019</b> , 234, 8075-8081      | 25 |
| 497 | LncRNA and mRNA signatures associated with neoadjuvant chemoradiotherapy downstaging effects in rectal cancer. <b>2019</b> , 120, 5207-5217                           | 14 |
| 496 | Cancer Immunotherapy: The Dawn of Antibody Cocktails. <b>2019</b> , 1904, 11-51                                                                                       | 14 |
| 495 | Practicing Pathology in the Post-genomic Era: Challenges and Opportunities. <b>2019</b> , 3-9                                                                         |    |
| 494 | HER2-targeted therapy: an emerging strategy in advanced colorectal cancer. <b>2019</b> , 28, 29-38                                                                    | 16 |
| 493 | ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer. <b>2019</b> , 144, 2008-2019                                        | 22 |
| 492 | Targeted therapies in pancreatic cancer: Promises and failures. <b>2019</b> , 120, 2726-2741                                                                          | 13 |

|     |                                                                                                                                                                                                                                         |    |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 491 | Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients. <b>2019</b> , 25, 269-278                                                                                                                | 3  |
| 490 | Effect of normalization methods on the performance of supervised learning algorithms applied to HTSeq-FPKM-UQ data sets: 7SK RNA expression as a predictor of survival in patients with colon adenocarcinoma. <b>2019</b> , 20, 985-994 | 25 |
| 489 | Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. <b>2020</b> , 146, 566-576                                                          | 13 |
| 488 | Meta-GDBP: a high-level stacked regression model to improve anticancer drug response prediction. <b>2020</b> , 21, 996-1005                                                                                                             | 44 |
| 487 | Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC. <b>2020</b> , 27, 293-300                                                                    | 28 |
| 486 | Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). <b>2020</b> , 25, e266-e275                  | 2  |
| 485 | The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer. <b>2020</b> , 59, 152-159                                                                                                                                     | 8  |
| 484 | Pathways of Colorectal Carcinogenesis. <b>2020</b> , 158, 291-302                                                                                                                                                                       | 86 |
| 483 | RNA sequencing for research and diagnostics in clinical oncology. <b>2020</b> , 60, 311-323                                                                                                                                             | 34 |
| 482 | Gene mutation and surgical technique: Suggestion or more?. <b>2020</b> , 33, 210-215                                                                                                                                                    | 10 |
| 481 | Colorectal cancer in Saudi Arabia as the proof-of-principle model for implementing strategies of predictive, preventive, and personalized medicine in healthcare. <b>2020</b> , 11, 119-131                                             | 13 |
| 480 | Designing clinical studies for biomarker discovery: The Design criteria. <b>2020</b> , 441-466                                                                                                                                          |    |
| 479 | MicroRNA-141-3p affected proliferation, chemosensitivity, migration and invasion of colorectal cancer cells by targeting EGFR. <b>2020</b> , 118, 105643                                                                                | 13 |
| 478 | Molecular Pathways, Screening and Follow-up of Colorectal Carcinogenesis: An Overview. <b>2020</b> , 16, 88-96                                                                                                                          | 1  |
| 477 | Therapeutic Targeting of the Colorectal Tumor Stroma. <b>2020</b> , 158, 303-321                                                                                                                                                        | 23 |
| 476 | Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. <b>2020</b> , 31, 30-40                                                                          | 58 |
| 475 | Genomics and the History of Precision Oncology. <b>2020</b> , 29, 35-49                                                                                                                                                                 | 8  |
| 474 | SNPs are related to colorectal cancer susceptibility and survival in Chinese people. <b>2020</b> , 14, 13-22                                                                                                                            | 1  |

|     |                                                                                                                                                                                                                                                     |    |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 473 | Development and Analytical Validation of a DNA Dual-Strand Approach for the US Food and Drug Administration-Approved Next-Generation Sequencing-Based Praxis Extended RAS Panel for Metastatic Colorectal Cancer Samples. <b>2020</b> , 22, 159-178 | 1  |
| 472 | Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers. <b>2020</b> , 59, 298-301                                                                                                   | 1  |
| 471 | Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq Assay. <b>2020</b> , 24, 103-111                                                   | 1  |
| 470 | Novel activating KRAS mutation candidates in lung adenocarcinoma. <b>2020</b> , 522, 690-696                                                                                                                                                        | 1  |
| 469 | Colorectal Cancer. <b>2020</b> , 1219-1280.e15                                                                                                                                                                                                      | 3  |
| 468 | EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer. <b>2020</b> , 39, 6856-6870                                                                                                                   | 11 |
| 467 | The Stress-Like Cancer Cell State Is a Consistent Component of Tumorigenesis. <b>2020</b> , 11, 536-546.e7                                                                                                                                          | 22 |
| 466 | Reliability of digital PCR in detecting KRAS mutation in colorectal cancer using plasma sample: A systematic review and meta-analysis. <b>2020</b> , 99, e21171                                                                                     | 1  |
| 465 | Harnessing Omics Approaches on Advanced Preclinical Models to Discovery Novel Therapeutic Targets for the Treatment of Metastatic Colorectal Cancer. <b>2020</b> , 12,                                                                              | 0  |
| 464 | Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. <b>2020</b> , 8, 179-191                                                                                                                   | 20 |
| 463 | and mutations in metastatic colorectal cancer: future perspectives for personalized therapy. <b>2020</b> , 8, 192-205                                                                                                                               | 18 |
| 462 | Personalised mapping of tumour development in synchronous colorectal cancer patients. <b>2020</b> , 5, 27                                                                                                                                           | 1  |
| 461 | . <b>2020</b> ,                                                                                                                                                                                                                                     | 1  |
| 460 | Predicting Chemotherapeutic Response for Far-advanced Gastric Cancer by Radiomics with Deep Learning Semi-automatic Segmentation. <b>2020</b> , 11, 7224-7236                                                                                       | 11 |
| 459 | The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future. <b>2020</b> , 21,                                                                                                                                                    | 3  |
| 458 | Monitoring of Early Changes of Circulating Tumor DNA in the Plasma of Rectal Cancer Patients Receiving Neoadjuvant Concomitant Chemoradiotherapy: Evaluation for Prognosis and Prediction of Therapeutic Response. <b>2020</b> , 10, 1028           | 10 |
| 457 | Associations between nutritional factors and KRAS mutations in colorectal cancer: a systematic review. <b>2020</b> , 20, 696                                                                                                                        | 1  |
| 456 | Biomarkers in Colorectal Cancer: Current Research and Future Prospects. <b>2020</b> , 21,                                                                                                                                                           | 39 |



|     |                                                                                                                                                                                                                                             |     |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 455 | Synthetic Lethality through the Lens of Medicinal Chemistry. <b>2020</b> , 63, 14151-14183                                                                                                                                                  | 11  |
| 454 | Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <b>2020</b> , 15, 733-741 | 10  |
| 453 | Metastatic colon cancer of the small intestine diagnosed using genetic analysis: a case report. <b>2020</b> , 15, 106                                                                                                                       | 0   |
| 452 | Circularized blocker-displacement amplification for multiplex detection of rare DNA variants. <b>2020</b> , 56, 12331-12334                                                                                                                 | 4   |
| 451 | KRAS Inhibition with Sotorasib in Advanced Solid Tumors. <b>2020</b> , 383, 1207-1217                                                                                                                                                       | 469 |
| 450 | Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer. <b>2020</b> , 17, 605-613                             | 3   |
| 449 | Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. <b>2020</b> , 123, 1502-1512                             | 5   |
| 448 | Molecular Targets for the Treatment of Metastatic Colorectal Cancer. <b>2020</b> , 12,                                                                                                                                                      | 14  |
| 447 | Precision Medicine for the Management of Therapy Refractory Colorectal Cancer. <b>2020</b> , 10,                                                                                                                                            | 1   |
| 446 | The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with an increased tumour mutational burden. <b>2020</b> , 10, 18900                                                                           | 0   |
| 445 | Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS or KRAS mutations. <b>2020</b> , 10, 20678                                                                                                                         | 4   |
| 444 | Vitamin C Transporters and Their Implications in Carcinogenesis. <b>2020</b> , 12,                                                                                                                                                          | 5   |
| 443 | Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. <b>2020</b> , 12,                                                                                                                                            | 10  |
| 442 | Utility of circulating tumor cells and DNA in the management of advanced colorectal cancer. <b>2020</b> , 16, 1289-1299                                                                                                                     | 3   |
| 441 | Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy. <b>2020</b> , 25, 1523-1532                            | 9   |
| 440 | Clinical Theragnostic Potential of Diverse miRNA Expressions in Prostate Cancer: A Systematic Review and Meta-Analysis. <b>2020</b> , 12,                                                                                                   | 7   |
| 439 | The genomic landscape of metastasis in treatment-naïve breast cancer models. <b>2020</b> , 16, e1008743                                                                                                                                     | 4   |
| 438 | Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling. <b>2020</b> , 12,                                                                                                       | 21  |

|     |                                                                                                                                                                                                 |     |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 437 | Immunotherapy, Inflammation and Colorectal Cancer. <b>2020</b> , 9,                                                                                                                             | 66  |
| 436 | Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer. <b>2020</b> , 7, 1716618                                                                    | 7   |
| 435 | Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. <b>2020</b> , 121, 1320-1328                            | 5   |
| 434 | Causal Evidence and Dispositions in Medicine and Public Health. <b>2020</b> , 17,                                                                                                               | 9   |
| 433 | A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles. <b>2020</b> , 12, 24                                            | 12  |
| 432 | Clonal Hematopoiesis From Next Generation Sequencing of Plasma From a Patient With Lung Adenocarcinoma: A Case Report. <b>2020</b> , 10, 113                                                    | 1   |
| 431 | Effectiveness of Vigna unguiculata seed extracts in preventing colorectal cancer. <b>2020</b> , 11, 5853-5865                                                                                   | 3   |
| 430 | Active Compound of Semen ( Seeds) Suppressed KRAS-Driven Colorectal Cancer and Restored Muscle Cell Function during Cancer Progression. <b>2020</b> , 25,                                       | 2   |
| 429 | Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. <b>2020</b> , 147, 1-57                                                                         | 17  |
| 428 | Biochemical Markers of Colorectal Cancer - Present and Future. <b>2020</b> , 12, 4789-4797                                                                                                      | 18  |
| 427 | Novel and Traditional Nonclinical Biomarker Utilization in the Estimation of Pharmaceutical Therapeutic Indices. <b>2020</b> , 505-513                                                          |     |
| 426 | Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials. <b>2020</b> , 32, 163-170 | 2   |
| 425 | Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study. <b>2020</b> , 108, 715-721                                                                | 6   |
| 424 | Harnessing Natural Killer Cells Killing Function in Cancer. <b>2020</b> , 91-155                                                                                                                |     |
| 423 | Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling. <b>2019</b> , 9, 1559                |     |
| 422 | A Bispecific Inhibitor of the EGFR/ADAM17 Axis Decreases Cell Proliferation and Migration of EGFR-Dependent Cancer Cells. <b>2020</b> , 12,                                                     | 4   |
| 421 | Molecular profiling for precision cancer therapies. <b>2020</b> , 12, 8                                                                                                                         | 180 |
| 420 | and Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. <b>2020</b> , 9,                        | 19  |

|                 |                                                                                                                                                                                                               |    |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 4 <sup>19</sup> | Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. <b>2020</b> , 2020, 9037217                                                                     | 26 |
| 4 <sup>18</sup> | The heterogeneous clinical and pathological landscapes of metastatic -mutated colorectal cancer. <b>2020</b> , 20, 30                                                                                         | 22 |
| 4 <sup>17</sup> | The Clinical Relevance of Frequent Germline Genetic Variants Detected by Targeted Sequencing in Patients With Rectal Adenocarcinoma (READ). <b>2020</b> , 17, 291-299                                         | 1  |
| 4 <sup>16</sup> | Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines. <b>2020</b> , 16, 51                              | 7  |
| 4 <sup>15</sup> | Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study. <b>2020</b> , 19, 200-208.e1                | 2  |
| 4 <sup>14</sup> | Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. <b>2020</b> , 86, 102023                                                          | 19 |
| 4 <sup>13</sup> | Effectiveness of first-line cetuximab in wild-type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort. <b>2021</b> , 87, 1120-1128                              | 2  |
| 4 <sup>12</sup> | Mutation-Specific and Common Phosphotyrosine Signatures of G12D and G13D Alleles. <b>2021</b> , 20, 670-683                                                                                                   | 7  |
| 4 <sup>11</sup> | Implementation of personalized medicine in a context of moral hazard and uncertainty about treatment efficacy. <b>2021</b> , 21, 81-97                                                                        |    |
| 4 <sup>10</sup> | Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer. <b>2021</b> , 26, 15-23                                                                                       | 3  |
| 4 <sup>09</sup> | Phase-specific cancer-immune model considering acquired resistance to therapeutic agents. <b>2021</b> , 391, 125555                                                                                           |    |
| 4 <sup>08</sup> | Identification of Two Subgroups of FOLFOX Resistance Patterns and Prediction of FOLFOX Response in Colorectal Cancer Patients. <b>2021</b> , 39, 62-72                                                        | 2  |
| 4 <sup>07</sup> | Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. <b>2020</b> , 148, 2542 | 1  |
| 4 <sup>06</sup> | Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X inhibitor ABT-263 in KRAS-mutant colorectal cancers. <b>2021</b> , 497, 123-136                                                  | 6  |
| 4 <sup>05</sup> | New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients. <b>2021</b> , 15, 65-79                                                                                            | 1  |
| 4 <sup>04</sup> | Trends in epidemiology, treatment and molecular testing of metastatic colorectal cancer in a real-world multi-institution cohort study. <b>2021</b> , 17, 84-93                                               | 4  |
| 4 <sup>03</sup> | Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. <b>2021</b> , 13, 17588359211018539                                                                              | 2  |
| 4 <sup>02</sup> | Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors. <b>2021</b> , 13, 1950264                                                                  | 6  |

|     |                                                                                                                                                               |   |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 401 | Mechanisms of Cetuximab Resistance and How to Overcome It. <b>2021</b> , 21-51                                                                                |   |
| 400 | Deep Tumor Profiling for Molecular Tumor Boards. <b>2021</b> , 352-360                                                                                        |   |
| 399 | New Molecular Targeted Therapy of Metastatic Colorectal Cancer. <b>2021</b> , 44, 11-18                                                                       | 0 |
| 398 | Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. <b>2021</b> , 151, 231-304                                                 | 3 |
| 397 | Prognostic Value of Autophagy, Microsatellite Instability, and Mutations in Colorectal Cancer. <b>2021</b> , 12, 3515-3528                                    | 3 |
| 396 | Chemical Approach Toward Controlling of Transient Protein Interactions. <b>2021</b> , 77-96                                                                   |   |
| 395 | A Multi-Learning Training Approach for Distinguishing Low and High Risk Cancer Patients. <b>2021</b> , 9, 115453-115465                                       |   |
| 394 | Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients. <b>2021</b> , 87, 555-565                 | 1 |
| 393 | Developing Novel Anticancer Drugs for Targeted Populations: An Update. <b>2021</b> , 27, 250-262                                                              | 1 |
| 392 | EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents?. <b>2021</b> , 13,                   | 2 |
| 391 | Radiogenomics in Colorectal Cancer. <b>2021</b> , 13,                                                                                                         | 8 |
| 390 | HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with Wild Type Metastatic Colorectal Cancer. <b>2021</b> , 13,                        | 4 |
| 389 | Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. <b>2021</b> , 21, 83                                 | 4 |
| 388 | Genomic analysis of response to neoadjuvant chemotherapy in esophageal adenocarcinoma.                                                                        |   |
| 387 | Clinical oncology research; Review on contemporary methodology standards. <b>2021</b> , 45, 100725                                                            | 1 |
| 386 | Dual Drug Targeting to Kill Colon Cancer Cells.                                                                                                               |   |
| 385 | RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <b>2021</b> , 146, 74-83                                                | 8 |
| 384 | CRISPR screens identify a novel combination treatment targeting BCL-X and WNT signaling for KRAS/BRAF-mutated colorectal cancers. <b>2021</b> , 40, 3287-3302 | 4 |

|     |                                                                                                                                                                                                                               |    |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 383 | A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast!. <b>2021</b> , 204, 123-125 | 2  |
| 382 | Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma. <b>2022</b> , 42, 112-155                                 | 9  |
| 381 | Early response in phosphorylation of ribosomal protein S6 is associated with sensitivity to trametinib in colorectal cancer cells. <b>2021</b> , 101, 1036-1047                                                               | 2  |
| 380 | Pharmacoepidemiology: A time for a new multidisciplinary approach to precision medicine. <b>2021</b> , 30, 985-992                                                                                                            |    |
| 379 | Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review. <b>2021</b> , 12, S191-S203                                 | 3  |
| 378 | Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. <b>2021</b> , 27, 4012-4024                                                                                        | 6  |
| 377 | Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma.                                                                                                                                  | 2  |
| 376 | Copy Number Variation and Rearrangements Assessment in Cancer: Comparison of Droplet Digital PCR with the Current Approaches. <b>2021</b> , 22,                                                                               | 1  |
| 375 | Comprehensive Clinical and Molecular Characterization of -Mutant Colorectal Cancer. <b>2021</b> , 5,                                                                                                                          | 7  |
| 374 | Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. <b>2021</b> , 11, 874-899                                                                                                                              | 26 |
| 373 | Evolution of the liver biopsy and its future. <b>2021</b> , 6, 20                                                                                                                                                             | 4  |
| 372 | Potential Role of KRAS and BRAF in Epithelial Ovarian Cancer. <b>2021</b> , 19, 1                                                                                                                                             | 1  |
| 371 | Uptake of KRAS Testing and Anti-EGFR Antibody Use for Colorectal Cancer in the VA. <b>2021</b> , 5,                                                                                                                           |    |
| 370 | Precision oncology in metastatic colorectal cancer - from biology to medicine. <b>2021</b> , 18, 506-525                                                                                                                      | 27 |
| 369 | Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer. <b>2021</b> , 6, 144                                                                                                      | 11 |
| 368 | Intra-Tumoral Genomic Heterogeneity in Rectal Cancer: Mutational Status Is Dependent on Preoperative Biopsy Depth and Location. <b>2021</b> , 13,                                                                             | 1  |
| 367 | Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss. <b>2021</b> , 26, e963-e970                                             | 0  |
| 366 | KRAS and NRAS genes mutations as biomarkers in the therapy of colorectal cancer and the basic methods of their detection. <b>2021</b> , 12, 66-71                                                                             | 0  |

|     |                                                                                                                                                                                                                                                                             |         |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 365 | Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG-510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL-XL. <b>2021</b> , 15, 148 | 1       |
| 364 | Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. <b>2021</b> , 21, 518                                                                                                                                                | 5       |
| 363 | Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients. <b>2021</b> , 22,                                                                                                                                                      | 1       |
| 362 | Analysis of KRAS G12/G13 in colorectal cancer using an economical digital PCR assay that unequivocally differentiates missense and synonymous alleles. <b>2021</b> , 99, 2554                                                                                               | 1       |
| 361 | EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. <b>2021</b> , 13,                                                                                                                                                                                     | 23      |
| 360 | International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. <b>2021</b> , 160, 2572-2584                                                                                                                               | 28      |
| 359 | SK4 oncochannels regulate calcium entry and promote cell migration in KRAS-mutated colorectal cancer. <b>2021</b> , 96, 102384                                                                                                                                              | 4       |
| 358 | Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. <i>Cancer Research</i> , <b>2021</b> , 81, 4641-4651                                                                                                                                                             | 10.1 10 |
| 357 | DNA Mutations via Chern-Simons Currents.                                                                                                                                                                                                                                    | 1       |
| 356 | Nucleic Acid Tests for Clinical Translation. <b>2021</b> , 121, 10469-10558                                                                                                                                                                                                 | 23      |
| 355 | The diverse molecular profiles of lynch syndrome-associated colorectal cancers are (highly) dependent on underlying germline mismatch repair mutations. <b>2021</b> , 163, 103338                                                                                           | 0       |
| 354 | Cancer Genomic Profiling in Colorectal Cancer: Current Challenges in Subtyping Colorectal Cancers Based on Somatic and Germline Variants. <b>2021</b> , 5, 213-228                                                                                                          |         |
| 353 | Combination Therapy with KRAS and P38 $\beta$ siRNA Suppresses Colorectal Cancer Growth and Development in SW480 Cell Line. <b>2021</b> , 1                                                                                                                                 | 2       |
| 352 | 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis. <b>2021</b> , 22,                                                                  | 3       |
| 351 | Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. <b>2021</b> , 13,                                                                                                                                                                    | 0       |
| 350 | Molecular-genetic mechanisms of the signal cascade RAS-RAF-MEK-ERK associated with the development of the tumor process and the purpose of targeted drugs for colorectal cancer. <b>2021</b> , 11, 25-35                                                                    |         |
| 349 | Complete pathological response in rectal cancer utilising novel treatment strategies for neo-adjuvant therapy: A systematic review. <b>2021</b> , 47, 1862-1874                                                                                                             | 3       |
| 348 | Cell competition in intratumoral and tumor microenvironment interactions. <b>2021</b> , 40, e107271                                                                                                                                                                         | 9       |

|     |                                                                                                                                                                                                                                      |   |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 347 | Antibody therapy in pancreatic cancer: mAb-ye we're onto something?. <b>2021</b> , 1876, 188557                                                                                                                                      | 0 |
| 346 | Pan-Cancer Molecular Biomarkers: A Paradigm Shift in Diagnostic Pathology. <b>2021</b> , 14, 507-516                                                                                                                                 | 0 |
| 345 | Precision Dosing of Targeted Therapies Is Ready for Prime Time. <b>2021</b> ,                                                                                                                                                        | 1 |
| 344 | Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. <b>2021</b> , 6,                                                                                                                       | 0 |
| 343 | Infrequent RAS mutation is not associated with specific histological phenotype in gliomas. <b>2021</b> , 21, 1025                                                                                                                    | 1 |
| 342 | A human antibody against human endothelin receptor type A that exhibits antitumor potency. <b>2021</b> , 53, 1437-1448                                                                                                               | 5 |
| 341 | Expression Characteristics and Clinical Correlations of BRD1 in Colorectal Cancer Samples. <b>2021</b> , 20, 1533033821103967                                                                                                        | 0 |
| 340 | Genomic Alterations of KRAS and NRAS in B&H Colorectal and Non-small Cell Lung Cancer Patients. <b>2021</b> , 589-598                                                                                                                | 0 |
| 339 | Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo. <b>2021</b> , 23, 1549-1560                                                                                        | 1 |
| 338 | A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110 $\beta$ in cell lines and tumor tissues. <b>2021</b> , 146, 6566-6575 | 0 |
| 337 | Redirecting the Cellular Waste Disposal Machinery to Target Transcription. <b>2021</b> , 643-663                                                                                                                                     | 0 |
| 336 | Update on the role of EGFR inhibitors in cancer therapeutics. <b>2007</b> , 135, 257-75                                                                                                                                              | 3 |
| 335 | Genetic Markers in Sporadic Tumors. <b>2008</b> , 43-84                                                                                                                                                                              | 2 |
| 334 | Targeted Therapy in Colorectal Cancer. <b>2008</b> , 101-123                                                                                                                                                                         | 2 |
| 333 | Repeat Hepatectomy for Colorectal Liver Metastases. <b>2016</b> , 168, 203-20                                                                                                                                                        | 2 |
| 332 | Stratifying Cancer Therapies by Molecular Interactions and Imaging. <b>2017</b> , 315-358                                                                                                                                            | 1 |
| 331 | An Introduction to Pharmacogenomics and Personalized Medicine. <b>2015</b> , 1053-1065                                                                                                                                               | 1 |
| 330 | Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology. <b>2016</b> , 198, 45-87                                                                                                                              | 2 |

|     |                                                                                                                                                                                                                                             |     |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 329 | Molecular Prognostic Markers in Colon Cancer. <b>2010</b> , 321-341                                                                                                                                                                         | 1   |
| 328 | Colorectal Cancer. <b>2014</b> , 1278-1335.e14                                                                                                                                                                                              | 1   |
| 327 | Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab. <b>2020</b> , 30, 1400-1416.e611                                                                                                                          |     |
| 326 | Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). <b>2020</b> , 19, 301-310.e1 | 3   |
| 325 | Sensitive, enzyme-free and label-free electrochemical sensor for K-ras G12D point mutation detection based on double cascade amplification reaction. <b>2020</b> , 870, 114270                                                              | 3   |
| 324 | 226 ENMC International Workshop:: Towards validated and qualified biomarkers for therapy development for Duchenne muscular dystrophy 20-22 January 2017, Heemskerk, The Netherlands. <b>2018</b> , 28, 77-86                                | 8   |
| 323 | A population of stress-like cancer cells in melanoma promotes tumorigenesis and confers drug resistance.                                                                                                                                    | 2   |
| 322 | Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. <b>2011</b> , 121, 4311-21                                                                                                    | 159 |
| 321 | Epidermal growth factor receptor inhibits colitis-associated cancer in mice. <b>2012</b> , 122, 2780-92                                                                                                                                     | 52  |
| 320 | KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver. <b>2020</b> , 10, 142                                                                                                              | 2   |
| 319 | Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. <b>2020</b> , 40, 161-173                                                                                                   | 4   |
| 318 | KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic. <b>2010</b> , 2,                                                                                                                                              | 6   |
| 317 | Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. <b>2009</b> , 4, e6555                                                                                                 | 71  |
| 316 | Profiling critical cancer gene mutations in clinical tumor samples. <b>2009</b> , 4, e7887                                                                                                                                                  | 295 |
| 315 | KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. <b>2009</b> , 4, e8199                                                                                        | 128 |
| 314 | DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. <b>2010</b> , 5, e13978                                                                                        | 85  |
| 313 | 1, 9-Pyrazoloanthrones downregulate HIF-1 $\beta$ and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy. <b>2010</b> , 5, e15823                                                                                               | 14  |
| 312 | Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel. <b>2012</b> , 7, e51153                                                                                                                   | 20  |



|     |                                                                                                                                                                                                                                              |     |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 311 | The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. <b>2013</b> , 8, e59380                                                                                                                                    | 10  |
| 310 | Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients. <b>2014</b> , 9, e86789                                                                                       | 14  |
| 309 | Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study. <b>2014</b> , 9, e112201                                         | 24  |
| 308 | KRAS mutation analysis by PCR: a comparison of two methods. <b>2015</b> , 10, e0115672                                                                                                                                                       | 19  |
| 307 | Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer. <b>2015</b> , 10, e0126417                                                                                 | 38  |
| 306 | Validation of a Multiplex Allele-Specific Polymerase Chain Reaction Assay for Detection of KRAS Gene Mutations in Formalin-Fixed, Paraffin-Embedded Tissues from Colorectal Cancer Patients. <b>2016</b> , 11, e0147672                      | 12  |
| 305 | Heterogeneity of KRAS Mutation Status in Rectal Cancer. <b>2016</b> , 11, e0153278                                                                                                                                                           | 12  |
| 304 | Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. <b>2016</b> , 11, e0153533                                                                                     | 17  |
| 303 | Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR. <b>2016</b> , 11, e0163070                                                                                                                                 | 6   |
| 302 | Unforeseen clonal evolution of tumor cell population in recurrent and metastatic dermatofibrosarcoma protuberans. <b>2017</b> , 12, e0185826                                                                                                 | 8   |
| 301 | A Systematic Literature Review and Meta-Analysis Describing the Prevalence of , and Gene Mutations in Metastatic Colorectal Cancer. <b>2020</b> , 13, 184-198                                                                                | 5   |
| 300 | [The RAS paradox of the EGFR-targeted therapy in colorectal cancer]. <b>2008</b> , 52, 185-91                                                                                                                                                | 2   |
| 299 | Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: The Rationale for Combination Therapies. <b>2015</b> , 3,                                                                                                                   | 12  |
| 298 | Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <b>2011</b> , 3, 192-222                                                                        | 437 |
| 297 | TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. <b>2016</b> , 7, 59441-59457 | 5   |
| 296 | Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab. <b>2016</b> , 7, 68111-68121                                                                                  | 13  |
| 295 | Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation. <b>2016</b> , 7, 73525-73540                                                                                                                | 33  |
| 294 | Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine. <b>2017</b> , 8, 48534-48544                                                                                       | 5   |

|     |                                                                                                                                                                                       |    |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 293 | Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines. <b>2017</b> , 8, 11020-11029                                      | 7  |
| 292 | ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer. <b>2017</b> , 8, 17164-17190                                                | 17 |
| 291 | Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. <b>2014</b> , 5, 2807-19                                  | 29 |
| 290 | Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. <b>2014</b> , 5, 8544-57                                                      | 46 |
| 289 | Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. <b>2018</b> , 9, 17756-17769                   | 21 |
| 288 | Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study. <b>2018</b> , 9, 33702-33709 | 4  |
| 287 | Broad-spectrum receptor tyrosine kinase inhibitors overcome and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer. <b>2019</b> , 10, 1320-1333             | 8  |
| 286 | AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab. <b>2015</b> , 6, 11507-18                                      | 28 |
| 285 | Clinical next generation sequencing to identify actionable aberrations in a phase I program. <b>2015</b> , 6, 20099-11038                                                             |    |
| 284 | Resistance to EGFR inhibitors: molecular determinants and the enigma of head and neck cancer. <b>2011</b> , 2, 894-5                                                                  | 9  |
| 283 | Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling. <b>2015</b> , 6, 33091-10522                                                               |    |
| 282 | miR-200c inhibits breast cancer proliferation by targeting KRAS. <b>2015</b> , 6, 34968-78                                                                                            | 58 |
| 281 | Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. <b>2015</b> , 6, 38166-80          | 13 |
| 280 | Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression. <b>2016</b> , 7, 10064-72                                                                        | 19 |
| 279 | Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma. <b>2016</b> , 7, 21496-509                                           | 18 |
| 278 | Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2. <b>2012</b> , 3, 1533-45                                    | 38 |
| 277 | Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. <b>2016</b> , 7, 22543-55                                                   | 9  |
| 276 | Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). <b>2016</b> , 7, 18953-64             | 9  |

|     |                                                                                                                                                                                                  |     |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 275 | Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells. <b>2016</b> , 7, 64766-64777                                               | 19  |
| 274 | Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. <b>2016</b> , 7, 29492-506                                                                  | 23  |
| 273 | Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. <b>2016</b> , 7, 42988-42995 | 49  |
| 272 | Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. <b>2018</b> , 4,                                                                               | 2   |
| 271 | Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma. <b>2019</b> , 7, 427                                                                  | 26  |
| 270 | First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. <b>2009</b> , 2, 73-82                                                                       | 3   |
| 269 | Molecular characterization of head and neck cancer: how close to personalized targeted therapy?. <b>2012</b> , 16, 209-22                                                                        | 12  |
| 268 | Targeting Mutant KRAS for Anticancer Therapy. <b>2019</b> , 19, 2098-2113                                                                                                                        | 4   |
| 267 | Coexistence of and Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity. <b>2017</b> , 19, 113-117                                                      | 29  |
| 266 | Rectal cancer and the pathologist. <b>2018</b> , 73, 534-547                                                                                                                                     | 3   |
| 265 | KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis. <b>2014</b> , 18, 1-132                                       | 59  |
| 264 | Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. <b>2010</b> , 17 Suppl 1, S3-17                                                           | 44  |
| 263 | Pharmacogenomics in colorectal cancer: the first step for individualized-therapy. <b>2007</b> , 13, 5888-901                                                                                     | 23  |
| 262 | Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. <b>2010</b> , 16, 1177-87                                                                   | 18  |
| 261 | Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. <b>2010</b> , 16, 4823-31                                                                       | 39  |
| 260 | KRAS mutation testing in metastatic colorectal cancer. <b>2012</b> , 18, 5171-80                                                                                                                 | 129 |
| 259 | Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. <b>2014</b> , 20, 3858-74                                                                           | 39  |
| 258 | Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. <b>2014</b> , 20, 4230-43                                                                                   | 62  |

|     |                                                                                                                                                                                              |     |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 257 | Recent applications of chemosensitivity tests for colorectal cancer treatment. <b>2014</b> , 20, 16398-408                                                                                   | 14  |
| 256 | Comparative study of mutations in SNP loci of K-RAS, hMLH1 and hMSH2 genes in neoplastic intestinal polyps and colorectal cancer. <b>2014</b> , 20, 18338-45                                 | 4   |
| 255 | Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis. <b>2015</b> , 21, 4365-72                                                      | 5   |
| 254 | Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer. <b>2016</b> , 22, 490-500                          | 20  |
| 253 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <b>2016</b> , 22, 6345-61                                                      | 69  |
| 252 | Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. <b>2016</b> , 22, 6944-54                                                                            | 47  |
| 251 | Detection of G12D in colorectal cancer stool by droplet digital PCR. <b>2017</b> , 23, 7087-7097                                                                                             | 9   |
| 250 | PLC $\beta$ -dependent invasion and migration of cells expressing NSCLC-associated EGFR mutants. <b>2020</b> , 57, 989-1000                                                                  | 2   |
| 249 | EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis. <b>2014</b> , 26, 59-71        | 10  |
| 248 | Colorectal carcinoma: Pathologic aspects. <b>2012</b> , 3, 153-73                                                                                                                            | 282 |
| 247 | Integrating anti-EGFR therapies in metastatic colorectal cancer. <b>2013</b> , 4, 285-98                                                                                                     | 17  |
| 246 | Markers of resistance to anti-EGFR therapy in colorectal cancer. <b>2013</b> , 4, 308-18                                                                                                     | 35  |
| 245 | Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. <b>2015</b> , 6, 314-21                                                                   | 21  |
| 244 | The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer. <b>2014</b> , 13, 13 | 3   |
| 243 | Predictive Modeling of Drug Treatment in the Area of Personalized Medicine. <b>2015</b> , 14, 95-103                                                                                         | 11  |
| 242 | Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum Samples. <b>2012</b> , 5, 15-22                                                             | 39  |
| 241 | EGFR Expression Is Unreliable to Decide for Cetuximab Treatment in Patients with Metastatic Colorectal Cancer: Results from ERBITUX-OUEST <b>2016</b> , 06, 56-67                            | 1   |
| 240 | Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer. <b>2017</b> , 9, 407-415                                    | 23  |

|     |                                                                                                                                                                          |     |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 239 | Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. <b>2015</b> , 7, 2245-63                                  | 8   |
| 238 | Genomic Profiling of Thyroid Nodules: Current Role for ThyroSeq Next-Generation Sequencing on Clinical Decision-Making. <b>2017</b> , 26, 24-35                          | 10  |
| 237 | Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants. <b>2014</b> , 5, 806-23      | 19  |
| 236 | Molecular Markers in Sex Differences in Cancer. <b>2019</b> , 35, 331-341                                                                                                | 15  |
| 235 | New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs. <b>2013</b> , 32, 233-41 | 2   |
| 234 | Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. <b>2009</b> , 133, 1539-51                                       | 253 |
| 233 | The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. <b>2009</b> , 133, 1600-6                                             | 92  |
| 232 | Practical and molecular evaluation of colorectal cancer: new roles for the pathologist in the era of targeted therapy. <b>2010</b> , 134, 853-63                         | 12  |
| 231 | Molecular diagnostics of colorectal cancer. <b>2011</b> , 135, 578-87                                                                                                    | 41  |
| 230 | Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran. <b>2016</b> , 17, 1729-32                       | 7   |
| 229 | Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. <b>2013</b> , 10, 192-205                                                              | 37  |
| 228 | PPIP5K2 promotes colorectal carcinoma pathogenesis through facilitating DNA homologous recombination repair. <b>2021</b> , 40, 6680-6691                                 |     |
| 227 | Development of a Single Quantum Dot-Mediated FRET Nanosensor for Sensitive Detection of Single-Nucleotide Polymorphism in Cancer Cells. <b>2021</b> , 93, 14568-14576    | 8   |
| 226 | Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. <b>2021</b> , 12, 978                                          | 1   |
| 225 | Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance. <b>2021</b> , 9, e12338                                        | 2   |
| 224 | Combination treatment. <b>2007</b> , 135-140                                                                                                                             |     |
| 223 | Anticorps anti-EGFR. <b>2008</b> , 35-44                                                                                                                                 |     |
| 222 | Monoclonaux contre inhibiteurs de tyrosine kinase. <b>2008</b> , 81-97                                                                                                   |     |

- 221 Cellular sensitivity to EGF receptor inhibitors. **2008**, 340-355
- 220 The intersection of EGFR and the Ras signaling pathway. **2008**, 84-90
- 219 Pharmacogenomics in Drug Development: A Pharmaceutical Industry Perspective. **2008**, 313-325
- 218 EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer. **2008**, 281-324
- 217 Prérequis avant la mise en route d'une chimiothérapie pour cancer colorectal. **2009**, 30-46
- 216 Progress in the treatment of colorectal cancer: the impact of new drugs. **2009**, 176-190
- 215 The EGFR pathway as an example for genotype: phenotype correlation in tumor genes. **2010**, 576, 341-50
- 214 Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008. **2009**, 2, 13-9
- 213 Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. **2009**, 2, 161-70 2
- 212 Inherent Resistance to Epidermal Growth Factor Receptor Antibodies in Refractory Metastatic Colorectal Cancer. **2009**, 9, 165-174 1
- 211 Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. **2009**, 2, 251-60 1
- 210 [The development of the first line treatment of metastatic colorectal cancer (mCRC)]. **2009**, 53, 237-46
- 209 KRAS Testing in Metastatic Colorectal Cancer: Implications on the Use of Biologic Agents. **2009**, 3, 48-53
- 208 Pharmacogenetics in Colorectal Cancer. **2010**, 61-86
- 207 Genetische Aberration, Genexpressionprofile und Epigenetik. **2010**, 67-75
- 206 Molekulare Diagnostik und Response-Prädiktion. **2010**, 187-197
- 205 Novel and Traditional Nonclinical Biomarker Utilization in the Estimation of Pharmaceutical Therapeutic Indices. 1
- 204 Practical Gastrointestinal Oncology Correlative Science. **2011**, 43-66

- 203 Anticancer Drug Development in Pediatric Patients. **2011**, 589-601
- 202 Current and Future Methods for Diagnosis of Neoplastic Liver Disease. **2011**, 907-916
- 201 Matching cancer genomes to established cell lines for personalized oncology. **2011**, 243-52 6
- 200 Diagnostic and Prognostic Cancer Biomarkers: From Traditional to Systems Approaches. **2011**, 329-366
- 199 The Use of Decision Analysis Tools for the Selection of Clinical Laboratory Tests: Developing Diagnostic and Forecasting Models Using Laboratory Evidence. **2011**, 305-322 1
- 198 A Single Institutional Experience with Panitumumab in Metastatic Colorectal Cancer. **2012**, 03, 948-955
- 197 Predictive Markers in Colon Cancer. **2013**, 1-23
- 196 Molecular Pathology of Colon and Small Bowel Cancers: Sporadic Type. **2013**, 131-140
- 195 Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer. **2013**, 125-141
- 194 L'Anatomopathologie "à l'ère de la médecine personnalisée" : du diagnostic "à la théranostique". **2013**, 373-384
- 193 Les anti-EGFR personnalisés selon le statut tumoral KRAS. **2013**, 159-175
- 192 Mutational Activation of KRAS and BRAF in Colorectal Cancer. **2013**, 121-156 1
- 191 Comprehensive Genomic Alterations in Common Cancer Cell Lines Revealed by Exome Sequencing. **2013**, 165-182
- 190 The Clinical Significance of Mutations in Colorectal Cancer. **2013**, 231-245
- 189 Reinforcement of Appropriate Use of Drugs by Developing Simple Genotyping Methods and Their Clinical Application. **2013**, 39, 61-76
- 188 Signal Transduction Inhibitors of the HER Family. **2013**, 17-50
- 187 Beyond the standard of care: the role of cytopathology in molecular testing of cancer. **2014**, 160, 273-82
- 186 Rationally designed treatment for metastatic colorectal cancer: current drug development strategies. **2014**, 20, 10288-95 3

- 185 Application of Pharmacogenomics in Global Alzheimer's Disease Clinical Trials and Ethical Implications. **2014**, 353-370
- 184 Pharmacogenomics and Personalized Medicine: Bridging Genetic Knowledge and Clinical Practice. **2014**, 1-16
- 183 Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers. **2014**, 3, 175-8 1
- 182 Genomic Applications in Colorectal and Pancreatic Tumors. **2015**, 415-434
- 181 Portfolio Optimization of Therapies and Their Predictive Biomarkers. **2015**, 155-180 0
- 180 Pharmacogenetics and Antineoplastic Therapies. **2015**, 275-305
- 179 Systemic Treatment for Metastatic or Recurrent Disease. **2015**, 221-244
- 178 CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons. **2015**, 4, 160 2
- 177 Molecular Profiling in Resectable Colorectal Liver Metastases: The Role of KRAS Mutation Status in Assessing Prognosis in the Preoperative Setting. **2015**, 6, 470-4 3
- 176 Incorporating Clinical Biomarkers into Clinical Trials. **2016**, 57-67
- 175 Pharmacology: Cultural and Genetic Considerations. **2016**, 353-374
- 174 Gastrointestinal Malignancy: Genetic Implications to Clinical Applications. **2016**, 168, 393-479
- 173 Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. **2016**, 27-107
- 172 CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons. **2015**, 4, 160 2
- 171 An Empirical Analysis of Topic Modeling for Mining Cancer Clinical Notes. 0
- 170 An International Inter-Laboratory Digital PCR Study Demonstrates High Reproducibility for the Measurement of a Rare Sequence Variant.
- 169 Anti-EGFR therapy in colorectal carcinoma. **2017**, 11, 66-71
- 168 Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status. **2017**, 12, e0175484 1



- 167 The application of the modern target medications for the treatment of metastatic colorectal cancer. **2018**, 7, 21
- 166 Molecular Cytology Applications in Metastases. **2018**, 247-259
- 165 Traitement du cancer colorectal m astatique : ciblage mol culaire. **2018**, 12, 178-183
- 164 Principles of Adjuvant and Neoadjuvant Therapy for Locally Advanced Rectal Cancer. **2019**, 445-463
- 163 Molecular Diagnostics and Genomic Profiling in Individualized Therapies of Gastrointestinal Cancers. **2019**, 613-631
- 162 KRAS as Potential Target in Colorectal Cancer Therapy. **2019**, 389-424 0
- 161 Opportunities and challenges of implementing Pharmacogenomics in cancer drug development.. **2019**, 2, 43-52 0
- 160 GEFT protein expression in digestive tract malignant tumors and its clinical significance. **2019**, 18, 5577-5590 2
- 159 The genomic landscape of metastasis in treatment-na ve breast cancer models.
- 158 Immunohistochemical evaluation of the prognostic and predictive power of epidermal growth factor receptor ligand levels in patients with metastatic colorectal cancer. **2020**, 38, 127-136
- 157 DNA Mutations via Chern-Simons Currents. **2021**, 136, 1080 1
- 156 Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer. **2021**, 22, 4
- 155 Establishing Novel Molecular Subtypes of Appendiceal Cancer. **2021**, 1 0
- 154 Carcinomas of the Gastrointestinal Tract. **2021**, 427-472
- 153 Identification of a Prognostic Risk Signature of Kidney Renal Clear Cell Carcinoma Based on Regulating the Immune Response Pathway Exploration. **2020**, 2020, 6657013 2
- 152 Chapter 17: Oncology: Somatic Disease and Pharmacogenomics. **2020**,
- 151 Cancer Imaging with Radiolabeled Monoclonal Antibodies. **2020**, 739-760 2
- 150 Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer. **2021**, 7, FSO757

|     |                                                                                                                                                                   |    |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 149 | Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence.                                 | 0  |
| 148 | Automated synthesis of F radiolabelled indole containing Oncrasin-like molecules; a comparison of iodonium salts and boronic ester chemistry. <b>2020</b> , 5, 23 |    |
| 147 | Resistance to anti-EGFR targeted therapy mediated by oncogenetic mutations in colorectal cancer: Revision of the dogma?. <b>2020</b> , 2-2                        |    |
| 146 | Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. <b>2016</b> , 7, S11-20                                                  | 7  |
| 145 | Analysis of KRAS gene mutation associated with infection in patients with gastric cancer. <b>2019</b> , 22, 529-533                                               | 1  |
| 144 | [ADAM17 knockdown increases sensitivity of SW480 cells to cetuximad]. <b>2018</b> , 38, 1366-1371                                                                 | 1  |
| 143 | Predictive and prognostic markers in colorectal cancer. <b>2007</b> , 1, 237-46                                                                                   | 9  |
| 142 | Cetuximab in the management of colorectal cancer. <b>2007</b> , 1, 77-91                                                                                          | 12 |
| 141 | EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. <b>2009</b> , 3, 215-24                                                         | 24 |
| 140 | Accomplishments in 2008 in biologic markers for gastrointestinal cancers-focus on colorectal cancer. <b>2009</b> , 3, S73-8                                       | 2  |
| 139 | BITC Sensitizes Pancreatic Adenocarcinomas to TRAIL-induced Apoptosis. <b>2010</b> , 2009, 45-55                                                                  | 24 |
| 138 | Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. <b>2009</b> , 2, 17-27                      | 3  |
| 137 | Evolving role of cetuximab in the treatment of colorectal cancer. <b>2009</b> , 1, 79-88                                                                          | 3  |
| 136 | Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. <b>2011</b> , 36, 263-79                                           | 14 |
| 135 | Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. <b>2011</b> , 1, 650-62        | 22 |
| 134 | Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. <b>2011</b> , 84, 371-80                                                 | 44 |
| 133 | A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. <b>2012</b> , 5, 112-8                         | 5  |
| 132 | Alternate dosing of cetuximab for patients with metastatic colorectal cancer. <b>2013</b> , 6, 47-55                                                              | 7  |

|     |                                                                                                                                                                       |    |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 131 | Translating clinical research of Molecular Biology into a personalized, multidisciplinary approach of colorectal cancer patients. <b>2014</b> , 7, 17-26              | 3  |
| 130 | Advances in cancer immunotherapy. <b>2013</b> , 15, 120-5                                                                                                             | 8  |
| 129 | A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. <b>2011</b> , 31, 255-61                   | 21 |
| 128 | Establishment of genetically diverse patient-derived xenografts of colorectal cancer. <b>2014</b> , 4, 824-37                                                         | 18 |
| 127 | Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study. <b>2014</b> , 7, 581-7                                                        | 41 |
| 126 | K-ras Mutation in Colorectal Cancer, A Report from Southern Iran. <b>2015</b> , 40, 454-60                                                                            | 9  |
| 125 | Heterochromatin Protein 1 Binding Protein 3 Expression as a Candidate Marker of Intrinsic 5-Fluorouracil Resistance. <b>2016</b> , 36, 845-52                         | 2  |
| 124 | MicroRNA-195 suppresses colorectal cancer cells proliferation via targeting FGF2 and regulating Wnt/βcatenin pathway. <b>2016</b> , 6, 2631-2640                      | 17 |
| 123 | Molecular Profiles Guide Colorectal Cancer Treatment. <b>2016</b> , 33, 505-535                                                                                       | 1  |
| 122 | The emerging role of long non-coding RNAs in the drug resistance of colorectal cancer. <b>2018</b> , 11, 4735-4743                                                    | 4  |
| 121 | Objective Quantitation of EGFR Protein Levels using Quantitative Dot Blot Method for the Prognosis of Gastric Cancer Patients.. <b>2021</b> , 21, 335-351             | 0  |
| 120 | Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers. <b>2021</b> , 13,                                                             |    |
| 119 | Depletion of METTL3 alters cellular and extracellular levels of miRNAs containing mA consensus sequences.. <b>2021</b> , 7, e08519                                    | 1  |
| 118 | Exemple des tumeurs digestives. <b>2008</b> , 27, 23-27                                                                                                               |    |
| 117 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.. <b>2022</b> , 23,                                  |    |
| 116 | Accès aux tests génétiques en oncologie. <b>2022</b> , 206, 433-433                                                                                                   |    |
| 115 | The path to the clinic: a comprehensive review on direct KRAS inhibitors.. <b>2022</b> , 41, 27                                                                       | 7  |
| 114 | Antibody Conjugated PLGA Nanocarriers and Superparamagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma.. <b>2022</b> , 23, | 2  |

|     |                                                                                                                                                                                                                                                     |   |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 113 | Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines.. <b>2022</b> , 11,                                                                                                                                    | 0 |
| 112 | A Trial Protocol of Precision Medicine for Patients with RAS Wild Metastatic Colorectal Cancer Using Liquid Biopsy (RAS-liquid Study): A Prospective, Multicenter Observational Study.. <b>2022</b> , 6, 52-57                                      | 0 |
| 111 | A Deep Learning solution for triaging patient with cancer from their predicted mutational status using histopathological images.                                                                                                                    |   |
| 110 | Metastatic colorectal cancer in both sides of Aegean Sea: practice patterns and outcome.. <b>2022</b> , 1-25                                                                                                                                        |   |
| 109 | EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors.. <b>2022</b> , 1                                                                                                                                                                        | 1 |
| 108 | Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. <b>2009</b> , 11, 737-47                                                                                                                                        | 3 |
| 107 | Biomarker-Driven Adaptive Phase III Clinical Trials. <b>2021</b> , 1-12                                                                                                                                                                             |   |
| 106 | Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma.. <b>2022</b> ,                                                                                                                                         | 0 |
| 105 | Preoperative Neutrophil-BMI Ratio As a Promising New Marker for Predicting Tumor Outcomes in Colorectal Cancer.. <b>2022</b> , 21, 15330338211064077                                                                                                | 2 |
| 104 | is associated with metastasis and glutathione/glycosphingolipid metabolism in colon adenocarcinoma.. <b>2022</b> , 13, 246-255                                                                                                                      |   |
| 103 | Adenomyosis as a Risk Factor for Myometrial or Endometrial Neoplasms-Review.. <b>2022</b> , 19,                                                                                                                                                     | 1 |
| 102 | A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study.. <b>2022</b> , 1 | 1 |
| 101 | Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis.. <b>2022</b> , 14,                                                                            |   |
| 100 | Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience. <b>2022</b> , 44, 1332-1352                                                                                  | 0 |
| 99  | Colorectal cancer carcinogenesis: From bench to bedside.. <b>2022</b> , 14, 654-663                                                                                                                                                                 | 1 |
| 98  | The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways.. <b>2022</b> , 10, 751367                                                                                                                   | 0 |
| 97  | Landscape of , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in -Mutated Cancers.. <b>2022</b> , 6, e2100245                                                                                                    | 2 |
| 96  | Dual drug targeting to kill colon cancers.. <b>2022</b> ,                                                                                                                                                                                           | 0 |

|    |                                                                                                                                                                        |   |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 95 | Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers.. <b>2022</b> , 13, 1618                                            | 3 |
| 94 | The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles.. <b>2021</b> , | 4 |
| 93 | Artificial intelligence, molecular subtyping, biomarkers, and precision oncology. <b>2021</b> ,                                                                        | 1 |
| 92 | Targeting KRAS G12C with Covalent Inhibitors. <b>2022</b> , 6,                                                                                                         | 1 |
| 91 | KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer.. <b>2022</b> , 1                        | 0 |
| 90 | Data_Sheet_1.docx. <b>2020</b> ,                                                                                                                                       |   |
| 89 | Table_1.docx. <b>2020</b> ,                                                                                                                                            |   |
| 88 | The HER family as therapeutic targets in colorectal cancer.. <b>2022</b> , 103681                                                                                      | 0 |
| 87 | Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy.. <b>2022</b> , 8, eabl9171                                     | 1 |
| 86 | Genetic Characteristics of Resectable Colorectal Cancer with Pulmonary Metastasis.. <b>2022</b> , 2022, 2033876                                                        | 0 |
| 85 | The prognostic value of KRAS mutation in locally advanced rectal cancer.. <b>2022</b> , 37, 1199                                                                       | 1 |
| 84 | Clinical management of metastatic colorectal cancer in the era of precision medicine.. <b>2022</b> ,                                                                   | 8 |
| 83 | Mutation of KRAS in colorectal adenocarcinoma in Greenland.                                                                                                            |   |
| 82 | Prädiktive Testung von Tumorgewebe und ihre klinischen Konsequenzen. <b>2022</b> , 1-15                                                                                |   |
| 81 | NK Cell-Based Immunotherapy in Colorectal Cancer. <b>2022</b> , 10, 1033                                                                                               | 1 |
| 80 | Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence.                                      | 0 |
| 79 | Prognostic Models Incorporating RAS Mutation to Predict Survival in Patients with Colorectal Liver Metastases: A Narrative Review. <b>2022</b> , 14, 3223              | 0 |
| 78 | Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer.                                                                                   | 0 |

|    |                                                                                                                                                      |   |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 77 | Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy. | 0 |
| 76 | Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4/6.                                                                       | 1 |
| 75 | Embryologic Origin of the Primary Tumor and RAS Status Predict Survival after Resection of Colorectal Liver Metastases. <b>2022</b> , 58, 1100       |   |
| 74 | Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk. <b>2022</b> , 22,                                          | 1 |
| 73 | Biomarker-Driven Adaptive Phase III Clinical Trials. <b>2022</b> , 2367-2378                                                                         | 0 |
| 72 | Identification of Tissue Types and Gene Mutations From Histopathology Images for Advancing Colorectal Cancer Biology. <b>2022</b> , 3, 115-123       | 0 |
| 71 | Chapter 21: Oncology: Rasburicase/G6PD Case. <b>2022</b> ,                                                                                           | 0 |
| 70 | Abbreviations. <b>2022</b> ,                                                                                                                         | 0 |
| 69 | Chapter 29: Pharmacogenomics in Ethical and Social Contexts. <b>2022</b> ,                                                                           | 0 |
| 68 | Appendix 2: Glossary. <b>2022</b> ,                                                                                                                  | 0 |
| 67 | Chapter 27: Rheumatology/Musculoskeletal Pain: Codeine/CYP2D6 Case. <b>2022</b> ,                                                                    | 0 |
| 66 | Chapter 8: Cardiology: Simvastatin/SLCO1B1 Case. <b>2022</b> ,                                                                                       | 0 |
| 65 | Chapter 28: Information Resources for Pharmacogenomics. <b>2022</b> ,                                                                                | 0 |
| 64 | Chapter 18: Oncology: Somatic Disease and Pharmacogenomics. <b>2022</b> ,                                                                            | 0 |
| 63 | Chapter 17: Neurology: Fosphenytoin/Phenytoin/CYP2C9, HLA-B Case. <b>2022</b> ,                                                                      | 0 |
| 62 | Chapter 9: Cardiology: Warfarin/CYP2C9, VKORC1, CYP4F2 Case. <b>2022</b> ,                                                                           | 0 |
| 61 | Chapter 25: Rheumatology/Musculoskeletal Pain: Allopurinol/HLA-B Case. <b>2022</b> ,                                                                 | 0 |
| 60 | Chapter 12: Infectious Diseases: Abacavir/HLA-B Case. <b>2022</b> ,                                                                                  | 0 |

|    |                                                                                                                                                                                 |   |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 59 | Chapter 15: Infectious Diseases: Gentamicin/MT-RNR1 Case. <b>2022,</b>                                                                                                          | ○ |
| 58 | Pharmacogenomics: Foundations, Competencies, and the Pharmacists' Patient Care Process, 2nd Edition. <b>2022,</b>                                                               | ○ |
| 57 | Chapter 13: Infectious Diseases: Atazanavir/UGT1A1 Case. <b>2022,</b>                                                                                                           | ○ |
| 56 | Chapter 30: Pharmacogenomics and Secondary/Incidental Findings. <b>2022,</b>                                                                                                    | ○ |
| 55 | Chapter 16: Neurology: Carbamazepine/HLA-A, HLA-B Case. <b>2022,</b>                                                                                                            | ○ |
| 54 | Dedication. <b>2022,</b>                                                                                                                                                        | ○ |
| 53 | Chapter 3: Pharmacogenomics Testing. <b>2022,</b>                                                                                                                               | ○ |
| 52 | Identification of hub genes related to CD4+ memory T cell infiltration with gene co-expression network predicts prognosis and immunotherapy effect in colon adenocarcinoma. 13, | ○ |
| 51 | Chapter 24: Metabolic/Respiratory: Ivacaftor/CFTR Case. <b>2022,</b>                                                                                                            | ○ |
| 50 | Chapter 23: Psychiatry: Paroxetine/CYP2D6 Case. <b>2022,</b>                                                                                                                    | ○ |
| 49 | Copyright. <b>2022,</b>                                                                                                                                                         | ○ |
| 48 | Chapter 2: Pharmacogenomics: Drug Exposure and Response. <b>2022,</b>                                                                                                           | ○ |
| 47 | Chapter 22: Psychiatry: Amitriptyline/CYP2C19, CYP2D6 Case. <b>2022,</b>                                                                                                        | ○ |
| 46 | Chapter 6: The Pharmacists' Patient Care Process (PPCP). <b>2022,</b>                                                                                                           | ○ |
| 45 | Chapter 10: Endocrinology: Glipizide/G6PD Case. <b>2022,</b>                                                                                                                    | ○ |
| 44 | Chapter 1: Foundations of Pharmacogenomics. <b>2022,</b>                                                                                                                        | ○ |
| 43 | Chapter 20: Oncology: Capecitabine/DPYD Case. <b>2022,</b>                                                                                                                      | ○ |
| 42 | Preface. <b>2022,</b>                                                                                                                                                           | ○ |

|    |                                                                                                                                                  |   |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 41 | Chapter 14: Infectious Diseases: Voriconazole/CYP2C19 Case. <b>2022,</b>                                                                         | 0 |
| 40 | Chapter 19: Oncology: Mercaptopurine/TPMT, NUDT15 Case. <b>2022,</b>                                                                             | 0 |
| 39 | Chapter 7: Cardiology: Clopidogrel/CYP2C19 Case. <b>2022,</b>                                                                                    | 0 |
| 38 | Chapter 4: Pharmacists' Competencies in Genomics. <b>2022,</b>                                                                                   | 0 |
| 37 | Appendix 1: Competency Connections. <b>2022,</b>                                                                                                 | 0 |
| 36 | Chapter 5: Implementation of Pharmacogenomics across Practice Settings. <b>2022,</b>                                                             | 0 |
| 35 | Chapter 26: Rheumatology/Musculoskeletal Pain: Azathioprine/TPMT, NUDT15; Celecoxib/CYP2C9 Case. <b>2022,</b>                                    | 0 |
| 34 | Chapter 11: Immunology: Tacrolimus/CYP3A5 Case. <b>2022,</b>                                                                                     | 0 |
| 33 | RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma. <b>2022, 13,</b>                                    | 0 |
| 32 | Genetic alterations shaping tumor response to anti-EGFR therapies. <b>2022, 64, 100863</b>                                                       | 0 |
| 31 | Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies. <b>2022, 14, 5160</b> | 1 |
| 30 | Precision Medicine in Oncology Drug Development. 1-15                                                                                            | 0 |
| 29 | Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI. <b>2022, 14, 4834</b>                                       | 0 |
| 28 | Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. <b>2022, 28, 2171-2182</b>                                        | 9 |
| 27 | The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer.                                          | 0 |
| 26 | A PAM-free CRISPR/Cas12a ultra-specific activation mode based on toehold-mediated strand displacement and branch migration.                      | 0 |
| 25 | Translational proteomics and phosphoproteomics: Tissue to extracellular vesicles. <b>2022,</b>                                                   | 0 |
| 24 | Somatic mutations in colorectal cancer: regional experience. <b>2022, 24, 291-296</b>                                                            | 0 |



|    |                                                                                                                                                                                                                                   |   |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 23 | Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. <b>2022</b> , 23, 13696                                                                                                               | 0 |
| 22 | Current concepts of anti-EGFR targeting in metastatic colorectal cancer. 12,                                                                                                                                                      | 0 |
| 21 | DNN-PNN: a parallel deep neural network model to improve anticancer drug sensitivity. <b>2022</b> ,                                                                                                                               | 1 |
| 20 | Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53-Mutated Metastatic Colorectal Cancer. <b>2022</b> , 14, 5921                                                                                                | 0 |
| 19 | ACY1 Downregulation Enhances the Radiosensitivity of Cetuximab-Resistant Colorectal Cancer by Inactivating the Wnt/ $\beta$ Catenin Signaling Pathway. <b>2022</b> , 14, 5704                                                     | 0 |
| 18 | A review on the role of fatty acids in colorectal cancer progression. 13,                                                                                                                                                         | 1 |
| 17 | A narrative review of cancer molecular diagnostics: past, present, and future. Publish Ahead of Print,                                                                                                                            | 0 |
| 16 | The function of miR-145 in colorectal cancer progression; an updated review on related signaling pathways. <b>2022</b> , 154290                                                                                                   | 0 |
| 15 | Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT. <b>2022</b> , 9, 1-92                                                                                                      | 0 |
| 14 | Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial. <b>2022</b> , 14, 175883592211413 | 0 |
| 13 | Fasting and fasting mimicking diets in cancer prevention and therapy. <b>2023</b> ,                                                                                                                                               | 0 |
| 12 | KRAS mutational analysis: a new supplementary diagnostic tool for extrahepatic biliary stenosis.                                                                                                                                  | 0 |
| 11 | Utilisation des tests génomiques en oncologie : avis d'experts Français selon la méthode Delphi. <b>2023</b> ,                                                                                                                    | 0 |
| 10 | Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers. <b>2023</b> , 106082                                                                        | 0 |
| 9  | Targeting ERBB2 overcomes resistance to the anti-EGFR therapeutic antibody cetuximab. <b>2023</b> , 75-81                                                                                                                         | 0 |
| 8  | Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors. <b>2023</b> , 38,                                                                             | 0 |
| 7  | Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors. <b>2023</b> , 13, 395                                                                                                        | 0 |
| 6  | Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. <b>2023</b> , 13-27                                                                                                                                 | 0 |

- 5 MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS-mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. **2023**, 145-150 ○
- 4 Case report: Long-term survival in a patient with metastatic colorectal cancer treated with trifluridine/tipiracil in the third-line setting. 13, ○
- 3 Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. 12, ○
- 2 The Effect of RAS/BRAF Mutation Status on Prognosis and Relapse Pattern in Early Stage Colon Cancers. ○
- 1 The Effect of RAS/BRAF Mutation Status on Prognosis and Relapse Pattern in Early Stage Colon Cancers. ○